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Abstract and Keywords 
Quinone reductase 2 (NQO2) is a mammalian enzyme that catalyzes the reduction of quinone 
using an unusual co-substrate, dihydronicotinamide riboside (NRH). In addition, NQO2 has a 
secondary function, which is to modulate the 20S proteasomal degradation of p53 in a redox-
dependent manner. This alternate function has been characterized in its sister enzyme 
quinone reductase 1 (NQO1) and yeast quinone reductase Lot6p, but relatively few studies 
have investigated the role of NQO2 beyond quinone catalysis. From studies of Lot6p, it was 
proposed that quinone reductases could be categorized as flavin redox switches. In this 
thesis, the how NQO2 functions as a flavin redox switch and how inhibitors can modulate 
NQO2 was investigated. Initially, a method was developed to reconstitute recombinant 
NQO2 with FAD. Having purified functional NQO2, reduced structures of NQO2 were 
solved in complex with four different inhibitors: the antimalarial drug chloroquine, CK2 
inhibitor DMAT, DNA intercalating agent ethidium bromide, and acridine orange. In all four 
reduced structures, the hydrogen bond network and the orientation of inhibitors in the active 
site of NQO2 were changed by the presence of water molecules compared to the oxidized 
structures. For the structure of reduced NQO2 in complex with chloroquine, there was also a 
global conformational change. These reduced structures together showed that NQO2 has two 
functional states, and indicated mechanistic features of a flavin redox switch in NQO2. To 
understand how these inhibitors affect NQO2 signalling in cells, the CK2 inhibitors and 
DNA intercalating agents were further studied in tissue culture. Even though the cytotoxicity 
of these compounds was not dependent on NQO2, p53 levels were modulated in an NQO2-
dependent manner. In conclusion, this thesis has shown that in addition to quinone catalysis, 
NQO2 functions as a flavin redox switch, and NQO2 inhibitors have the ability to modulate 
this process.  
Keywords 
Quinone reductase 2, flavoprotein, antimalarial drugs, primaquine, chloroquine, CK2 
inhibitors, TBB, TBBz, DMAT, DNA intercalating agents, ethidium bromide, acridine 
orange, doxorubicin, X-ray crystallography, enzyme kinetics, ping-pong mechanism, flavin 
redox switch, 20S proteasomal degradation, p53 degradation.  
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1 
Chapter 1  
1 Introduction to Quinone Reductase 2 
1.1 General Introduction  
Cancer is the uncontrolled growth of cells caused by the induction of oncogenes, and 
inactivation of tumor suppressors. On this basis, the development of molecular targeted 
therapy operates on the principle that if these drivers of cancer can be controlled 
individually, then a regimen of therapeutic agents can ultimately reverse the process of 
cancer progression. This principle was clearly demonstrated by the success of the drug 
imatinib to induce complete cytogenetic remission in patients with chronic myelogenous 
leukemia (CML) by targeting the BCR-Abelson kinase (BCR-Abl) (1). The hallmark of 
CML is a translocation of chromosome 9 to chromosome 22 in which the normally 
inactive Abl kinase is fused to BCR, forming the onco-gene BCR-Abl (2). By inhibiting 
the onco-protein that drives the proliferation of cells, imatinib successfully prevented 
cells with BCR-Abl from multiplying. While this illustrated the success of molecular 
targeted therapy, cancer is rarely driven by a single onco-protein.  
Validation studies revealed that imatinib also bound to other targets. Using a chemical 
proteomics approach, two groups independently showed that quinone reductase 2 
(NQO2) was a prominent non-kinase target of imatinib (3, 4). NQO2 is a detoxification 
enzyme, which alternatively functions to stabilize the tumor suppressor p53 from 
degradation (5, 6)1. The antileukemic effects of imatinib are dependent on p53 activation 
in addition to BCR-Abl inhibition, so the interaction between imatinib and NQO2 may 
contribute to the therapeutic effects of the drug (7). These studies together illustrated the 
                                                
1 Reference 6 by Gong et al. has been retracted as of February 1st, 2015. Retraction: 
NRH:Quinone Oxidoreductase 2 and NAD(P)H:Quinone Oxidoreductase 1 Protect Tumor 
Suppressor p53 against 20S Proteasomal Degradation Leading to Stabilization and 
Activation of p53. (2015). Cancer Research, 75(3), 615–615. 
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point that although compounds are designed to inhibit one target, they can act in 
combination with other targets to elicit a favorable therapeutic effect.   
Protein kinase CK2 (CK2) is another dysregulated kinase in cancer. The overexpression 
of CK2 in cancer attenuates apoptosis by the phosphorylation of caspases and caspase 
substrates, and inhibition of CK2 can induce apoptosis in cancer cells (8). In the past two 
decades, numerous CK2 inhibitors have been developed, yet how the inhibitors affect the 
phosphorylation pattern in cells is still poorly understood. In an attempt to identify CK2 
substrates and to validate the inhibitors’ mechanism of action, an inhibitor-resistant CK2 
construct was made to restore CK2 activity in the presence of inhibitors (9). Despite the 
restoration of CK2 activity in the presence of two inhibitors, TBBz and DMAT, both 
inhibitors still induced apoptosis in cells. Thus, CK2 inhibition was not entirely 
responsible for cell death and the inhibition of other proteins contributed to apoptosis. 
Using a proteomics approach, NQO2 was again identified to be an unintended off-target 
binding protein of TBBz and DMAT (9). Together, this raises the possibility that the 
efficacy of CK2 inhibitors is also partially due to the off-target inhibition of NQO2.  
Initially discovered in the 1960’s by William-Ashman and coworkers, NQO2 was 
purified as a mammalian cytosolic flavo-protein. It catalyzed the reduction of quinone 
using dihydronicotinamide riboside (NRH), but not NAD(P)H or dihydronicotinamide 
mononucleotide (NMNH) (10). NQO2 was left unstudied for almost three decades until it 
was discovered to be genetically and structurally related to the widely-known enzyme 
quinone reductase 1 (NQO1) (11). The identification of NQO2 as a homologue of NQO1 
suggested that the two enzymes shared the same catalytic machinery and function, but 
their substrate and inhibitor specificity was strikingly different (11). For the next ten 
years, several groups identified NQO2 to be the target of different bioactive compounds. 
These compounds included targeted kinase inhibitors (imatinib and nilotinib (3, 4), CK2 
inhibitors (9), PKC inhibitors (12)), antimalarial compounds (primaquine, chloroquine, 
and quinacrine (13)), natural flavonoid (quercetin (5)), stilbenoid (resveratrol (14)), and 
hormone (melatonin (15)). While these inhibitors can prevent NQO2 catalysis at 
micromolar to low nanomolar concentrations, how they disrupt normal cell functions in 
an NQO2-dependent manner is uncertain. During this period, NQO1 was shown to 
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stabilize p53 from 20S proteasomal degradation (16). This led to the discovery that 
NQO2, like NQO1, also modulated p53 protein levels (6, 17). Recently, NQO2 was also 
shown to indirectly regulate the AKT/cyclin-D1/Rb and the NFκB signalling pathways 
(18, 19). Together, it would appear that NQO2 has cellular signalling functions in 
addition to quinone reduction. Similarly, studies of yeast quinone reductase Lot6p also 
showed that Lot6p has a cell signalling function (20). Lot6p was a poor catalyst of 
quinones but was able to stabilize transcription factor Yap4 from 20S proteasomal 
degradation in an NADH dependent manner (20, 21). In this regard, it was postulated that 
quinone reductase could be categorized in a larger protein family called the flavin redox 
switch. From these studies, it would appear that NQO2 has physiological roles as a flavin 
redox switch.  
In this thesis, I hypothesize that NQO2 functions as a flavin redox switch that senses 
intracellular NRH and recognizes potential cytotoxic compounds to modulate p53 levels 
in cells. To this end, several oxidized and reduced structures of NQO2 in complex with 
inhibitors were solved. The structural changes in NQO2 upon reduction revealed 
mechanistic features in NQO2 that resembled flavin redox switches. Extending the 
investigation of inhibitors to cell culture, it was also found that inhibitors modulate p53 
differently compared to NQO1. In this chapter, major concepts pertaining to the role of 
NQO2 as a flavin switch will be presented. First, NQO2 catalysis will be introduced 
because it is fundamental to NQO2’s function as an enzyme and as a flavin redox switch. 
Next, the biological process of p53 stabilization from 20S proteasomal degradation, and 
how quinone reductase could function as a flavin redox switch will be explained in 
greater detail. Finally, several NQO2 inhibitors will be introduced to show the diversity 
of compounds that bind NQO2 and affect p53 modulation. 
1.2 Structure and Kinetics of Quinone Reductase 2 
Historically, NQO2 was thought to function as a detoxification enzyme because it was a 
homologue of quinone reductase 1 (NQO1) with 48% sequence identity ((11)). NQO1 
catalyzes an obligate two-electron reduction of quinone to hydroquinone, and prevents 
the catalysis of single electron reductions of quinone by phase I enzymes such as 
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cytochrome P450, which generates semi-quinone species. Since semi-quinones can 
undergo redox-cycling that generates harmful reactive oxygen species, NQO1 functions 
to detoxify quinone compounds. In this regard, NQO2 was anticipated to perform the 
same function.  
NQO2 is a 26 kDa metallo-flavo-protein that is catalytically active as a dimer. 
Structurally, each monomer is composed of a Rossmann fold that coordinates one copy of 
flavin adenine dinucleotide (FAD). NQO2 is catalytically dead when depleted of its 
flavin co-enzyme, but its activity can be restored using FAD or a high concentration of 
flavin mononucleotide (FMN) (10). The active site of the enzyme is located at the 
interface between the two protomers where the isoalloxazine ring of FAD makes up the 
base of the active site, and residues from the second protomer make up the top (Figure 
1.1). Each NQO2 protomer coordinates one FAD co-enzyme, and there are two active 
sites in the NQO2 dimer. Since most crystal structures of NQO2 are composed of a dimer  
 
Figure 1.1 Surface Representation of Quinone Reductase 2. 
Each protomer of NQO2 (coloured as red or blue) coordinates an FAD co-enzyme and 
the active site is made up of the isoalloxazine ring from one protomer and residues from 
the other protomer (at the center of the figure).  
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in the asymmetric unit, the two protomers are not identical. It is currently not known 
whether the two subunits act independently or cooperatively, since structural studies 
show that inhibitors can occupy the two active sites in different orientations. Another 
feature of NQO2 is the presence of a metal ion located roughly 10 Å	  away	  from	  the	  active	  site	  (22).	  Between	  the	  metal	  ion	  and	  the	  active	  site	  are four residues that make 
up an electron transport bridge.	  The	  identity	  of	  the	  metal	  ion	  is	  copper	  when	  isolated	  from a mammalian source, and zinc when purified from Escherichia coli using a 
recombinant construct. However, the role of the metal ion in the catalysis of quinone is 
currently unknown since 100 mM EDTA did not decrease its catalytic activity (23). In 
the following sections, a detailed introduction on each component of NQO2 catalysis 
(FAD co-enzyme, nicotinamide co-substrate, quinone substrate, and inhibitors) and how 
they influence the role of NQO2 as a flavin redox switch will be presented. 
1.2.1 The Ping-pong Mechanism of NQO2 Catalysis 
Flavin redox switches are a class of proteins that can adopt different conformations 
depending on the redox state of its co-enzyme FAD. For NQO2, the redox state of FAD 
is dependent on the amounts of substrates and co-substrate available in the environment. 
In this regard, a comprehensive understanding of NQO2 catalysis is required to 
appreciate the complexity of NQO2 as a flavin redox switch. Similar to NQO1, NQO2 is 
able to catalyze the reduction of quinone using a ping-pong mechanism (Figure 1.2)(11). 
This catalytic mechanism can be described as two half-reactions: an oxidation reaction of 
NRH, and a reduction reaction of quinone. In the oxidation half-reaction, a nicotinamide 
co-substrate enters the active site and transfers two electrons to the isoalloxazine rings of 
FAD, reducing FAD to FADH2. The oxidized nicotinamide would then exit the active 
site, leaving NQO2 in its reduced state. In the reduction half-reaction, a quinone substrate 
enters the active site to pick up the two electrons, producing hydroquinone. After the 
hydroquinone leaves the active site, NQO2 returns to its original oxidized state. In 
summary, the dihydronicotinamide co-substrate and the quinone substrate alternately 
occupy the active site, and NQO2 cycles through two redox states for each catalytic turn 
over. 
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Figure 1.2 Ping-pong Mechanism of NQO2 Catalysis and Inhibition. 
Due to the nature of the ping-pong mechanism where each catalytic turn over requires the 
entry and exit of two substrates, NQO2 catalysis is not considered to be an enzyme with 
high catalytic rates. In a review of enzyme catalysis documented in the BRENDA 
database, it was found that the median catalytic turnover (Kcat) was roughly 10 s-1 (24). 
Compared to carbonic anhydrase, one of the fastest enzymes known, with Kcat value of 
over 1 × 105 s-1, the catalysis of menadione reduction using NRH by NQO2 is relatively 
slow (Kcat = 43 s-1)(5). To further understand the efficiency of NQO2 catalysis, the 
steady-state kinetics for a ping-pong mechanism described by equation 1.1 will be 
examined. 
 
Equation 1.1 Ping-pong Mechanism. 
The rate of quinone reduction is dependent on the two Michaelis constants (Km) for the 
quinone substrate (A) and the nicotinamide co-substrate (B), the substrate concentrations, 
and the maximum velocity (Vmax). A detailed examination of this equation indicates that 
the catalysis of NQO2 in practice could be much slower than theoretical estimates. To 
illustrate this point, consider the catalytic rate when both substrate concentrations are 
present at their respective Km values (ie. substitute all the variables with 1). The Vobs/Vmax 
will be at 1/3, meaning that the rate of catalysis is only one third of maximum velocity. 
At five times the concentration of their respective Km values (ie. Substitute [A], [B] with 
5, and Km(A) and Km(B) with 1), Vobs/Vmax will be at 25/35, or 71%. Therefore, the 
theoretical kcat or Vmax is only attainable at very high concentrations of both substrate and 
co-substrate. From these calculations, it appears that NQO2 catalysis is largely dependent 
Vobs
Vmax
=
[A][B]
KM(A)[B]+KM(B)[A]+[A][B]
  
 
7 
on the availability of both the quinone substrate and dihydronicotinamide co-substrate. 
Without dihydronicotinamide, NQO2 will likely be in an oxidized state even in the 
presence of quinone, and vice versa. In this regard, the catalytic efficiency of NQO2 as a 
detoxification enzyme may be much lower in a cellular context. As a flavin redox switch, 
the redox state of NQO2 is intimately tied to the presence of substrates and co-substrates 
in cells. 
1.2.2 The FAD Co-enzyme 
FAD is crucial to NQO2’s enzymatic and signalling function. As an enzyme, the obligate 
two-electron transfer to quinone is only possible with the FAD co-enzyme. During a 
catalytic turnover, a hydride ion (a proton and two electrons) is transferred to the 
isoalloxazine ring of FAD. At this stage, FAD would be reduced to FADH- where one 
proton and one electron reside at the N5 atom of FAD, while the other electron is shared 
between the N1, O2, and O4 atom in a tautomeric state (Figure 1.3). In NQO1, theoretical 
calculations showed that the second electron preferentially resides at the O2 atom and 
could be protonated by a nearby residue (25). Upon reduction, the electron transfer at the 
N5 atom breaks the planarity of the three ringed members of isoalloxazine. In protein-
free FADH2, the isoalloxazine ring is characterized by a “butterfly bend” of 10 - 28º 
along the N5-N10 axis (26). In the protein bound form, the butterfly bend varies. For 
example, the FAD ring bent up to 34º in reduced thioredoxin reductase, while the 
bending of FAD in NQO2 was roughly 5° (27, 28). Maintaining FADH- in a planar 
formation requires relatively little energy, around 4 kcal/mol according to Dixon and 
coworker’s estimation (26), which could be stabilized by a single hydrogen bond (~4.3 
kcal/mol). As an enzyme, the relatively planar geometry of FAD could contribute to its 
catalytic efficiency and substrate specificity. As a signalling molecule, the additional 
hydrogen bond could alter the conformation of the protein (29).  
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Figure 1.3 Chemical Structure of the Isoalloxazine Ring, FMN, and FAD. 
1.2.3 The Nicotinamide Co-substrate 
The discovery of NQO2 in 1962 by William-Ashman and coworkers showed that NQO2 
was unable to use the common co-substrates NAD(P)H and NMNH, but used NRH 
instead (Figure 1.4) (10). This was followed up in 1997 by Jaiswal and co-workers who 
showed that while NQO1 efficiently catalyzed the reduction of quinone using NAD(P)H 
(kcat/Km = 440 min-1 µM-1), NQO2 used NAD(P)H poorly with a catalytic efficiency 
roughly 700-fold lower than NQO1 (kcat/Km = 0.62 min-1 µM-1) (5). Instead, NQO2 used 
NRH nearly as efficiently as NQO1 used NAD(P)H (kcat/Km = 95 min-1 µM-1). To further 
illustrate that NQO1 and NQO2’s co-substrates are exclusive to each other, a study also 
showed that NQO1 used NRH 500-fold less efficiently than NAD(P)H, as NRH inhibited 
NQO1 catalysis with a Ki value of 2.39 mM (30). Since then, several other N-alkyl-
dihydronicotinamide derivatives have been identified to be co-substrates of NQO2 with 
an appreciable kinetic efficiency (31). Though virtually all in vitro studies of NQO2 
utilized these dihydronicotinamide derivatives, it is not known why NQO1 and NQO2 
use the dihydronicotinamide co-substrates exclusively.  
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Figure 1.4 Chemical Structure of Nicotinamide Derivatives and 
Dihydronicotinamide. 
Quinone reductase is part of the flavodoxin superfamily that can catalyze a diverse range 
of quinones. They are widely found in organisms ranging from bacteria to mammals. 
Base on sequence similarity, quinone reductases can be organized into three groups: 
those with C-terminal domains (NQO1-like), those lacking C-terminal domains (NQO2-
like), and those lacking C-terminal domains with an internal deletion of 18 residues 
(flavodoxin-like) (32). In a review of quinone reductase from 14 species of plants, fungi 
and bacteria, it was surprising that NQO2 was the only enzyme that preferentially used 
NRH (33). A structural study of NQO1 in complex with NADP+ showed that the C-
terminal domain of NQO1 coordinated the negatively-charged phosphate and AMP 
moiety of NADH during catalysis (34). But neither truncation of the C-terminal domain 
of NQO1, nor insertion of the C-terminal domain from NQO1 to NQO2, changed their 
co-substrate specificity (35). This indicated that the C-terminal domain alone was 
inadequate in conferring substrate specificity towards NADH. Mutating residues in the 
NQO2 active sites to resemble NQO1 was also unable to alter the co-substrate specificity 
to use NADH (36). Instead, it increased the overall catalytic activity of NQO2 using 
NRH and synthetic BNAH. These studies together indicated that NQO2 had evolved to 
avoid using NADH, yet it is unclear whether NRH is readily available in cells.   
Knox and coworkers have a long-standing interest in using the prodrug CB1954 in 
treating cancer. They have found that reduction of CB1954 by NQO2 can increase the 
cytotoxicity of CB1954 up to three orders of magnitude (31). V79 cells are Chinese 
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hamster lung fibroblast cells that have minimal NQO2 expression and activity. In these 
cells, the toxicity of CB1954 was only increased 1.4 times in the presence of NRH. But 
when NQO2 was transfected into these cells, the IC50 of CB1954 was increased up to 
3000-fold (31). Strikingly, the presence of NQO2 did not change the IC50 of CB1954 in 
cells without NRH co-treatment. This indicated that NRH and other NQO2 co-substrates 
were absent in normal proliferating cells, and suggested that NQO2 by itself was not 
catalytically active. In contrast, NQO1 substrates mitomycin C and EO9 were readily 
reduced without the addition of NADH (37, 38). Furthermore, how NRH is produced in 
cell is currently unknown. Given that NQO2 requires a high concentration of co-substrate 
to efficiently catalyze quinone, the lack of NRH in cells challenges the perspective that 
NQO2 functions primarily as a catalyst. 
1.2.4 The Quinone Substrates  
The notion that NQO2 is a detoxification enzyme is based on its similarity to NQO1 in 
catalyzing a two-electron transfer to quinone. For NQO1, menadione (vitamin K3) and 
several benzo- and napthoquinones are classic examples of the quinone substrate (39). 
NQO2 was also able to reduce menadione, but it did so 15-fold less efficiently than 
NQO1 when its preferred co-substrate was used (5). Furthermore, while napthoquinones 
are common substrates of NQO1, they were not recognized by NQO2 (40). In a screen of 
commercially available quinones, only one substrate, coenzyme Q0 was identified for 
NQO2 (40). Since coenzyme Q0 is not a naturally occurring compound, it is unclear what 
natural quinone compounds NQO2 recognizes. From these observations, it appears that 
NQO1 and NQO2 catalyze different quinone substrates.  
At high concentrations, menadione exhibits substrate inhibition for both NQO1 and 
NQO2. This indicates that it could act as both a substrate and an inhibitor of the system 
depending on its concentration (23, 41). How menadione behaves in an enzymatic assay 
is well characterized, but whether menadione acts as a substrate or inhibitor in cells is not 
clear. On one hand, mice deficient of NQO1 were more susceptible to menadione toxicity 
compared to wild-type mice (42). On the other hand, mice deficient of NQO2 were less 
sensitive to menadione toxicity when challenged with the same compound compared to 
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wild-type mice (43). Therefore, NQO1 and NQO2 deletion had opposite effects in mice 
treated with menadione. In the scenario where NQO1 is actively metabolizing menadione 
in the presence of NAD(P)H, the deletion of NQO1 could sensitizes cells to menadione 
toxicity. In contrast, if NQO2 is being inhibited by menadione by the lack of NRH in 
healthy cells, this interaction could elicit cellular signals that increase menadione’s 
cytotoxicity. As such, the deletion of NQO2 would abrogate this signalling event, 
rendering menadione less cytotoxic. Drawing from these speculations, it demonstrates 
that the physiological function of NQO2 is very complex. NQO2 function could be vastly 
different from NQO1, and the role of NQO2 as a detoxifying enzyme or a signalling 
protein is intimately linked to the availability of a reducing co-substrate.  
In addition to menadione, several synthetic substrates of NQO2 have been identified. 
They include prodrug CB1954, several quinone methides, acetaminophen and potentially 
paraquat (Figure 1.5). The prodrug CB1954 is a dinitrobenzamide aziridine that functions 
as a DNA alkylating agent. Upon a four electron transfer to the nitrogen groups by 
quinone reductase, CB1954 is able to form DNA crosslinks and is up to 3000-fold more 
cytotoxic than its parent compound (31). Initially, it was found that rat NQO1 can 
activate CB1954 and selectively kill Walker 256 (rat breast carcinoma) cells while 
sparing HEK295 (human embryonic kidney) cells (44). However, human NQO1 was not 
able to catalyze this reaction, and CB1954 was unable to selectively kill human cancer 
cells. Instead, human NQO2 reduced the CB1954 1000-fold more efficiently than NQO1 
when cells were supplemented with NRH or other NQO2 co-substrates (5). This 
illustrates that the substrates are unique to NQO1 and NQO2.  
Both NQO1 and NQO2 were able to reduce ortho- and para-quinone methides in vitro 
(45). In these molecules, one of the two carbonyl groups was replaced with a methylene 
group. Biologically, these compounds were more reactive than quinone and could 
undergo redox cycling when reduced (46). Finally, paraquat and acetaminophen toxicity 
were shown to be mediated by NQO2 and their toxicity diminished in the presence of 
NQO2 inhibitors (47, 48). Paraquat is an herbicide that is lethal when ingested and could 
be an indirect substrate of NQO2. Acetaminophen is a common medication and was 
shown to be a weak substrate of NQO2. From these observations, it appears NQO2-
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mediated reduction of compounds is responsible for activating toxic compounds rather 
than detoxifying them.  
 
 
Figure 1.5 Chemical Structure of NQO2 Substrates.  
 
1.2.5 ROS Generation and Auto-oxidation 
It was recently shown that NQO2 can produce reactive oxygen species (ROS) in the 
presence of substrates and co-substrates (49). When the first structural analysis of NQO2 
was published (PDB ID: 1QR2), Foster and co-workers noted a bound metal ion in 
NQO2. It was connected to the O(2) atom of FAD through the following four residues, 
forming an electron transfer bridge: Y155, N161, Y132, and H173 (22). The metal ion 
was not present in NQO1 and it was proposed that it could be important in the reduction 
of quinone in NQO2. However, mutating the residues that coordinated the metal ion did 
not significantly change the rate of quinone reduction, and EDTA did not noticeably 
affect NQO2 activity either (23, 36). Thus, the role of the bound metal ion is currently 
unknown. When NQO2 was isolated from a mammalian source, it was found to contain 
copper. Since copper is a reactive metal, it is possible that this metal participates in ROS 
generation (50). As an enzyme, the generation of ROS indicates that it could mediate 
oxidative stress in cells. As a flavin redox switch, auto-oxidation represents a mechanism 
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of switching from a reduced state to an oxidized state that could be important in 
temporally regulating NQO2’s signalling function.  
1.2.6 The Inhibition Mechanism  
In 1962, William-Ashman and coworkers showed that a small concentration of 
anthracene derivatives (10 nM) was able to inhibit the catalytic activity of NQO2 (10). 
They further showed that much like the dihydronicotinamide co-substrates, inhibitors of 
NQO1 and NQO2 were exclusive to one another. The active site of NQO2 is a large 
hydrophobic pocket and numerous molecules with a restricted planar moiety could inhibit 
NQO2 catalysis. In the past two decades, numerous bioactive compounds were found to 
inhibit NQO2 using two methods: pull-down of NQO2 from a compound-conjugated 
matrix, and direct screening. The former identified types of molecules such as kinase 
inhibitors, antimalarial compounds, natural stilbenoids, and hormones. The latter 
identified compounds like flavonoids (40) and DNA intercalating agents (51). All of 
these compounds also disrupt cellular proliferation, but it is currently unknown whether 
this results from NQO2 inhibition.  
The interactions between a compound and an enzyme can be described by enzyme 
inhibition or by direct binding experiments. For NQO2, which catalyzes using a ping-
pong mechanism, inhibitors can either compete against dihydronicotinamide, quinone, or 
both substrates (Figure 1.2). Described in terms of direct binding, inhibitors can directly 
bind to oxidized, reduced, or both redox states of NQO2. To investigate the mode of 
inhibition, Kwiek and co-workers presented a comprehensive analysis of three NQO2 
inhibitors: the antimalarial drugs primaquine (PQ), chloroquine (CQ), and quinacrine 
(QC) (23). In their study, PQ competed with the dihydronicotinamide co-substrate for the 
oxidized FAD site. In contrast, CQ and QC competed with the quinone substrate for the 
reduced FAD site. A direct binding assay further confirmed that PQ bound oxidized 
NQO2 while CQ did not. These observations showed that not only could these 
compounds inhibit catalysis, but they also have a binding preference towards a specific 
redox-state of NQO2. By directly binding to either redox-states, NQO2 inhibitors could 
stabilize the protein in an oxidized or reduced state. For a flavin redox switch, these 
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interactions could propagate distinct signals in a cellular environment. From this 
perspective, NQO2 inhibitors could induce signalling events even when concentrations of 
a substrate or co-substrate are low in a cell.  
1.2.7 Role of NQO2 Catalysis 
In this section, each component of NQO2 catalysis was expounded. The substrates, co-
substrates, and inhibitors of NQO1 and NQO2 are almost exclusive to one another, and 
the inferred detoxification role of NQO2 was challenged. To catalyze quinones 
efficiently, NQO2 would require a high concentration of dihydronicotinamide co-
substrate. However, it appears that little, if any, endogenous levels of NQO2 
dihydronicotinamide co-substrate are present in cells. Furthermore, inhibitors of NQO2 
also have the potential to stabilize NQO2 in a redox-specific state. From these 
observations, the ability of NQO2 to reduce quinone is questioned. In the following 
section, how NQO2 could function as a flavin redox switch will be explored. 
1.3 NQO2 as a Flavin Redox Switch  
The wild-type p53 gene is a tumor suppressor that protects a cell from genomic instability 
by inducing cell cycle arrest or apoptosis in response to genomic stress. In a study of p53-
mediated apoptosis, p53 activated redox-related genes to generated ROS that damaged 
the mitochondria (52). Among the p53-induced genes identified was one that shared 
sequence homology with mammalian NADPH-quinone oxidoreductase and ζ crystallin, 
and was named p53-inducible gene 3 (PIG3). Based on this finding, Asher and coworkers 
speculated that oxidoreductase could regulate p53 in a feedback loop, and experimentally 
showed that p53 degradation was modulated by NQO1 (16). However, PIG3 and NQO1 
were very different proteins in terms of sequence, structure, and function. Instead of 
detoxifying quinone to prevent ROS generation, PIG3 produced ROS (53, 54). 
Regardless, since the discovery that NQO1 can modulate p53 degradation, NQO2 was 
also shown to modulate p53 (6, 23). In this section, an introduction of the flavin redox 
switch will be presented and the notion that quinone reductase can function as a flavin 
redox switch will be illustrated. Next, the specific mechanism of how NQO1 and NQO2 
stabilize p53 from 20S proteasomal degradation will be presented.  
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1.3.1 Flavin Redox Switch 
Flavin redox switches are a class of proteins that senses specific physiological conditions 
and propagate a signal for the cell to respond to (29). In the presence of a specific 
substrate, electron donor, or light, the reduction of its flavin co-enzyme FAD or FMN 
activates the flavin redox switch. The reduced isoalloxazine ring of flavin then alters the 
hydrogen bond network within the protein, leading to a change in protein conformation. 
In turn, the activated reduced state is responsible for regulating transcription factors, 
controlling membrane binding, and modulating post-translational modifications. The 
flavin redox switch can be turned off by the oxidation of flavin in most cases, but it is 
irreversible in some. An example of a flavin redox switch is phototropin, which regulates 
photosynthetic proteins in plants. They are light sensing proteins that contain two light-
oxygen-voltage (LOV) domains and a kinase domain. The FMN co-enzyme in the LOV 
domain is reduced by light and makes a covalent bond with a nearby cysteine residue. 
This causes a conformational change in the LOV domain, resulting in the activation of 
the kinase domain. The phosphorylation of phototropin substrates then induces the 
production of photosynthetic proteins in cells. 
Most flavin redox switches are characterized by having a PER-ARNT-SIM2 (PAS) 
domain; this encompasses the LOV domain (55). In contrast, quinone reductase is 
composed of a flavodoxin-like domain that is structurally and sequentially distinct from 
the PAS domain (33). As such, the function of quinone reductase as a flavin redox switch 
cannot be directly inferred. In yeast, Lot6p is the sole orthologue of human NQO1 and 
NQO2, and it was found to physically associate with the 20S proteasome in a redox-
dependent manner (20). Specifically, Lot6p modulated the degradation of Yap4, a yeast 
transcription factor involved in oxidative stress response (20, 56). Further investigation 
showed that oxidative stress induced apoptosis-like cell death in a Lot6p-dependent 
manner (57). As an enzyme, Lot6p was shown to be a poor catalyst because it reduced 
quinone slower than non-enzymatic reactions (21). From this perspective, it was 
                                                
2 PER – Period protein; ARNT – aryl hydrocarbon receptor nuclear translocator protein; and SIM 
– single-minded protein.  
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speculated that Lot6p functioned primarily as a regulator of 20S proteasome rather than 
as a catalyst. Furthermore, inhibitors of NQO1 and NQO2 (curcumin and resveratrol 
respectively) inhibited Lot6p catalysis and also stabilized the protein from thermal 
denaturation (58). This indicated a possible role for inhibitors to affect how Lot6p 
regulates the 20S proteasomal degradation of Yap4. While there is no p53 homologue in 
yeast, these studies demonstrated that the quinone reductase family could have a 
functional role in modulating protein degradation as a flavin redox switch in addition to 
quinone catalysis.  
1.3.2 The p53 Tumor Suppressor 
The tumor suppressor p53 is the “master guardian and executioner” of the genome (59). 
It is a transcription factor that induces cell cycle arrest or apoptosis in response to a 
diverse range of genotoxic and oncogenic stress. Structurally, p53 is composed of an N-
terminal unstructured region, a stable DNA binding domain region, and a trans-activation 
C-terminal region. A number of post-translational modifications in p53 drives the 
translocation of p53 into the nucleus where it forms a homo-tetramer to induce various 
pro-apoptotic genes (60). In the COSMIC database that curates all available cancer 
genomes, the p53 gene was found to be mutated in roughly 30% of all cancer types 
(http://cancer.sanger.ac.uk/, accessed July 11, 2015)(61). Since cells with defective p53 
are impeded from activating apoptosis in the presence of genomic stress, cancers lacking 
p53 function could tolerate a higher level of genomic instability and become more 
aggressive. Recently, it was shown that restoration of wildtype-p53 led to cancer 
remission in a mouse model (62). Therefore, being able to manipulate NQO2 as a flavin 
redox switch using NQO2 specific inhibitors could be an avenue of inducing wildtype-
p53 in cells. 
1.3.3 Mechanism of p53 Degradation by 20S proteasome 
The degradation of p53 has been an area of extensive research because it is rapidly 
degraded and only has a half-life of 20 minutes (63). In the conventional pathway of p53 
degradation, the protein is first poly-ubiquitinated by hdm2 E3 ligase. It is then 
recognized by the 26S proteasome and degraded in an ATP-dependent manner (Figure 
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1.6). NQO1 was initially identified to protect p53 from proteasomal degradation because 
it was thought that oxidoreductases could regulate p53 (16). It was shown that 
dicoumarol, an inhibitor of NQO1, enhanced the degradation p53. Furthermore, the 
inhibitor-induced degradation was prevented by the overexpression of NQO1, the 
treatment with proteasome inhibitor MG132, and the presence of SV40 large T antigen. 
The degradation of p53 was independent on the hdm2 regulation pathway, and wild-type 
NQO1 was necessary to mediate the effects of dicoumarol (64). Surprisingly, mutant p53 
with the most frequently mutated arginine residues (R174H, R273H, and R248H) were 
resistant to NQO1 inhibitor-induced degradation (65). Mechanistically, p53 was degraded 
by the 20S core proteasome particle (proteasome 26S without the 19S regulatory subunit) 
alone, without ubiquitination or the addition of ATP (66). This alternate degradation 
pathway of p53 was regulated by NQO1 in a NADH dependent manner, and was thought 
to be the default pathway of p53 degradation in cells (67, 68). Since the 20S core 
proteasome could degrade intrinsically disordered proteins, it was speculated that the 
proteasome recognized the unstructured regions of p53 (68, 69). In addition to p53, 
NQO1 also prevented 20S proteasomal degradation of p73 and ornithine decarboxylase, 
 
Figure 1.6 p53 Degradation Pathway by 26S and 20S Proteasome. 
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which indicated that NQO1 could modulate other proteins with intrinsically disordered 
regions (66, 70). These studies together showed that NQO1 can stabilize the basal levels 
of proteins including p53 by regulating the 20S proteasome, and NQO1 inhibitors can 
prevent this to some degree (71). 
Similar to NQO1, NQO2 was also shown to stabilize p53 in the presence of NRH. Mice 
deficient of NQO2 were highly sensitive to tumorigenesis in a chemically induced skin 
cancer model and had a lowered basal level of p53 (72). Moreover, mice deficient of both 
NQO1 and NQO2 were more susceptible to tumorigenesis, and its p53 regulation was 
drastically impaired compared to the single knockout mice (73). At the molecular level, 
the degradation of p53 by 20S proteasome was verified using an in vitro degradation 
assay of [35]S-methionine-labeled p53, and NQO2 was able to stabilize p53 in an NRH 
dependent manner (6). From these studies, it is clear that NQO1 and NQO2 can modulate 
basal expression of p53 by controlling its 20S proteasomal degradation. To date, the only 
known physiological condition known to activate p53 in an NQO1/NQO2 dependent 
manner is the inhibition of pyrimidine nucleotide synthesis (17). However, the 
mechanism behind how NQO1 or NQO2 modulates this process is currently unknown.  
The function and regulation of p53 rely on numerous signals and cellular conditions in 
addition to 20S proteasomal degradation. In light of the complex modulation of p53, how 
NQO2 behaves as a flavin redox switch and how NQO2 inhibitors affect this switch 
remains poorly understood. In the following section, several inhibitors of NQO2 will be 
introduced to illustrate the potential link between NQO2 inhibition and cell signalling. 
1.4 Inhibitors of NQO2 
1.4.1 Discovery of NQO2 Inhibitors 
NQO2 inhibitors normally characterized to prevent catalysis of quinone reduction could 
stabilize NQO2 in a specific redox-state to modulate p53 stabilization in cells. Since the 
discovery of NQO2, a number of proteomic studies have identified NQO2 to be the target 
of biologically active compounds such as antimalarial drugs, kinase inhibitors, 
resveratrol, and melatonin. These unrelated compounds bound to NQO2 with a sub-
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micromolar affinity and they represent the majority NQO2 inhibitors studied in depth to 
date. While these compounds perturb biological processes, most of these inhibitors also 
bind to other targets. Accordingly, how NQO2 mediates their biological effects remains 
ambiguous. Another approach to discovering NQO2 inhibitors was by screening known 
or newly synthesized compounds that inhibited NQO2 catalysis. Motivated by making a 
more selective NQO2 inhibitor, NQO2 inhibitors with nanomolar affinity have been 
developed. In this section, a brief overview of the inhibitors used in this thesis will be 
presented, with an emphasis on how they were discovered to bind NQO2. The following 
well-characterized compounds will also be introduced because they affect cellular p53 
levels in some way: 9-aminoacridine, imatinib and nilotinib, melatonin, and resveratrol. 
The list of all the compounds discussed here is presented in figure 1.7.  
1.4.2 Primaquine and Chloroquine 
Primaquine (PQ) and chloroquine (CQ) are antimalarial drugs routinely used to treat 
parasitic infections of Plasmodium sporozoites transferred by mosquitos. The two 
inhibitors target different stages of malarial infection: PQ clears infections from the liver 
while CQ clears infections from blood (74, 75). To investigate how these drugs function, 
Graves and co-workers employed a proteomics strategy to search for a protein target of 
PQ and CQ (13). Cell lysate from malaria-infected blood cells was immobilized on an 
ATP-sepharose column and proteins that eluted in the presence of PQ and CQ were 
identified. Surprisingly, no parasitic protein was found. Instead, NQO2 was identified 
and was potently inhibited by the concentration of drugs used in clinical treatment. This 
discovery demonstrated the possibility that inhibition of NQO2 could contribute to 
antimalarial effects. 
The interaction between the two drugs and NQO2 also indicated that NQO2 could be 
involved in other diseases for which PQ and CQ are used as therapeutics. Specifically, 
PQ is used to treat pneumocystis pneumonia, and is active against leishmaniasis and 
trypanosomiasis in vivo (76–78). CQ has been used to treat rheumatoid arthritis, systemic 
lupus erythematosus, amoebic hepatitis, and is under clinical trials for use in HIV-
1/AIDS (79, 80). Furthermore, CQ is cytotoxic to several human cancer cell lines and is 
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Figure 1.7 Chemical Structures of NQO2 Inhibitors. 
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being investigated for use as a cancer therapeutic agent (81–83). Mechanistically, CQ 
was shown to stabilize wild-type p53 from degradation and induced apoptosis in 
glioblastoma cells (84). However, it is unclear how NQO2 mediate the pharmacological 
effects of these two inhibitors. To understand how the two inhibitors affect NQO2 as a 
flavin redox switch, a structural analysis of NQO2 and the two inhibitors will be 
presented in chapter 3.  
1.4.3 CK2 Inhibitors TBB, TBBz, and DMAT 
Protein kinase CK2 (CK2) is a serine/threonine protein kinase, involved in cell cycle 
control, cell proliferation signalling, tumorigenesis, and other cellular processes (8, 85, 
86). Since it is overexpressed in many tumor types, it is a potential cancer therapeutic 
target and numerous CK2 inhibitors have been developed (87). In particular, 4,5,6,7-
tetrabromobenzotriazole (TBB), 4,5,6,7-tetrabromobenzimidazole (TBBz), and 2-
dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), are three widely-used 
CK2 inhibitors that can induce apoptosis in cells (88, 89). Despite being optimized for 
CK2 specific inhibition, both TBBz and DMAT inhibit at least three other subfamilies of 
kinases unrelated to CK2 (DYRKs, PIM, and HIPK (90)). Therefore, the exact pathways 
through which CK2 inhibitors induce apoptosis in cells remain debatable. Using a similar 
approach to find targets for CQ and PQ, NQO2 was identified as a target of TBBz and 
DMAT (9). Specifically, NQO2 was eluted from an ATP-Sepharose column in the 
presence of TBBz and DMAT, but not TBB. This correlated with the observation that in 
cells TBBz and DMAT, but not TBB, induced apoptosis response even when CK2 
activity was restored. Together, this shows that inhibition of NQO2 may contribute to 
apoptosis.  
In prostate cancer cells, TBB induced apoptosis in cell lines that had wildtype p53 but not 
in cell lines with a mutant or no p53 expression (91). TBB and DMAT also induced p53 
expression and apoptosis in biliary tract cancer cells (92). However, the direct 
involvement of NQO2 in inhibitor-induced apoptosis has not been demonstrated. In 
Chapter 4, the inhibition of NQO2 by TBB, TBBz, and DMAT will be characterized, and 
cellular studies with these compounds will be presented in Chapter 6. 
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1.4.4 DNA Intercalating Agents 
In a virtual screen for NQO2 inhibitors, a number of planar molecules were identified 
(93, 94). Among these were 9-aminoacridine (9AA) and imidazoacridine-6-one C1311 
(C1311), which were also known to intercalate DNA. While DNA intercalating agents 
can cause DNA damage leading to p53 activation, 9AA induced p53 expression 
independent of genotoxic stress (82). C1311 was also shown to be cytotoxic to a number 
of solid tumors and leukemia, but p53 status was not a determinant of the inhibitor’s 
efficacy (95). When C1311 was modified so that the DNA intercalating properties were 
diminished without changing its ability to inhibit NQO2, it became less cytotoxic (96). 
From these findings, even though NQO2 inhibition was not responsible for the 
cytotoxicity of the compounds, p53 could still be modulated in an NQO2 dependent 
manner. In chapter 5, an investigation into whether other DNA intercalating agents can 
also inhibit NQO2 or not will be presented.  
1.4.5 Imatinib and Nilotinib 
Imatinib and nilotinib are inhibitors of BCR-Abl. In normal cells, wild-type Abl is under 
strict regulation and remains inactive. In CML, a chromosomal translocation of the Abl 
gene to the BCR gene makes the fusion gene BCR-Abl. This renders the gene product 
BCR-Abl kinase constitutively active. By binding to the ATP site of BCR-Abl, imatinib 
and nilotinib inhibited the unregulated activity of BCR-Abl and reversed the oncogenicity 
of CML (1). Using an inhibitor-conjugated affinity matrix, two groups independently 
showed that NQO2 was a prominent unintended non-kinase target of imatinib and 
nilotinib (3, 4). This interaction was further characterized by X-ray crystallography, but 
how NQO2 inhibition contributes to the efficacy of these inhibitors is currently unknown 
(97). Using a mouse CML model, leukemic cells deficient of p53 were less sensitive to 
the cytotoxic effects of imatinib, even though BCR-Abl was inhibited (7). This showed 
that p53 was partially responsible for the antiproliferative effects of imatinib, and points 
to the possibility that NQO2 was involved.  
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1.4.6 Melatonin  
Melatonin is a hormone pivotal to the regulation of circadian rhythm, which was shown 
to have anticancer effects (98). Using radioactive-labeled melatonin, two high affinity 
targets (MT1 and MT2) and a low-affinity target (MT3) were discovered in hamsters 
(99). MT1 and MT2 were identified as membrane bound G-protein coupled receptors, 
and MT3 was identified as NQO2 (15). At one nanomolar concentration (1 nM), 
melatonin induced p53 expression (100). However, the induction of p53 was likely 
caused by MT1 and MT2 interactions because NQO2 inhibition would require a greater 
concentration of melatonin (KI = 130 µM; (101)). Based on the melatonin moiety, a 
number of high affinity NQO2 inhibitors were developed (101). The compound with the 
strongest affinity was S294343 with an IC50 of 14 nM, and it was recently used to study 
the NQO2-mediated toxicity of paraquat and the generation of ROS by NQO2 (47, 49). 
As high affinity inhibitors of NQO2 such as S29434 continue to be used, it would offer 
insight into how targeted NQO2 inhibition affects cell signalling pathways.  
1.4.7 Resveratrol 
Resveratrol is an antioxidant commonly found in grape skins and red wine. This 
compound has been studied intensively due to its potential role in cardioprotection and 
cancer prevention. Using a resveratrol-immobilized affinity column, NQO2 was 
identified to be a prominent target of resveratrol (14). To date, twenty other targets have 
been identified, but resveratrol binds to NQO2 with the highest affinity (Kd = 35nM) 
(102). Several studies have shown that resveratrol induced p53 expression, but the 
concentrations used in these experiments would also bind to targets other than NQO2 
(103, 104). As such, it is currently unclear how the inhibition of NQO2 by resveratrol 
contributes to p53 regulation. 
                                                
3
 S29434 was initially named as NMDPEF: N-[2-(2-methoxy-6H-dipyrido[2,3- a:3,2-e]pyrrolizin-11-
yl)ethyl]-2-furamide] 
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1.4.8 Effects of NQO2 Inhibition 
In this section, several inhibitors of NQO2 that are cytotoxic to cells were highlighted. 
Some of these compounds affected apoptosis and p53 induction independent of NQO2 
catalysis. Many of the inhibitors also bound to a wide range of proteins while others 
intercalated DNA. In addition, inhibitors of NQO2 can suppress NF-κB and affect 
AKT/Rb/Cyclin D1 signalling, which can modulate p53 (18, 19, 105). In light of the 
complex regulation of p53, it is difficult to specify how NQO2 inhibitors affect p53 
protein levels through direct binding to NQO2. Since inhibitors have the potential to alter 
NQO2’s function as a flavin redox switch by stabilizing NQO2 in either oxidized or 
reduced states, these inhibitors could directly modulate p53 levels though NQO2 
interactions.  
1.5 Scope of Thesis Project 
NQO2 is an enzyme inhibited by a myriad of compounds and has cellular signalling 
functions. My hypothesis is that NQO2 functions as a flavin redox switch that senses 
intracellular NRH and recognizes many potential cytotoxic compounds to modulate p53 
levels in cells. In this thesis, the structural understanding of how NQO2 functions as a 
flavin redox switch was advanced and how inhibitors interact with NQO2 were 
investigated. The studies of inhibitors were also extended into cellular systems to show 
that some inhibitors do modulate p53, but they do so in an unexpected manner. 
In preparing recombinant NQO2 expressed in Escherichia coli, it was found that NQO2 
lacked the co-enzyme FAD, which prevented accurate analysis of kinetic and structure 
studies. This led to the development of a method to fully reconstitute NQO2 with FAD 
(Chapter 2). Overcoming this hurdle, the oxidized NQO2 structure with the inhibitors PQ 
and CQ were solved. Next, the first crystal structure of reduced NQO2-inhibitor complex 
was obtained by reducing NQO2-CQ crystals in an anoxic environment. A global 
conformational change of NQO2 was seen in the reduced state, which showed that NQO2 
shared common features with other flavin redox switches (chapter 3).  
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The identification of NQO2 as a target of CK2 inhibitors prompted a kinetics and 
structural investigation with these inhibitors. Using a modified inhibited-kinetic model, 
the degree to which TBB, TBBz, and DMAT competed with the dihydronicotinamide co-
substrate or the quinone substrate was determined. Specifically, TBBz was found to bind 
oxidized NQO2 exclusively and DMAT bound both oxidized and reduced NQO2 with 
similar affinities, while TBB bound to NQO2 with a low affinity. Compared to the ATP 
binding site of CK2, the electrostatic potential of the NQO2 active site was different in 
charge. The difference in how the compounds bound NQO2 and CK2 indicated that the 
binding of NQO2 by kinase inhibitors was fortuitous rather than by design (Chapter 4).  
Next, three DNA intercalating agents were identified as novel inhibitors of NQO2. EtBr, 
AO, and doxorubicin were found to inhibit NQO2 with nanomolar affinities. Specifically, 
EtBr and AO were identified to be the highest affinity reduced-state inhibitors of NQO2. 
Structural analysis of these compounds with reduced NQO2 confirmed that hydrogen 
bond network in the NQO2 active site was different compared to its oxidized active site. 
It was further shown that a non-toxic concentration of AO could inhibit NQO2 catalysis 
in cells, thus AO is a suitable mechanistic probe of NQO2 function in cells (Chapter 5).  
To further understand how inhibitors affect the signalling role of NQO2, NQO2 
inhibitors were studied in tissue cultures. Endogenous NQO2 was knocked out in human 
HCT116 cancer cells using CRISPR/Cas9 technology to compare the role of NQO2 in 
cells treated with substrate, co-substrate, and inhibitors. It was found that while NQO2 
status did not affect the cytotoxicity of NQO2 inhibitors, the presence of NQO2 affected 
how inhibitors modulated p53 levels (Chapter 6).  
Using both structural and cellular techniques, the work presented in this thesis has 
advanced the molecular understanding of how NQO2 behaves as a flavin redox switch. 
Reduced NQO2 in complex with four different inhibitors were characterized in detail and 
together illustrated that NQO2 could be differentially modulated by state-specific 
inhibitors. In this regard, several anoxic techniques were also developed in 
crystallography and ITC to study reduced NQO2. Cellular investigations revealed that 
NQO2 modulation of signalling events was a very complex process. Altogether, this 
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thesis supports the role of NQO2 as a flavin redox switch and shows that inhibitors could 
modulate NQO2 in ways in addition to inactivating NQO2 catalysis.  
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Chapter 2  
2 Flavin Adenine Dinucleotide Content of Quinone 
Reductase 2: Analysis and Optimization for Structure-
Function Studies4 
Quinone reductase 2 (NQO2) is a broadly expressed enzyme implicated in responses to a 
number of compounds, including protein kinase inhibitors, resveratrol, and antimalarial 
drugs. NQO2 includes a flavin adenine dinucleotide (FAD) co-enzyme, but X-ray 
crystallographic analysis of human NQO2 expressed in Escherichia coli showed that 
electron density for the isoalloxazine ring of FAD was weak and there was no electron 
density for the adenine mononucleotide moiety. Reversed-phase high-performance liquid 
chromatography (HPLC) of the NQO2 preparation indicated that FAD was not present 
and only 38% of the protomers contained flavin mononucleotide (FMN), explaining the 
weak electron density for FAD in the crystallographic analysis. A method for purifying 
NQO2 and reconstituting with FAD such that the final content approaches 100% 
occupancy with FAD is presented here. The enzyme prepared in this manner has a high 
specific activity, and there is strong electron density for the FAD co-enzyme in the 
crystal structure. Analysis of NQO2 crystal structures present in the Protein Data Bank 
indicates that many may have sub-stoichiometric co-enzyme content and/or contain FMN 
rather than FAD. This method of purification and reconstitution will help to optimize 
structural and functional studies of NQO2 and possibly other flavoproteins. 
2.1 Introduction 
Quinone reductase 2 (NQO2) is an unusual enzyme with an interesting history. During 
the early 1960s, Williams-Ashman and coworkers observed that rat tissue extracts, 
especially from kidney, liver, and heart, have the ability to couple the oxidation of 
dihydronicotinamide riboside (NRH) to the reduction of menadione. This novel enzyme 
                                                
4	  This chapter has been published: Leung, K.K., Litchfield, D.W., and Shilton, B.H. (2012) Flavin 
adenine dinucleotide content of quinone reductase 2: analysis and optimization for structure-
function studies. Anal. Biochem. 420, 84–9	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activity could be distinguished from NAD(P)H-linked reducing activities because the 
NRH-dependent activity was inhibited by estradiol but not by dicoumarol (1). The 
enzyme in question was purified from bovine kidney and shown to include tightly bound 
flavin adenine dinucleotide (FAD) as a co-enzyme. At the time, this was the only enzyme 
known to couple oxidation of NRH to reduction of compounds such as menadione, and 
its physiological function was a mystery. Because a degradative pathway for NRH was 
not known, Williams-Ashman and coworkers speculated that the enzyme may unction to 
oxidize cellular NRH so that the resulting nicotinamide riboside (NR) could be degraded.  
These early observations did not receive further attention until 1990 when a human 
cDNA (complementary DNA) corresponding to the enzyme was discovered (2). The 
sequence had very strong similarity (49% identity) to quinone reductase 1 (NQO1), and 
on this basis the protein product was defined as ‘‘quinone reductase 2’’ (NQO2). The 
connection between NQO2 and the enzyme purified by the Williams-Ashman group was 
finally made in 1997 when Talalay and coworkers published a detailed enzymatic 
characterization of NQO2 and showed that it had properties similar to those described by 
Williams-Ashman and coworkers (3).  
NQO2 remains a fascinating and enigmatic enzyme. The substrates and physiological 
function of NQO2 are not well defined. NQO2 is the only enzyme listed in the BRENDA 
database (http://www.brenda-enzymes.org) that preferentially uses NRH as a reductant, 
but the biological ‘‘rationale’’ for this preference is not obvious and it is not known what 
nicotinamide derivative is the dominant co-substrate under physiological conditions. Its 
‘‘sister’’ enzyme, NQO1, uses NADH or NADPH as a co-substrate and is thought to 
provide a cytoprotective function, acting as a detoxification protein that catalyzes an 
obligatory two-electron transfer to quinone substrates, thereby preventing a single 
electron reduction and the generation of reactive radical species (4). Despite the structural 
similarities between the enzymes, an analogous cytoprotective function for NQO2 is not 
consistently supported by the available data; however, NQO2 is receiving increasing 
attention because of its interaction with, and/or modification of, a number of drugs and 
biologically active molecules, including kinase inhibitors, resveratrol, and antimalarial 
drugs (5).  
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NQO2 catalysis proceeds via a ping-pong kinetic mechanism, where the bound FAD co-
enzyme is first reduced by NRH or a related dihydronicotinamide derivative and then the 
substrate replaces the nicotinamide at the active site. NQO2 is inhibited by compounds 
with planar aromatic ring systems, and in all cases examined so far the inhibitors bind 
adjacent to the isoalloxazine ring of FAD and are coordinated by tryptophan residues in 
the catalytic pocket. Our interest in NQO2 arose because it was identified as a target for 
two inhibitors of the protein kinase CK2 (6). To understand the specificity determinants 
for this interaction, we co-crystallized a recombinant form of NQO2 with the inhibitors; 
although the crystals diffracted to high resolution and yielded excellent electron density 
maps for protein atoms, the electron density for the FAD co-enzyme was weak and there 
was no electron density for the inhibitors. We traced the origin of this problem to a sub-
stoichiometric amount of FAD in the enzyme preparation, resulting in a low occupancy 
for bound FAD in the crystals. The relatively low occupancy of FAD in the crystals 
means that there is a smaller contribution from the co-enzyme to the diffraction 
intensities, which is accounted for in the crystallographic model by elevated atomic 
displacement parameters (ADPs) for the FAD. An analysis of the ADPs for the FAD co-
enzyme in available NQO2 structures indicates that this may be a fairly common 
occurrence for recombinant NQO2 expressed in Escherichia coli. To obtain stronger 
electron density for FAD and bound substrate or inhibitor, a simple step was added to the 
purification procedure that yields enzyme with a stoichiometric amount of FAD. Crystals 
of this NQO2 preparation yield greatly improved electron density maps for the entire 
FAD co-enzyme, and this modification will help us to obtain detailed information on 
inhibitor binding.  
2.2 Materials and Methods 
2.2.1 Reagents 
FAD, flavin mononucleotide (FMN), phenylmethanesulfonyl fluoride (PMSF), and 
bovine serum albumin (BSA) were purchased from Sigma–Aldrich. Tris base, 
(NH4)2SO4, Hepes, NaH2PO4, and NaCl were purchased from EMD Chemicals. 
Lysozyme, ampicillin, dithiothreitol (DTT), and guanidine–HCl were purchased from 
Bioshop Canada. Routine protein determinations were made using the Lowry assay with 
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a BSA standard. Enzymatic substrates 3-(4,5-dimethylthiozol-2-yl)-2,5-
diphenyltetrazolium (MTT), 1-(3-sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine 
(SCDP), and menadione were purchased from Sigma–Aldrich. 
2.2.2 Cloning and Protein Expression 
Full-length human NQO2 was cloned into the vector pPro-Ex HTa (Invitrogen) to a 
His6–NQO2 fusion construct with a tobacco etch virus (TEV) protease cleavage site 
between the hexahistidine tag and NQO2. The construct was verified by sequencing and 
transformed into an E. coli BL21(DE3) background for protein expression. Cultures were 
grown at 37°C in 2×YT medium with ampicillin (3 mM) to an OD600 of 0.6 to 0.9, and 
induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG, 4.2 mM), cells 
were grown for an additional 4 h. Cells were harvested by centrifugation and resuspended 
in 50mM sodium phosphate, 500 mM NaCl, and 20 mM imidazole (pH 7.0) (buffer A), 
treated with lysozyme (0.1 mg/ml) and PMSF (1 mM), and lysed using a French press at 
10 kPa.  
2.2.3 Protein Purification 
All steps were carried out at 4 °C. The cell lysate was applied to a Chelating Sepharose 
Fast Flow column (5 ml, GE Healthcare) with bound Ni2+ and equilibrated with buffer A. 
The column was washed exhaustively with buffer A, and protein was eluted by raising 
the imidazole concentration to 250 mM. NQO2-containing fractions were treated with 
TEV protease (7) at a 1:100 protease/ protein ratio, including DTT (5 mM), at 4 °C 
overnight. Three further additions of TEV protease and DTT were made at 6-h intervals; 
complete cleavage of the affinity tag was confirmed by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE), and untagged NQO2 was dialyzed into 
50 mM Tris–HCl (pH 8.0) in preparation for anion-exchange chromatography. The 
partially purified NQO2 was applied to a 1.6  × 15-cm column of Q-Sepharose HP (GE 
Healthcare) equilibrated with 50 mM Tris–HCl and eluted with a linear gradient of NaCl 
from 0 to 500 mM over 200 ml. Fractions containing NQO2 were pooled, concentrated to 
5 ml, and applied to a 2.6 × 65-cm column of Superdex 200 (GE Healthcare) equilibrated 
with 50 mM Tris–HCl and 150 mM NaCl (pH 8.0) and running at 2 ml/min. Fractions 
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containing NQO2 were pooled and concentrated to 15 to 35 mg/ml by ultrafiltration. 
Purified NQO2 was aliquoted, flash-frozen, and stored at -80 °C for analysis and 
crystallization.  
2.2.4 Optimization of FAD Content in NQO2 
To remove bound FMN and achieve stoichiometric amounts of bound FAD, the 
purification method outlined above was used with the following changes. Pooled 
fractions from the anion exchange column were concentrated to 5ml (protein 
concentration ~10 mg/ml or 390 µM) and supplemented with guanidine–HCl and FAD to 
final concentrations of 3 M and 10 mM, respectively. The solution was incubated on ice 
for 5 min and applied to the gel filtration column equilibrated with 50mM Tris–HCl, 150 
mM NaCl, and 10 µM FAD (pH 8.0).  
2.2.5 Crystallization, X-ray Diffraction, and Refinement 
NQO2 was crystallized by hanging drop vapor diffusion against reservoirs containing 0.1 
M Hepes and 1.3 to 2.0 M (NH4)2SO4 (pH 7.0). Data were collected at beamline CMCF-1 
of the Canadian Light Source or a laboratory source. Data were processed using 
MOSFLM (8) and Scala (9); structure solution and refinement was carried out using 
PHENIX (10) with 1QR2 (11) as the starting model.  
2.2.6 Determination of Flavin Nucleotide Content in NQO2 
Preparations 
The amounts of NQO2 in the final preparations (Table 1) were determined by amino acid 
analysis (Advanced Protein Technology Centre, Hospital for Sick Children, Toronto, 
Canada, http://www.sic kkids.ca/Research/APTC/Amino-Acid-Analysis/index.html). The 
FAD and FMN contents of NQO2 were quantified by reversed-phase HPLC based on a 
published method (12). To release bound nucleotide, samples of NQO2 were heated to 
100 °C for 10 min and passed through a syringe filter (0.45 µm nominal pore diameter) to 
remove denatured protein. To resolve FAD and FMN, a Symmetry C300 C18 column 
(Waters) was developed isocratically with 10% (by volume) methanol and 10 mM 
ammonium acetate (pH 5.0). The eluent was monitored at 450 nm, and integrated peak 
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areas were calibrated to the amount of flavin nucleotide using a series of 50-µl injections 
of mixtures containing 86 to 860 pmol of FAD and 156 to 1560 pmol of FMN. NQO2 
samples were diluted to a concentration of less than 40µM so that less than 2000 pmol 
FAD/FMN would be sampled in each 50-µl injection.  
2.2.7  Steady-state Kinetic Assay 
Enzyme activity was measured using a coupled assay, where menadione reduced by 
NQO2 subsequently reduces MTT. The assay buffer contained 240 µM (0.1 mg/ml) 
MTT, 500 µM SCDP as co-substrate (13), and 50 µM menadione as substrate. The assay 
was carried out in a 1-ml volume under stirring at 30 °C. The reaction was initiated by 
injection of 2 to 3 ng (1 µl of 2–3 mg/ml) of NQO2-containing solution. The change in 
absorbance was monitored at 610 nm using a Cary 100 spectrophotometer with 
associated kinetics software (Varian Instruments). The change in absorbance was 
converted to moles of menadione reduced per minute using an extinction coefficient for 
MTT of 11.3 × 103 M-1 cm-1.   
2.2.8 B-factor Analysis 
Average atomic displacement factors (ADPs), or B-factors, were calculated using the 
‘‘What If’’ web interface (http://swift.cmbi.ru.nl/servers/html/index.html) and Moleman 
(http://xray.bmc.uu.se/usf/). The average ADPs and normalized ADPs (nADPs) for FAD, 
and the separate FMN and adenosine monophosphate (AMP) moieties, were calculated in 
Excel. Hydrogen atoms were not included in these calculations.  
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2.3 Results 
2.3.1 Expression, Purification, and Crystal Structure Analysis of 
NQO2 
NQO2 was expressed as a hexahistidine-tagged construct with a TEV protease cleavable 
linker. After affinity purification and removal of the affinity tag, NQO2 was purified by 
ion exchange and gel filtration chromatography. Analysis of the final preparations by 
SDS–PAGE indicated that the affinity tag had been removed and the protein was greater 
than 90% pure (Figure 2.1). This method of purification yielded NQO2 that readily 
formed crystals diffracting to high resolution. For preparation 1, the refined structure 
yielded excellent agreement with crystallographic data and good stereochemical 
parameters (Table 2.1). However, the average ADP for the FAD co-enzyme was 40.4Å2, 
nearly double the average ADP for protein atoms (22.3 Å2) and higher than the average 
solvent ADP (30.5 Å2). Closer analysis showed that the FAD could be divided into FMN 
and AMP on  the basis of average ADP values of 28.2 and 57.2 Å2, respectively (Table 
2.1). Consistent with these high ADPs, electron density for the isoalloxazine ring and 
associated ribityl was relatively weak and discontinuous and was almost absent for the 
AMP moiety (Figure 2.2A).  
 
Figure 2.1 SDS-PAGE Analysis of Purified NQO2.  
The final preparation 1 (left lane) and preparation 2 (right lane) were analyzed, and the 
positions of molecular weight markers (kDa) are shown.  
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Table 2.1 Crystallographic Data and Refinement 
 NQO2 Preparation 1 NQO2 Preparation 2 
Wavelength (Å) 0.9791 1.5418 
Space Group P212121 P212121 
Unit Cell Dimenstions (Å) 55.95, 83.15, 106.57 56.45, 82.99,106.49 
Resolution 35.5 - 1.84 (1.94 - 1.84)a 15.0 - 1.96 (2.07 - 1.96)a 
Rsym  0.050 (0.168)a 0.066 (0.273)a 
I/σ(I) 24.8 (9.8) 14.8 (4.8) 
Completeness 99.1 (94.6) 97.7 (95.7) 
Redundancy 7.3 (6.6) 4.0 (3.9) 
Unique Reflections 55611 34670 
Rwork/Rfree 0.184/0.218 0.158/0.211 
Ramachandran Plotb (%)   
     Most Favoured 89.2 89.7 
     Additionally Allowed 10.3 9.8 
     Generously Allowed 0.5 0.5 
     Disallowedb 0 0 
RMS Deviations   
     Bond Lengths (Å) 0.018 0.018 
     Bond Angles (degrees) 1.795° 1.665° 
     Dihedral Angles (degrees) 17.7° 19.1° 
Mean B values (Å2)   
     Protein All Atoms 22.3 19.3 
     Main Chain Atoms 20.8 17.7 
     Side Chain Atoms 23.5 20.6 
     Solvent 30.5 27.5 
     FAD 40.4 20.4 
     FMN 28.2 13.9 
     AMP 57.2 29.3 
a Values in parentheses represent the highest resolution shell 
b As defined in Procheck (14). 
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Figure 2.2 Electron Density Maps for FAD in NQO2 Preparations. 
Electron density maps (2Fo-Fc, contoured at 1.2 𝜎) are shown for the FAD molecule in 
refined NQO2 crystal structures from preparation 1 (A), which contained 0.32 
equivalents of FMN per protomer, and preparation 2 (B), which was saturated with FAD. 
Crystallographic data and refinement statistics for the two structures are provided in 
Table 2.1. 
2.3.2 Analysis and Optimization of FAD Content of NQO2 
The relatively high ADPs and weak electron density for the bound co-enzyme prompted 
us to measure the flavin content of the NQO2 preparation. Using HPLC, FAD was not 
detectable in preparation 1; instead, 0.38 equivalents of FMN were present per NQO2 
protomer (Table 2). We attempted to increase the FAD content of the enzyme by simply 
adding 100 µM FAD to the protein solution obtained after Ni2+-NTA (nitrilotriacetic 
acid) affinity chromatography, which increased the amount of bound FAD but failed to 
exchange FAD for FMN (data not shown). We also attempted, unsuccessfully, to 
exchange FMN for FAD by gel filtration chromatography in the presence of 10 µM FAD 
(data not shown). The expected KD for flavin co-enzymes is in the mid- to low-nanomolar 
range (15) and a very slow rate of exchange is consistent with our inability to displace 
bound FMN. To facilitate rapid exchange of bound FMN with FAD, guanidine was 
included in the buffer to partially denature the protein (15); NQO2 was incubated briefly 
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on ice in a solution of 3 M guanidine–HCl along with a high concentration (10 mM) of 
FAD and then gel-filtered in a nondenaturing buffer (preparation 2) (Figure 2.1 and Table 
2.2). NQO2 prepared in this manner is fully saturated with FAD, and crystals formed 
from this preparation yield structures with relatively low ADPs for the bound FAD 
(Table 2.1). Electron density maps for the refined structure are strong and continuous for 
the entire FAD molecule (Figure 2.2B).  
2.3.3 Spectroscopic Properties of NQO2 
The absorption spectrum of NQO2 that is fully saturated with FAD (preparation 2) is 
provided in Figure 2.3 along with the absorption spectrum for preparation 1, which had 
0.38 equivalents of FMN per protomer and no FAD. The two spectra have been adjusted 
to represent a solution of NQO2 at a concentration of 1 mg/ml. At wavelengths above 
320nm, the spectra appear to be qualitatively similar and are characteristic of the oxidized 
flavin (16). The peak at 450 nm has absorbance of 0.20 and 0.52 for preparations 1 and 2, 
respectively, roughly in line with the relative flavin contents of the two preparations 
determined by HPLC (Table 2.2).  
 
Figure 2.3 Absorbance Spectra of NQO2 Preparations 1 and 2. 
Shown are the absorbance spectra for NQO2 preparation 1, with 0.38 equivalents of 
FMN (gray curve), and preparation 2, which is fully saturated with FAD (black curve). 
The curves have been scaled to represent the proteins at a concentration of 1 mg/ml.  
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Table 2.2 Flavin Co-enzyme Content of QR2 Preparations 
 Fractional Flavin Saturationa kcatb  (s-1) 
Preparation FMN FAD Total  
1c 0.38 ± 0.03 0 0.38 ± 0.03 31 ± 1 
2d 0 1.2 ± 0.1 1.2 ± 0.1 39 ± 3 
aAverage ± S.D. for three determinations. 
bAverage ± S.D. for four determinations with 500 µM SCDP as co-substrate and 50 µM 
menadione as substrate. 
c protein purification was unmodified 
d protein purification was modified by incubation with 3M guanidine and 10mM FAD 
prior to gel filtration
At wavelengths in the UV, the presence of the adenine ring in the bound FAD of 
preparation 2 increases the absorption of the complex and blue-shifts its maximum from 
280 to 273 nm compared with preparation 1, which contains only FMN. NQO2 that is 
fully saturated with FAD has an absorption maximum of 273 nm with an absorbance (1 
mg/ml solution) of 3.73, yielding an extinction coefficient at 273 nm of 1.06 × 105 M-1 
cm-1 with an A273/A450 ratio of 7.2. The extinction coefficient at 280 nm is slightly lower 
at 1.02 × 105 M-1 cm-1 with an A280/A450 ratio of 6.9. Together, the absorption maximum at 
273 nm with an A273/ A450 ratio of 7.2 should be a reasonably good indicator that an 
NQO2 preparation is fully saturated with FAD. Note that if one is not concerned with the 
nature of the bound flavin—whether FMN or FAD—the flavin content of NQO2 can be 
determined spectrophotometrically by denaturation of a known amount of NQO2 with 
0.2% SDS and then measure the liberated total flavin (as FMN and/or FAD) at 473 nm, 
where the two have the same extinction coefficient of 9200 M-1 cm-1 (12).  
2.3.4 FAD B-Factors and Occupancy in NQO2 Crystal Structures 
In the NQO2 crystals from preparation 2, which is saturated with FAD, the FMN moiety 
exhibits average ADPs that are significantly lower than the average ADPs for the protein 
(13.9 Å2 for FMN moiety vs. 19.3 Å2 for all protein atoms), whereas the AMP portion has 
average ADPs that are close to those of the bound solvent (29.3 Å2 for the AMP moiety 
vs. 27.5 Å2 for bound solvent). Because there is no difference in the occupancy in this 
case (i.e., there is no free FMN associated with the protein according to the HPLC 
analysis), the difference in ADPs must be due to increased motion or disorder in the AMP 
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portion of FAD. This is consistent with a surface accessibility calculation showing that 
less than 14% of the FMN portion is accessible to solvent compared with just over 27% 
for the AMP portion.  
The FAD ADP analysis was extended to NQO2 structures deposited in the Protein Data 
Bank (as of March 2011). To make comparisons of ADP between different structures, the 
ADPs were normalized to the protein ADP (nADP) (17); an nADP is equal to the 
difference between the ADP of the atom in question and the average ADP for the protein 
divided by the standard deviation of the protein ADPs. Thus, nADPs have a mean of 0 
and a standard deviation of 1, facilitating comparisons between structural models refined 
against different crystallographic datasets. The average nADP for the entire FAD 
molecule ranges from 0 to 3 for the available NQO2 structures (Figure 2.4, bottom 
panel). Each structural model incorporates FAD at full occupancy (i.e., an occupancy of 1 
in the coordinate file). Given that bacterial cultures can become depleted in FAD during 
protein overexpression, the most likely explanation for the range of nADPs for the FAD 
moiety is that the structures have sub-stoichiometric amounts of FAD and/or are 
populated by FMN in place of FAD. For example, in the case of the NQO2 preparations 
we have examined, the nADP for FAD in crystals from preparation 1, with only 0.38 
equivalents of FMN per subunit, was roughly 1.4 compared with an nADP of 0 for 
preparation 2, which was fully saturated with FAD.  
The FAD in these structures was further analyzed by dividing it into FMN and AMP 
portions (Figure 2.4, top and middle panels, respectively). Most of the structures, 
including that derived from NQO2 preparation 2 (this study), had negative values for the 
normalized ADP of FMN, indicating that its overall ADP is lower than the average for 
the protein. Based on these observations and the known FAD content of preparation 2, it 
is possible that structures with normalized ADPs above approximately -0.5 for the FMN 
portion have less than a full equivalent of bound co-enzyme. Similarly, for the AMP 
portion, a normalized ADP above approximately 1 may be due to the presence of FMN 
rather than FAD and/or the presence of apo protomers.
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Figure 2.4 nADP Distribution for FAD in NQO2 Crystal Structures. 
The average nADPs for the FAD molecules in available NQO2 crystal structures are 
shown in the bottom panel. Also shown are the average nADPs for the FMN and AMP 
portions (top and middle panels, respectively). All of the crystal structures except 3FW1 
were in space group P212121 with an NQO2 dimer in the asymmetric unit; the gray and 
black bars represent the A and B chains of the dimmer, respectively. 3FW1 was 
crystallized in space group I422 with one protomer in the asymmetric unit. The structures 
are described in the following references: 1QR2 and 2QR2, Foster and coworkers (11); 
2QWX, 2QX4, 2QX6, 2QX8, and 2QX9, Calamini and coworkers (18); 1XI2, Fu and 
coworkers (19); 3GAM and 3G5M, Maiti and coworkers (20); 2BZS, Abu Khader and 
coworkers (21); 2QMY and 2QMZ, Fu and coworkers (22); 1SG0, Buryanovskyy and 
coworkers (23); and 3FW1, Winger and coworkers (24). 
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2.4 Discussion 
It can be difficult to achieve stoichiometric ligand occupancy in protein crystals because 
the crystallization conditions often include high concentrations of salts and other 
molecules that can compete with and/or weaken the binding of the ligand. The result is 
that ligand will be present at partial occupancy, which manifests itself during refinement 
as elevated ADPs and relatively poor electron density for the ligand. This problem is 
compounded in NQO2 because the FAD co-enzyme itself is noncovalently bound. 
Ligands that bind tightly to NQO2 generally contain a planar polyaromatic moiety that 
stacks on the isoalloxazine ring of FAD; therefore, if the FAD co-enzyme itself is present 
at less than 1:1 stoichiometry, obtaining crystals with a full ligand occupancy will be 
impossible and the electron density for the bound ligand will be relatively poor.  
Flavin synthesis in E. coli is sufficient to support exponential growth and continues for 
up to 2 h after reaching stationary phase (25). However, overexpression in E. coli of 
FAD-containing proteins such as NQO2 can result in depletion of the flavin pool and/or 
insufficient production of FAD from FMN, leading to production of proteins with sub-
stoichiometric amounts of bound FAD. E. coli does not have the genes required for flavin 
import (26, 27); therefore, the addition of riboflavin to the culture medium will not solve 
this problem. Attenuating the expression of the recombinant gene by using a weak 
promoter or a lower concentration of IPTG improved the production of holo-
glycerophosphate oxidase (28), another FAD-linked enzyme. On this basis, differences in 
the expression vector and/or culture conditions could result in varying proportions of the 
FAD-bound, FMN-bound, and apo NQO2 enzymes that cannot be distinguished by 
conventional chromatographic techniques. This might explain some of the variation seen 
in NQO2 crystal structures available in the Protein Data Bank.  
We wanted large quantities of NQO2 for structural studies, and because the apo form of 
NQO2 appears to be quite stable, our approach was to saturate NQO2 with FAD after 
overexpression and partial purification. To effect full exchange of FMN with FAD, 
NQO2 was incubated for a short time with a high concentration of FAD under partially 
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denaturing conditions (3 M guanidine at 4 °C) and then gel-filtered to rapidly remove the 
denaturant and unbound FMN. This simple procedure yielded NQO2 that was fully 
saturated with FAD and easily crystallized. We are currently using enzyme prepared in 
this manner to obtain structures of NQO2 in complex with new ligands, and it is clear 
that fully saturating NQO2 with FAD has markedly improved the quality of the electron 
density maps.   
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Chapter 3  
3 Chloroquine Binding Reveals Flavin Redox Switch 
Function of Quinone Reductase 25 
Quinone reductase 2 (NQO2) is an FAD-linked enzyme and the only known human 
target of two antimalarial drugs, primaquine (PQ) and chloroquine (CQ). The structural 
differences between oxidized and reduced NQO2 and the structural basis for inhibition by 
PQ and CQ were investigated by x-ray crystallography. Structures of oxidized NQO2 in 
complex with PQ and CQ were solved at 1.4 Å resolution. CQ binds preferentially to 
reduced NQO2, and upon reduction of NQO2-CQ crystals, the space group changed from 
P212121 to P21, with 1-Å decreases in all three unit cell dimensions. The change in crystal 
packing originated in the negative charge and 4–5º bend in the reduced isoalloxazine ring 
of FAD, which resulted in a new mode of CQ binding and closure of a flexible loop 
(F126 – L136) over the active site. This first structure of a reduced quinone reductase 
shows that reduction of the FAD cofactor and binding of a specific inhibitor lead to 
global changes in NQO2 structure and is consistent with a functional role for NQO2 as a 
flavin redox switch. 
3.1 Introduction 
Despite 6 decades of routine use in treating malaria, the pharmacologic mechanisms of 
primaquine (PQ) and chloroquine (CQ) are not completely understood, although it is 
known that the two antimalarial drugs work at different stages of the Plasmodium life 
cycle. Malaria begins when Plasmodium sporozoites gain entry to the bloodstream via a 
bite from an infected mosquito, after which the parasite infects liver cells. During this 
liver stage infection, the 8-aminoquinoline, PQ (Figure 3.1), acts as hepatic schizontocide 
to clear infection (1). If left untreated, the parasites mature into merozoites and are 
                                                
5 This chapter has been published: Leung, K.K., and Shilton, B.H. (2013) Chloroquine binding 
reveals flavin redox switch function of quinone reductase 2. The Journal of Biological 
Chemistry, 288(16), 11242–51.  
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released into the bloodstream to infect erythrocytes. In erythrocytes, the parasites either 
spawn into more merozoites or mature into gametocytes capable of infecting mosquitoes 
through additional bites. During the erythrocytic stage of infection, the 4-aminoquinoline, 
CQ (Figure 3.1), acts as a blood schizontocide to clear infection (2). As such, PQ and CQ 
are routine medications for treating malaria. In recent years, however, the emergence of 
chloroquine-resistant Plasmodium falciparum has rendered CQ ineffective in most 
endemic areas. PQ, on the other hand, is still widely used as a prophylaxis of malaria 
because parasites rarely exhibit resistance against this drug.  
 
Figure 3.1 Structures of Primaquine and Chloroquine 
Primaquine (left) and chloroquine (right) are two antimalarial drugs that act at different 
stages of the Plasmodium life cycle.  
In terms of therapeutic mechanisms, PQ is thought to work by generating toxic oxygen 
species via its reactive metabolites (3). CQ, on the other hand, is thought to prevent a 
detoxification of excess heme in the parasite, which is generated as a result of its 
metabolism of hemoglobin (3). Despite these findings, no protein target has been 
identified for either drug in the parasite, causing some controversy about the mode of 
action of the two drugs (4, 5). This led Graves and coworkers (6) to search for target 
proteins of CQ and PQ using a proteomics approach. Surprisingly, no parasitic protein 
targets were identified; instead, two human proteins present in infected erythrocytes, 
quinone reductase 2 (NQO2) and aldehyde dehydrogenase 1, were identified. Of the two 
proteins, NQO2 was potently inhibited by concentrations of the quinoline drugs used in 
clinical treatment, whereas aldehyde dehydrogenase 1 was not. It is not known whether 
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the inhibition of NQO2 by PQ and/or CQ plays a role in the antimalarial effects of the 
drugs. 
The identification of NQO2 as a human target of PQ and CQ is intriguing because both 
drugs are used to treat non-malarial diseases. For instance, PQ is used to treat 
pneumocystis pneumonia and is active against leishmaniasis and trypanosomiasis in vivo 
(7–9). Similarly, CQ is used to treat rheumatoid arthritis, systemic lupus erythematosus, 
and amoebic hepatitis; is under clinical trials for use in HIV-1/AIDS; and is being 
investigated for use in cancer chemotherapy (10–12). Thus, the inhibition of NQO2 may 
contribute to the therapeutic effects of PQ and CQ against diseases other than malaria. 
NQO2 is a cytosolic and ubiquitously expressed metalloflavoprotein that catalyzes the 
two-electron reduction of quinone substrates. It has been the subject of extensive study 
over the last 15 years and binds a number of bioactive compounds, including imatinib 
(13, 14), inhibitors against CKII and PKC (15, 16), resveratrol (17), and melatonin (18, 
19); however, the only natural substrate identified is ubiquinone, and the physiological 
function of NQO2 is not understood (20). NQO2 is a member of the thioredoxin family 
of enzymes but is unique in that it uses dihydronicotinamide riboside (NRH) as a 
reducing co-substrate rather than NADH or NADPH. The oxidized form of the co-
substrate, nicotinamide riboside, is involved in NAD metabolism (21), but the cellular 
source of the reduced form, NRH, is not known, and it is not clear why NQO2 has 
evolved to use NRH. In addition to an enzymatic role in quinone reduction, NQO2 
stabilizes the p53 tumor suppressor against 20S proteasomal degradation in the presence 
of NRH (22, 23).  Furthermore, NQO2 is capable of generating reactive oxygen species 
(24). Yet the current understanding of NQO2 and its inhibition does not adequately 
explain the effects of PQ and CQ on malaria and non-malarial diseases.  
PQ and CQ inhibit NQO2 with different mechanisms. Kinetic studies show that PQ and 
CQ both inhibit NQO2 in the micromolar range, with KI values of 1.0 and 0.6 µM, 
respectively (25), but PQ exhibits competitive inhibition against the reducing co-substrate 
(NRH), whereas CQ competes with the quinone substrate. This pattern of inhibition can 
be explained by the ping-pong kinetic mechanism that NQO2 uses. The tightly bound 
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FAD co-enzyme is first reduced by NRH to FADH2; nicotinamide riboside is replaced by 
the quinone substrate, which is then reduced by FADH2. As such, NQO2 can exist as 
either the oxidized (NQO2ox) or reduced (NQO2red) form, and inhibitors may have a 
higher affinity for one or the other.  
To provide a structural basis for the difference in specificity between PQ and CQ, we 
solved high resolution crystal structures of NOQ2ox in complex with either PQ or CQ as 
well as NQO2red in complex with CQ. The NQO2red-CQ complex is particularly 
interesting because CQ is present in a completely different orientation compared with the 
NQO2ox-CQ complex and this difference in binding is accompanied by movement of an 
active site loop, a change in crystal packing, and a change in space group symmetry. The 
structure of the NQO2red-CQ complex provides support for the idea that, in common with 
some other flavin-containing proteins (26), NQO2 acts as a redox-sensitive “switch” that 
is responsive to the presence of cellular NRH in conjunction with binding of certain 
bioactive compounds. 
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3.2 Methods 
3.2.1 Protein expression and Purification 
Recombinant NQO2 was expressed in Escherichia coli and purified as described 
previously (27). A critical step in the purification was full reconstitution of the enzyme 
with the FAD cofactor. When expressed in E. coli, recombinant NQO2 typically contains 
substoichiometric levels of flavin mononucleotide (FMN) and no FAD. A partial 
denaturation of NQO2 and reconstitution with FAD was incorporated into the 
purification procedure, leading to full saturation of the enzyme with FAD, as reported 
previously (27). 
3.2.2 Crystallization of NQO2 
NQO2ox was co-crystallized with 1 mM PQ or CQ by hanging drop vapor diffusion 
against reservoirs containing 0.1 M HEPES, pH 7.5, and 1.3–2.0 M (NH4)2SO4. To 
prepare NQO2red-CQ crystals, crystals of NQO2-CQ were soaked in 1 µl of reducing-
soak solution consisting of 0.1 M HEPES, pH 7.5, 2.0 M (NH4)2SO4, 10 mM 1-(3-
sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine (SCDP; an NRH analog), and 1 
mM chloroquine, for 2 min; the soak was repeated until crystals turned pale yellow. 
Whereas larger rod shaped crystals (0.5 mm × 0.2 mm) cracked when introduced into the 
reducing soak, medium size crystals (0.3 mm × 0.1 mm) remained intact. The reduced 
crystals were transferred to a soak of 1 mM chloroquine, 2.0 M (NH4)2SO4, 0.1 M 
HEPES, pH 7.5, to decrease the of the amount of SCDP, which may be competitive with 
CQ at high concentrations. Crystals were then briefly passed through a cryoprotectant 
solution (20% glycerol, 2.0 M (NH4)2SO4, 0.1 M HEPES, pH 7.5) and plunged into liquid 
nitrogen. To prevent autoxidation of NQO2, the entire crystal mounting process from 
harvesting to cryocooling was performed under an anoxic atmosphere in a glove bag 
purged with N2. To prepare for the reduction protocol, the glove bag was initially 
evacuated and flushed with nitrogen for 5 min. All soaking solutions were then 
deoxygenated by sparging with nitrogen gas inside the glove bag. In the dry nitrogen 
atmosphere, crystals and crystal soak solutions quickly evaporated; therefore, to maintain 
an appropriate level of humidity, the nitrogen used to flush the glovebag was bubbled 
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through a flask of crystallization reservoir solution (0.1 M HEPES, pH 7.5, 2.0 M 
(NH4)2SO4).  
3.2.3 X-ray Data Collection, Refinement, and Analysis 
Data were collected at the CMCF-1 beamline of the Canadian Light Source, processed 
using XDS (28) or MOSFLM (29), and merged using Scala (30). The structures were 
solved by molecular replacement with Protein Data Bank entry 1QR2 as a starting model 
(31); refinement was carried out using PHENIX (32). Given the high resolution of the 
crystallographic data, NCS restraints were not used for any of the refinements. 
Topology files for PQ and CQ were generated using PHENIX.ELBOW in conjunction 
with small molecule crystal structures of the two compounds (33, 34). For refinement of 
the NQO2red structure, the FAD topology file was modified to allow bending along the 
N5–N10 axis of FAD: the planarity restraints incorporating N5 and N10 of the 
isoalloxazine ring were removed so that it was separated into two planes, one 
incorporating the pyrimidine ring and the second incorporating the benzyl ring. Also, the 
bond length, bond angle, and dihedral angle restraints involving N5 and N10 were 
removed. The degree of bending in the isoalloxazine ring was calculated by finding 
equations for the two planes using principal component analysis incorporating all atoms 
in each of the two planes. The final structures for NQO2ox-PQ, NQO2ox-CQ, and 
NQO2red-CQ were deposited in the Protein Data Bank as 4FGJ, 4FGK, and 4FGL 
respectively.  
To validate the observed changes in FAD structure and, in particular, to assess the 
contribution of the FAD and FADH2 stereochemical restraint files to the structure of the 
isoalloxazine ring, each model was refined using an identical simulated annealing 
strategy with the FADH2 stereochemical restraint file to assess the degree of bending 
along the N5–N10 axis. In each case, the refinement was performed three times using the 
same starting model with a different random seed to calculate a final average bending 
angle. To ensure an “active” convergence to an optimal conformation, FAD in the 
starting model of NQO2 was bent to an angle of around 30°. 
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3.3 Results 
3.3.1 Oxidized NQO2-Primaquine Complex 
NQO2 was co-crystallized with PQ in space group P212121. Crystals of NQO2-PQ 
diffracted to 1.35 Å and contained a homodimer in the asymmetric unit; the structure was 
solved by molecular replacement and refined to an Rfree value of 0.167 (Table 3.1). 
Primaquine was initially modeled in a single orientation in both active sites of the 
homodimer (Figure 3.2A), and after several rounds of refinement, a second orientation 
was incorporated to fully account for the electron density (Figure 3.2B). The occupancies 
for bound PQ molecules refined to values of around 0.5 for each of the conformations, 
indicating that PQ binds with roughly equal affinity in each mode. In both orientations, 
the quinoline ring of PQ is buried in the active site, making planar stacking interactions 
with the FAD isoalloxazine ring and the phenyl ring of F178. PQ also makes contact with 
additional aromatic residues (W105, F106, and F126), which form the interior wall of the 
active site. As well, both orientations of PQ make a water-mediated hydrogen bond with 
the side chain of Asn161. In the first orientation of PQ (Figure 3.2A), a water molecule 
(position 557 in A chain and 450 in B chain) mediates hydrogen bonding between the 
aromatic nitrogen in the quinoline ring and the side chain of N161. In the alternate 
orientation (Figure 3.2B), the quinoline ring is flipped 180°, and the water molecule 
mediates a hydrogen bond between the 6-methoxy group of PQ and the side chain of 
N161. 
3.3.2 Oxidized NQO2-Chloroquine Complex 
NQO2 catalysis proceeds by a ping-pong mechanism. The reducing co-substrate, NRH, 
binds in the active site, reduces the FAD, and then dissociates; the quinone substrate then 
enters the active site and undergoes a two-electron reduction. Thus, NQO2 can exist in 
either an oxidized (NQO2ox) or reduced (NQO2red) state, and inhibitors of NOQ2 will 
exhibit a preference for one or the other. Kinetic studies indicate that CQ exhibits 
competitive inhibition against the quinone substrate and therefore binds preferentially to 
NQO2red (25). However, high concentrations of CQ will also compete against the 
reducing co-substrate, NRH, indicating that CQ also has affinity with NQO2ox. To fully 
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characterize CQ binding to NQO2, we co-crystallized NQO2ox in complex with CQ. 
NQO2ox-CQ crystals diffracted to 1.4 Å, and the structure was refined to an Rfree of 0.175 
(Table 3.1). 
 
Table 3.1 Crystallographic Data Collection and Refinement Statistics. 
Crystal Oxidized NQO2 Reduced NQO2 
Ligand Primaquine Chloroquine Chloroquine 
Wavelength (Å) 1.033217 1.033217 0.97949 
Space Group P212121 P212121 P21 
Unit Cell Dimensions (Å) 
56.5, 83.0, 
106.5 
56.37, 83.11, 
106.60 
54.31, 105.71, 
82.00 
β = 90.17° 
Resolution 30.1 - 1.35 32.7 - 1.40 48.3 - 1.20 
aRsym  0.066 (0.63) 0.065 (0.50) 0.041 (0.288) 
aI/σ(I) 10.4 (2.4) 14.5 (3.7) 19.3 (4.4) 
aCompleteness 99.5 (98.8) 99.6 (99.0) 99.8 (99.9) 
Redundancy 4.8 7.3 3.7 
Unique Reflections 110793 98537 287298 
Rwork/Rfree 0.1413/0.1666 0.1325/0.1745 0.1059/0.1362 
Ramachandran Plotb (%) 
     Most Favoured 
     Additionally Allowed 
     Generously Allowed 
     Disallowed 
 
90.7 
8.8 
0.5 
0 
 
89.9 
9.5 
0.5 
0 
 
89.9 
9.6 
0.4 
0.1 
RMS Deviations 
     Bond Lengths (Å) 
     Bond Angles (deg) 
     Dihedral Angles (deg) 
 
0.008 
1.255 
14.594 
 
0.007 
1.223 
14.471 
 
0.009 
1.174 
14.188 
Mean A.D.P. values (Å2) 
     Protein All Atoms 
     Main Chain  
     Side Chain  
     Solvent 
     FAD 
     Inhibitor 
 
12.8 
11.7 
13.8 
25.0 
12.3 
17.5 
 
18.1 
16.3 
19.6 
28.6 
17.3 
26.3 
 
12.7 
11.3 
13.8 
25.3 
11.4 
22.1 
a Values in parentheses refer to the highest resolution shell. 
b Ramachandran plot statistics were calculated using PROCHECK (35). 
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Figure 3.2 Binding of Primaquine and Chloroquine to Oxidized NQO2 
(A - B) PQ is bound to the A subunit in two alternate conformations. The B subunit of the 
NQO2ox-PQ homodimer contained similar electron density and was modeled in the same 
way as the A subunit. (C - D) The active sites for the NQO2 ox -CQ structure. Electron 
density in the NQO2 ox-CQ subunit A (C) was different from that observed in the B 
subunit (D), and CQ was modeled in two alternate conformations in the B subunit. The 
electron density represents the final 2Fo - Fc maps contoured at 1σ around the inhibitors. 
(E) The two positions of CQ in the B subunit correspond to two different conformations 
of the active site loop, comprising residues 126 –136. The active site loop in the “open” 
conformation (light shading) accommodates CQ when it is deeply buried in the active 
site, whereas the “closed” conformation (dark shading) is adopted when CQ is bound in a 
more peripheral location. One-letter amino acid codes are used.  
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Electron density for the bound CQ was initially quite poor, but a large peak (greater than 
10 σ) in the difference (Fo - Fc) electron density map was used to position the CQ 
chlorine atom, after which the rest of the CQ molecule was placed in the remaining 
electron density. For the “A” subunit of the homodimer, CQ is present in one position, 
with the quinoline ring less deeply buried than primaquine and the aminopentane arm 
projecting toward the solvent (Figure 3.2C). In the active site of the “B” subunit, 
additional difference density was observed after several rounds of manual adjustment and 
refinement, and an alternate orientation of CQ was modeled into the structure (Figure 
3.2D). The occupancies for the two modes of CQ binding to the B subunit refined to 0.52 
and 0.48. In conjunction with these two positions for CQ, an active site loop consisting of 
residues 126–136 was modeled in two different conformations (Figure 3.2E). In the 
position of CQ unique to the B subunit, in which the quinoline ring is more deeply buried 
in the active site, the bulky aminopentane arm of CQ interferes with the ability of the 
126– 136 loop to close over the active site, and therefore the loop adopts an “open” 
conformation (Figure 3.2E). There is no evidence of cooperative interactions or 
nonequivalence between the two subunits of NQO2, and therefore this minor difference 
in CQ binding between the A and B subunits probably originates from different crystal 
packing environments.  
3.3.3 Reduced NQO2-Chloroquine Complex 
The reduced form of NQO2 (NQO2red) was not sufficiently stable to allow for co-
crystallization with CQ. To obtain crystals of NQO2red in complex with CQ, crystals of 
NQO2ox-CQ were treated with SCDP (an NRH analog) in an anoxic environment until 
the crystal was bleached, indicating reduction of FAD to FADH2, and then frozen and 
stored in liquid nitrogen for data collection. Data from three such crystals of NQO2red-CQ 
were collected and processed (Table 3.2). In all three cases, the crystallographic data for 
NQO2red could be processed using the P212121 space group, with unit cell dimensions ~1 
Å shorter in all three directions compared with those for NQO2ox-CQ. However, data 
processed in P212121 yielded unacceptably high Rsym values, making it clear that the 
crystals had undergone a structural transition to a lower symmetry space group with four 
rather than two protomers in the asymmetric unit. Data processed and merged in P21 
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yielded acceptable Rsym values (Table 3.2), and the highest resolution data set was used 
for refinement and analysis (Table 3.1). The NQO2 structure underwent several rounds of 
manual rebuilding and refinement to yield an Rfree of 0.17. Analysis of the 
crystallographic data indicated the presence of pseudomerohedral twinning, and further 
refinement in Phenix using the twin operator (h, - k, -l) yielded an estimated twin fraction 
of 0.15, with a final Rfree value of 0.136 and improved electron density maps. This is the 
first structure of a reduced quinone reductase, and the combined effects of FAD reduction 
and chloroquine binding are described below.  
3.3.4 Chloroquine Binding to Reduced NQO2 
The reduced isoalloxazine ring is expected to be deprotonated and carry a negative 
charge when it is bound to NQO2. In solution, N1 of FADH2 exhibits a pKa of 6.8 (36); 
when FAD is bound to NQO2, N1 accepts a hydrogen bond from the amide nitrogen of 
G149, making it highly unlikely that N1 is protonated in NQO2red. Instead, the negative 
charge, which would be delocalized between N1 and O2, is neutralized by two hydrogen 
bonds donated to O2, one from the ring hydroxyl of Y155 and a second from the amide 
of G150.  
Table 3.2 Space Group Change upon Reduction of NQO2-chloroquine Crystals 
 Crystal 1a  
(1.24 Å resolution) 
Crystal 2a  
(1.35 Å resolution) 
Crystal 3a,b  
(1.15 Å resolution) 
 P212121c P21c P212121c P21c P212121c P21c 
Unit Cell 
     a 
     b 
     c 
     β 
 
53.75 
81.68 
105.67 
90 
 
53.67 
105.61 
81.68 
90.14 
 
53.90 
81.84 
105.66 
90 
 
53.68 
105.56 
81.66 
90.35 
 
54.24 
82.02 
105.71 
90 
 
54.29 
105.71 
82.01 
90.16 
Rsym 0.171 0.070 0.327 0.061 0.347 0.061 
a Crystals of NQO2ox in complex with chloroquine were soaked with SCDP, an NRH 
analogue, to effect reduction of the FAD cofactor. 
b Crystal 3 was used for structure solution, refinement, and detailed analysis. 
c Data were indexed, processed and merged in either P212121 or P21 using Mosflm and 
Scala.  
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Reduction of FAD drastically changes the nature of its interaction with CQ. In NQO2ox, 
CQ tends to be rather deeply buried and able to make direct contact with aromatic 
residues that line the back wall of the active site (Figure 3.2C), with the chlorine atom 
positioned above C5A of the isoalloxazine ring. In the NQO2red structure, the quinoline 
ring of CQ has flipped so that the opposite face interacts with the surface of reduced 
FAD, and the chlorine atom is positioned roughly above O2 on the periphery of the 
isoalloxazine ring (Figure 3.3A-B). The mode of CQ binding in NQO2red allows CQ to 
participate in a water mediated hydrogen-bonding network that is centered on the proton 
on N5, a characteristic feature of reduced FAD (Figure 3.3C). The keystone for this 
network is a water molecule (HOH 32, 312, 204, and 92 in chains A, B, C, and D, 
respectively) that accepts hydrogen bonds from the N5 proton of FAD and also from the 
proton on N4 of the CQ quinoline ring. The keystone water donates a hydrogen bond to a 
second water molecule (HOH 149, 154, 157, and 63 in chains A, B, C, and D, 
respectively) that in turn donates hydrogen bonds to O4 of the FAD and to the carbonyl 
oxygen of G174. The relative positions of these water molecules are conserved in all four 
subunits of the asymmetric unit. The geometry of the interaction between the keystone 
water and the FAD N5 atom deviates from what would be expected for a good hydrogen 
bond; the angle between CQ-N4, the keystone water, and FAD-N5 is 79 ± 1° (mean ± 
S.D. for four subunits) rather than a more typical angle of 110°. In addition to these 
hydrogen bonds, the aromatic rings of W105, F106, F126, and F178 enclose the two 
water molecules; indeed, the keystone water appears to donate a hydrogen bond to the 
indole ring of W105, whereas the second water may donate a hydrogen bond to the 
benzene ring of F178 (37).  
The 2Fo - Fc electron density for bound CQ is extremely well defined in one of the NQO2 
dimers (C and D chains) of the asymmetric unit, and there is clear density for a third 
water molecule in the active sites of the CD dimer (Figure 3.3B). This third water 
molecule donates a hydrogen bond to the second water and to the chlorine atom on CQ, 
and it accepts a hydrogen bond from the side-chain amide nitrogen of N161. In the 
second dimer (A and B chains) of the asymmetric unit, there was additional electron 
density for the bound CQ, and therefore a second CQ molecule was included in a slightly  
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Figure 3.3 Binding of Chloroquine to reduced NQO2. 
(A-B) CQ binds NQO2red active sites in the two dimers of the asymmetric unit; the electron 
density corresponds to 2Fo - Fc maps contoured at 1σ around CQ. (A) In the active site of the A 
subunit, CQ bound in two alternative positions, one of which corresponds to the position 
observed in the C and D subunits, whereas the second is shifted slightly. The electron density and 
positions of bound CQ were similar for the B subunit. (B) In the active site of the C subunit, CQ 
was modeled in the same single position. The electron density in the D subunit was similar. (C) 
The hydrogen bonding network, with the “keystone water” bridging N4 of CQ and N5 of the 
FAD isoalloxazine ring. (D) The active site loop (residues 126–136) is shown in the fully closed 
conformation (green) observed in NQO2red-CQ; in this state, residue I128 makes van der Waals 
contact with CQ. For reference, the conformations of the loop observed in crystals of oxidized 
NQO2 are shown in gray. 
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different orientation from the first (Figure 3.3A). For the A and B subunits, the third 
water molecule was not present. This minor difference in CQ binding between the two 
reduced NQO2 dimers in the asymmetric unit may be a product of their interaction with 
each other or may be due to differences in the surrounding crystal packing environment.  
Regarding the stereochemistry of the bound inhibitors, it is noteworthy that both CQ and 
PQ have a single stereocenter and exist as racemic mixtures. For the structures of 
NQO2ox with bound PQ or CQ, the electron density for the aminopentane arm was 
generally weak, and it was not possible to discern whether the protein selectively bound a 
single enantiomer. In the case of NQO2red, however, the (R)-CQ enantiomer was built 
into the structure, and there was enough electron density for the aminopentane arm to 
exclude binding of the (S)-CQ enantiomer. In this regard, binding of CQ to reduced 
NQO2 may be stereoselective for the (R)-enantiomer.  
3.3.5 Structural Changes in FAD 
Crystals of NQO2ox in complex with CQ were consistently isomorphous with other 
oxidized forms, indicating that the CQ itself is not sufficient for the observed structural 
change in crystals of the NQO2red-CQ complex. Instead, the origin of the change in 
structure is the reduction of the FAD cofactor. The FAD isoalloxazine ring is planar, but 
reduction should lead to a “butterfly bend” along the N5–N10 axis (38) (Figure 3.4). The 
electron density of the isoalloxazine ring in NQO2red-CQ indicated that the bending upon 
reduction is relatively minor. Refinement using a modified stereochemical restraint set 
for FAD, in which planar restraints and associated bond and angle restraints around N5 
and N10 were removed, indicated an angle of ∼4-5° between the two planes of the 
“butterfly wings” (Figure 3.4).  
To validate that the small change in the FAD isoalloxazine structure was due to reduction 
of the FAD, and not simply removal of stereochemical restraints, the refined NQO2 
structures were subjected to simulated annealing refinement against data from both 
oxidized and reduced crystals. In the absence of stereochemical restraints around N5 and 
N10, the isoalloxazine ring of NQO2ox in complex with PQ refined to an average bend of 
∼1.6°; for NQO2ox in complex with CQ, the average bend was 2.3°; whereas for NQO2red 
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Figure 3.4 Structural Changes in the Isoalloxazine ring. 
(A) Chemical structure and atom designations in the FAD isoalloxazine ring, and the axis 
for the “butterfly bend” that is brought about by reduction of FAD to FADH2. (B) An 
edge-on view of the structure of the isoalloxazine ring for the following: NQO2ox with PQ 
(black), NQO2ox with CQ (red), and NQO2red with CQ (blue). (C) Binding of PQ induces 
a slight (∼1.6°) concave bend in the isoalloxazine system, whereas binding of CQ induces 
a convex bend of ∼2.3°. Reduction of FAD further increases this bend to 4.8°. To 
determine the bend in the isoalloxazine rings, the crystal structures were subjected to 
simulated annealing without stereochemical restraints at the N5 and N10 positions. FAD 
bending along the N5-N10 axis (butterfly bend) was calculated using the atomic positions 
of the dimethylbenzene and pyrimidine “wings” and principal component analysis to find 
the angle between the two best fit planes. Error bars, S.D.  
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in complex with CQ, the bend was 4.8° (Figure 3.4C). It is noteworthy that for NQO2ox, 
PQ brings about a small “upward” bend in the ring, forming a very slight concave 
binding surface, whereas with CQ, the isoalloxazine system bends in the opposite 
direction, with CQ binding to a slightly convex surface. Reduction of the FAD further 
enhances this bend by 2–3°. Other notable changes occur around N5, which moves 
toward a tetrahedral configuration in NQO2red; the C4A-N5-C5A bond angle was 
decreased from 116–117° in NQO2ox-CQ and NQO2ox-PQ to 112° in NQO2red-CQ 
(Table 3.3). In contrast, there was no significant difference in the C10-N10-C9A angle 
between the oxidized and reduced forms. Thus, binding of CQ to NQO2ox appears to 
push the isoalloxazine ring toward a slightly bent conformation, and reduction of FAD to 
FADH2 results in a further increase in the bend as well as the transition of N5 toward a 
tetrahedral configuration.  
Table 3.3 Conformational Changes in the Isoalloxazine Ring upon Reduction 
NQO2 Inhibitor Subunit N5-N10 benda,b 
C4X-N5-C5X 
anglea 
C10-N10-C9A 
anglea 
Oxidized Primaquine A -1.56 ± 0.01 117.1 ± 0.2 120.0 ± 0.1 
B -1.64 ± 0.00 116.9 ± 0.1 118.6 ± 0.1 
Average -1.60 117.0 119.3 
Chloroquine A 1.69 ± 0.00 118.2 ± 0.2 118.9 ± 0.1 
B 2.94 ± 0.11 113.8 ± 0.2 116.5 ± 0.2 
Average 2.32 116.0 117.7 
Reduced Chloroquine A 4.61 ± 0.28 112.2 ± 0.5 117.6 ± 0.3 
B 5.24 ± 0.05 112.1 ± 0.4 118.8 ± 0.5 
C 5.36 ± 0.19 112.3 ± 1.2 116.1 ± 0.2 
D 3.94 ± 0.30 113.1 ± 1.1 117.9 ± 0.2 
Average 4.79 112.4 117.6 
a Both oxidized and reduced structures were subjected to three separate rounds of 
simulated annealing refinement in the absence of planar restraints for N5-N10 axis and 
angle restraints for the C4X-N5-C5X/C10-N10-C9A angles. 
b The “butterfly” bend along the N5-N10 axis was calculated using the atomic positions 
of the dimethylbenzene and pyrimidine “wings” and principal component analysis to find 
the angle between the two best-fit planes.  
 
3.3.6 Conformational Changes in Reduced NQO2-Chloroquine 
The monoclinic crystals of NQO2red-CQ contained four NQO2 protomers, two functional 
dimers, in the asymmetric unit, rather than the single functional dimer observed in the 
  
68 
asymmetric unit of orthorhombic crystals of NQO2ox. Thus, reduction and CQ binding 
caused a reorientation of the two dimers, removing the crystallographic symmetry that 
related them in orthorhombic crystals of NQO2ox (Figure 3.5A).  
The active sites in the NQO2 dimer are at the interface of the two protomers. One of the 
protomers is largely responsible for binding FAD, whereas the second protomer 
contributes elements that cover the surface of the isoalloxazine ring. One such element is 
an irregular loop formed by residues 126–136 (Figure 3.3D). In NQO2red-CQ, the loop 
closes over the active site, with I128 coming into direct contact with the CQ quinoline 
ring, which becomes sandwiched between the side chain of I128 and the isoalloxazine 
ring of FAD. This conformation is seen in the B, C, and D chains of the NQO2red-CQ 
structure, with the loop in a slightly more open conformation in the A chain.  
The loop movement outlined above, as well as other changes in the structure that could 
explain the repacking of the crystal upon reduction of FAD and binding of CQ, are 
relatively small and difficult to distinguish from crystal packing artifacts. To assess the 
structural changes that take place upon reduction and binding of CQ, we made use of the 
four NQO2 protomers in the asymmetric unit of NQO2red-CQ to eliminate random 
changes in atomic positions and find regions that show a concerted difference from 
protomers in crystals of oxidized NQO2. All of the individual subunits from reduced and 
oxidized NQO2-CQ were superimposed, and average carbon α (CA) positions were 
calculated for each of the four oxidized protomers (two protomers from each of the 
NQO2ox-PQ and NQO2ox-CQ structures) and the four reduced protomers (contained in 
the NQO2red-CQ asymmetric unit). Differences in the average CA positions for the 
oxidized and reduced protomers were calculated, plotted, and mapped to the structure 
(Figure 3.5B,C). There were seven regions where consistent differences between the 
oxidized and reduced NQO2 subunits were observed. Two of these regions (regions 4 and 
5 in Figure 3.5C) make direct contact with the bound chloroquine and comprise the 126–
136 active site loop and an oddly structured connecting loop that includes N161; three 
other regions (regions 1, 2, and 3) form a surface patch that is not in direct contact with 
either the FAD cofactor or bound chloroquine; the last two regions (regions 6 and 7) 
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Figure 3.5 Conformational Changes in NQO2 upon Reduction and Binding of CQ. 
(A) Stereodiagram illustrating the relationship between NQO2 in the oxidized (red) and 
reduced (blue) states. CA traces of two dimers are shown, with the origin of the unit cells 
indicated by a yellow sphere; the FAD molecules are drawn as stick representations. To 
show the changes that take place in the crystal, the dimer from the orthorhombic 
(P212121) NQO2ox-CQ crystal has been superimposed on one of the dimers from the 
monoclinic (P21) crystal of NQO2red-CQ. In orthorhombic crystals of NQO2ox, there is a 
single dimer in the asymmetric unit, and the second dimer shown is related by 
crystallographic symmetry. When NQO2-CQ is reduced (blue), the relationship between 
the two dimers changes, and the crystallographic symmetry is broken, resulting in a 
monoclinic space group with two dimers in the asymmetric unit. (B) A plot of differences 
in average CA positions between protomers of oxidized NQO2 (NQO2ox-PQ and 
NQO2ox-CQ) and protomers of NQO2red-CQ. (C) Two views of the NQO2 dimer (CA 
trace) colored from blue to red according to the magnitude of the difference in average 
CA position between reduced and oxidized NQO2-CQ. The views are related by 90° 
rotation around a vertical axis; the FAD co-enzyme and bound CQ are represented as 
yellow and magenta CPK models. Regions of NQO2 (numbered 1–7) that demonstrate a 
significant shift upon reduction and binding of CQ (B) are indicated.    
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are at the N- and C-terminal ends, respectively, of a surface-exposed helix comprising 
residues 196–212. Region 7 is in direct contact with the adenosine moiety of FAD but is 
still far removed from the active site. In summary, only two of seven regions that exhibit 
structural changes between NQO2ox and NQO2red-CQ are in direct contact with CQ and 
the isoalloxazine ring. On this basis, the combination of reduction and CQ binding 
appears to exert a global change in structure, consistent with the observed reorientation of 
NQO2 dimers within the crystal lattice. 
3.4 Discussion 
NQO2 was identified as a human target of both CQ and PQ; kinetic studies showed that 
PQ binds preferentially to NQO2ox, whereas chloroquine binds to NQO2red (6, 25). 
Binding of inhibitors to NQO2red has not been studied, and the goal of the current work 
was to understand the structural basis for the difference in binding specificity. The 
NQO2red-CQ complex is the first structure of reduced NQO2, and it shows that the mode 
of CQ binding to NQO2red is completely different from what is observed for CQ binding 
to NQO2ox. The ring nitrogen of 4-aminoquinoline has a pKa of 9.2 (39), and therefore 
CQ will be protonated and positively charged at physiological pH; in contrast, the 
reduced form of the NQO2-bound isoalloxazine ring will have a negative charge, 
whereas the oxidized form will be neutral. The negative charge on the reduced 
isoalloxazine ring explains the preference of CQ for NQO2red and will contribute to the 
striking difference in the mode of CQ binding to NQO2red and NQO2ox.  
The difference in CQ binding to NQO2ox and NQO2red is noteworthy but not as 
surprising and interesting as the effect of reduction and CQ binding on the overall 
structure of NQO2. There are 40 NQO2ox structures in the Protein Data Bank, most of 
which were crystallized as complexes with different inhibitors. Of the 40 structures, 38 
were crystallized in the same orthorhombic space group observed for the NQO2ox-PQ and 
NQO2ox-CQ complexes; one structure was crystallized in I422 with a single protomer in 
the asymmetric unit; and one structure was crystallized in P1 with two dimers in the 
asymmetric unit. The monoclinic space group and close packing of the two dimers 
observed for NQO2red-CQ are therefore unique and arise due to the reduction of FAD and 
chloroquine binding rather than random crystal packing effects. The unexpected 
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conformational change in NQO2 provides a structural basis for the proposed role of 
quinone reductases as flavin redox switches (40, 41). Flavin redox switches are FAD- or 
FMN-containing proteins in which the oxidation state of the cofactor regulates 
interactions with other proteins, nucleic acids, or membranes (26). The oxidation state of 
the cofactor is coupled to the conformation of the switch protein through a hydrogen-
bonding network that incorporates the N5 atom of the isoalloxazine ring. For example, in 
the LOV family of light-sensing domains, light-induced reduction of the flavin involves 
reaction of a cysteine thiolate with C4A of the isoalloxazine ring; the ensuing protonation 
of N5 causes the side chain amide of a conserved glutamine residue to flip, and this 
change in hydrogen bonding in the vicinity of N5 is communicated to other parts of the 
protein (42, 43). In the case of NQO2, reduction of FAD leads to a unique mode of CQ 
binding; protonation of the isoalloxazine N5 allows it to donate a hydrogen bond to the 
“keystone” water that is held in place by a second hydrogen bond from CQ. Binding of 
CQ to NQO2red in this fashion stabilizes an active site loop in a “closed” conformation. 
Reduction and CQ binding also cause the isoalloxazine ring of FAD to bend by 4.8°. 
Because the active site of NQO2 is at the interface between the two protomers, the 
“local” changes in the active site affect the overall structure of the dimer. The 
reorientation of the dimers in the crystal lattice indicates global changes in structure 
and/or dynamics. Thus, the flavin switch function of NQO2 requires both reduction of 
FAD and binding of an appropriate ligand to the reduced isoalloxazine ring to stabilize 
the protein in an alternate conformation.  
Although the cellular function of NQO2 is not understood, it binds many drugs and 
bioactive compounds and has been implicated in apoptosis and cancer (22, 44–46). A role 
as a flavin redox switch, the function of which is dependent on cellular redox conditions 
and the presence of an appropriate ligand, could explain the elusive nature of NQO2 
cellular function. CQ is a good example of an NQO2-interacting compound that is used 
to treat a variety of diseases, but the mechanisms underlying the cellular effects of CQ are 
poorly understood. As an antimalarial, CQ is thought to interact with undimerized 
ferriprotoporphyrin and prevent its detoxification and storage as β-hematin (4). On the 
other hand, the process of hemoglobin digestion and storage of ferriprotoporphyrin by the 
parasite involves endocytosis and a number of steps in which endosomes must fuse with 
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digestive vacuoles, and CQ and related quinolone drugs may interfere with these 
processes (4). Along these lines, the accumulation of CQ in lysosomes is thought to be 
responsible for its inhibition of autophagy (47). Furthermore, CQ has effects on 
glucocorticoid signalling and has been linked to p53 function (48, 49). It is conceivable 
that some of the cellular effects of CQ are linked to its binding of NQO2 and the ensuing 
conformational switch, which would only occur under an appropriate metabolic state 
where NQO2 is reduced.  
Both NQO1 and NQO2 have been shown to protect p53 against 20S proteosomal 
degradation in the presence of their reduced nicotinamide co-substrates (22, 23, 50, 51). 
In fact, the stabilization and localization of a transcription factor is a common function of 
flavin redox switches. For example, the oxidized form of the flavin switch NifL forms an 
inactive complex with the transcription factor NifA; reduction of NifL leads to 
dissociation of the complex, allowing NifA to activate genes involved in nitrogen 
fixation. Lot6p, a yeast homologue of human NQO1 and NQO2 (52), provides an 
example of a quinone reductase that functions as a flavin redox switch; in this case, 
reduction of Lot6p helps it to stabilize the Yap4p transcription factor against 20S 
proteosomal degradation, similar to the way in which NQO1 and NQO2 appear to 
stabilize p53 (40, 53). Lot6p is actually a poor catalyst (the rate of the oxidative half-
reaction is slower than that of non-enzymatic model reactions), and this led Sollner and 
coworkers (41) to propose that Lot6p may have evolved primarily as a flavin redox 
switch to regulate 20S proteosomal degradation. The conformational switch that we have 
observed with NQO2 provides a structural basis for the proposed role of NQO2 and 
possibly other quinone reductases in the redox-dependent regulation of p53.  
As a flavin redox switch, it is not clear why NQO2 uses NRH as an electron donor 
instead of NAD(P)H, which is used by NQO1 and all other members of the flavodoxin 
family. NQO2 is the only enzyme known to use NRH, and although oxidized 
nicotinamide riboside exists as a metabolite of NAD, the origin of cellular NRH is not 
known. On this basis, the metabolic signal that facilitates conformational switching of 
NQO2 remains elusive. CQ has been reported to activate the p53 pathway, but whether 
this process involves NQO2 was not determined (49). In any case, there may be a number 
  
73 
of small molecule “inhibitors” of NQO2, as well as proteins or peptides, that could 
interact specifically with the reduced form of NQO2 and function in a manner similar to 
CQ to stabilize NQO2 in an alternate conformation. Thus, although there are many 
unanswered questions regarding the cellular function of NQO2, a flavin switch function 
that is dependent on the cellular redox state and the presence of an appropriate ligand 
provides an intriguing, met abolically regulated, link between NQO2, p53, and the poorly 
defined cellular effects of the many drugs and bioactive compounds that interact with 
NQO2. 
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Chapter 4  
4 Quinone Reductase 2 Is an Adventitious Target of 
Protein Kinase CK2 Inhibitors TBBz (TBI) and DMAT6 
Quinone reductase 2 (NQO2) exhibits off-target interactions with two protein kinase CK2 
inhibitors, 4,5,6,7-1H-tetrabromobenzimidazole (TBBz) and 2-dimethylamino-4,5,6,7-
tetrabromo-1H-benzimidazole (DMAT). TBBz and DMAT induce apoptosis in cells 
expressing an inhibitor-resistant CK2, suggesting that the interaction with NQO2 may 
mediate some of their pharmacological effects. In this study, we have fully characterized 
the binding of TBBz and DMAT to NQO2. Fluorescence titrations showed that TBBz 
and DMAT bind oxidized NQO2 in the low nanomolar range; in the case of TBBz, the 
affinity for NQO2 was 40-fold greater than its affinity for CK2. A related CK2 inhibitor, 
4,5,6,7-tetrabromobenzotriazole (TBB), which failed to cause apoptosis in cells 
expressing inhibitor-resistant CK2, binds NQO2 with an affinity 1000-fold lower than 
those of TBBz and DMAT. Kinetic analysis indicated that DMAT inhibits NQO2 by 
binding with similar affinities to the oxidized and reduced forms. Crystal structure 
analysis showed that DMAT binds reduced NQO2 in a manner different from that in the 
oxidized state. In oxidized NQO2, TBBz and DMAT are deeply buried in the active site 
and make direct hydrogen and halogen bonds to the enzyme. In reduced NQO2, DMAT 
occupies a more peripheral region and hydrogen and halogen bonds with the enzyme are 
mediated through three water molecules. Therefore, although TBB, TBBz, and DMAT 
are all potent inhibitors of CK2, they exhibit different activity profiles toward NQO2. We 
conclude that the active site of NQO2 is fundamentally different from the ATP binding 
site of CK2 and the inhibition of NQO2 by CK2 inhibitors is adventitious.  
                                                
6 This chapter was published: Leung, K. K., & Shilton, B. H. (2015). Quinone Reductase 2 Is an 
Adventitious Target of Protein Kinase CK2 Inhibitors TBBz (TBI) and DMAT. 
Biochemistry, 54, 47–59. 
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4.1 Introduction 
Protein kinases are often deregulated in cancer, and the development of kinase inhibitors 
for cancer chemotherapy has received much attention in the past 30 years (1). Protein 
kinase CK2 (CK2) is a constitutively active kinase that phosphorylates more than 200 
protein targets and regulates a myriad of cell signalling events in cell cycle, apoptosis, 
and transcriptional control (2, 3). With regard to apoptosis, CK2 attenuates cell
 
death by 
phosphorylation of caspases and caspase targets (4). Therefore, the overexpression of 
CK2 in many tumor types suggests that CK2 is involved in tumorigenesis by preventing 
cell death (5). As such, CK2 is an attractive cancer therapy target and CK2 inhibitors that 
cause apoptosis in cancer cells have been extensively developed over the past two 
decades (6). However, despite tremendous efforts to increase the specificity of inhibitors 
for CK2, many of these compounds exhibit off-target interactions.  
The tetrabromobenzene compounds 4,5,6,7-tetrabromobenzotriazole (TBB), 4,5,6,7-
tetrabromobenzimidazole (TBBz), and 2-dimethylamino-4,5,6,7-tetrabromo-1H-
benzimidazole (DMAT) are some of the most widely used inhibitors of CK2 (Figure 4.1). 
TBB inhibits CK2 activity in the submicromolar range with relatively high specificity 
over other kinases (7–9), and treatment of cells in culture with TBB leads to apoptosis 
(10). Further development of TBB led to the discovery of another potent inhibitor of 
CK2, TBBz, that is more selective for yeast CK2 (11, 12). Based on the 
tetrabromobenzene moiety in TBBz, another CK2 inhibitor, DMAT, was developed that 
was more selective for CK2 than TBB and bound with an affinity 10-fold greater than 
that of either TBB or TBBz (13, 14). Despite being optimized for CK2 inhibition, both 
TBBz and DMAT inhibit at least three other subfamilies of kinases: DYRKs, PIM, and 
HIPK2 (15). Furthermore, they also bind several non-kinase targets with ATP binding 
sites (16). Such nontargeted interactions may contribute to the cellular effects of the 
inhibitors.  
In a series of unbiased validation studies of the specificity of these inhibitors, Duncan and 
co-workers identified quinone reductase 2 (NQO2) as a particularly interesting non-
kinase target of TBBz and DMAT (17). Briefly, an inhibitor-resistant mutant of CK2 was 
transfected into cells to rescue them from CK2 inhibitor-induced apoptosis; however, 
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Figure 4.1 Chemical Structure and Electrostatic Properties of CK2 Inhibitors. 
Chemical structure and electrostatic properties of CK2 inhibitors 4,5,6,7-
tetrabromobenzotriazole (TBB), 4,5,6,7-tetrabromo-1H- benzimidazole (TBBz), and 2-
dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT). Partial charges were 
calculated and displayed on the molecular surfaces using Marvin 6.3.1 by ChemAxon 
(http://www.chemaxon.com).  
only TBB-treated cells were rescued, while TBBz- and DMAT-treated cells underwent 
apoptosis. Therefore, inhibition of CK2 alone did not fully account for the cell death 
caused by TBBz and DMAT treatment. This challenges the notion that CK2 is the bona 
fide target of the two inhibitors and indicates that TBBz and DMAT act through alternate 
mechanisms to cause cellular apoptosis. Further investigation using a proteomics 
approach identified a non-kinase target, NQO2, that eluted from an ATP-Sepharose 
affinity column when it was washed with TBBz and DMAT but not with a similar 
concentration of TBB. This corresponded to the rescue experiment in which TBBz and 
DMAT but not TBB caused cell death and suggests that NQO2 inhibition may contribute 
to the apoptotic effects of the drugs. Thus, it prompted our investigation of NQO2 
inhibition by the three inhibitors.  
Historically, NQO2 and related quinone reductases have been characterized as enzymes 
involved in quinone detoxification. They do so by catalyzing an obligate two-electron 
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transfer to a quinone to produce the relatively stable quinonol, thus preventing non-
enzyme-catalyzed single-electron transfer that produces redox active semiquinones (18). 
NQO2 is unusual, however, because it uses dihydronicotinamide riboside (NRH) as a 
reducing co-substrate, rather than NAD(P)H (19); moreover, in the presence of NRH, 
NQO2 was found to protect p53 from degradation by the 20S proteasome (20, 21). At the 
molecular level, reduction of NQO2 and binding of chloroquine (an antimalarial) were 
shown to induce a conformational change in NQO2, suggesting that NQO2 may function 
as a flavin redox switch (22). Therefore, in addition to its role in quinone detoxification, 
NQO2 appears to have a signalling function, possibly connecting the metabolic status of 
the cell to p53 levels. While its cellular functions remain to be determined, mice deficient 
for NQO2 develop skin tumors more frequently than wild-type mice in a chemical 
carcinogenesis model (23), indicating that NQO2 plays a role in cell proliferation and/or 
apoptosis.  
In addition to CK2 inhibitors, several chemotherapeutic inhibitors of the Abelson kinase 
and protein kinase C (PKC) were found to inhibit NQO2 with nanomolar and micromolar 
affinity, respectively (24–27). The fact that multiple kinase-directed drugs also inhibit 
NQO2 raised the question of whether the drug binding site of NQO2 somehow mimics 
the ATP binding site of kinases. In this study, we performed kinetic and structural 
analyses to characterize the inhibition of NQO2 by TBB, TBBz, and DMAT. The three 
inhibitors exhibit different binding profiles with respect to NQO2 that do not correspond 
to their interactions with CK2.  
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4.2 Methods 
4.2.1 Protein Expression and Purification 
Recombinant NQO2 was expressed in Escherichia coli and purified as previously 
described (28). A critical step in the purification was full reconstitution of the enzyme 
with the FAD co-enzyme. When expressed in E. coli, recombinant NQO2 typically 
contains substoichiometric levels of flavin mononucleotide (FMN) and no FAD. A partial 
denaturation of NQO2 and reconstitution with FAD was incorporated into the 
purification procedure, leading to full saturation of the enzyme with FAD (28).  
4.2.2 Affinity of Inhibitors by Fluorescence Quenching.  
To assess direct binding of inhibitors to oxidized NQO2 (NQO2ox), fluorescence 
quenching of FAD was monitored with an excitation wavelength of 350 nm and an 
emission wavelength of 430 nm. NQO2 (775 or 38.75 nM) was titrated with the indicated 
concentrations of TBB, TBBz, and DMAT. The binding data were fit to equation 4.1 to 
obtain the dissociation constant (KD) for binding of the inhibitors to NQO2ox. 
€ 
F −Fo
Fmax −Fo
=
KD + I +NQO2− (KD + I +NQO2)2 − 4(I )(NQO2)
2(NQO2)  
Equation 4.1 Fluorescence Quenching by Inhibitors 
where NQO2 and I are the final concentrations in the cuvette of the enzyme and inhibitor, 
respectively, Fo is the initial fluorescence reading in counts per second without an 
inhibitor, and F is the fluorescence after the addition(s) of TBBz or DMAT. KD and Fmax 
were determined by nonlinear regression using Prism 4.0b (GraphPad Software Inc., San 
Diego, CA). The data are presented as fractional saturation of NQO2 with an inhibitor (F 
- Fo)/(Fmax - Fo).  
4.2.3 Enzymatic Assays.  
Enzyme activity was measured by monitoring the consumption of 1-(3-sulfonatopropyl)-
3-carbamoyl-1,4-dihydropyrimidine (SCDP) (Sigma) co-substrate (a 
dihydronicotinamide riboside analogue) at an absorbance peak of 360 nm using a Cary 
100-Bio spectrophotometer (Varian). The reaction was initiated by addition of NQO2 at a 
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final concentration of 154 pM to a stirring cuvette containing SCDP (10-365 µM) as co-
substrate and menadione (0.5-50 µM) (Sigma) as the substrate at 30 °C. The linear 
portion of the decrease in absorbance was determined using Cary Kinetics Software 
(Varian) and converted to turnover number (inverse seconds) using the extinction 
coefficient of SCDP (ε360 = 4480 M−1 cm−1). Because menadione inhibits the reaction at 
high concentrations by competing with SCDP for binding to the oxidized enzyme, kinetic 
data were fit to Equation 4.2 that describes a ping-pong kinetic mechanism with substrate 
inhibition (29). 
Vobs =
Vmax[SCDP][Md]
KM(SCDP)app [Md]+KM(Md)[SCDP]+[SCDP][Md]
where KM(SCDP)app = KM(SCDP)(1+
[Md]
KI(Md)
)
 
Equation 4.2 Ping-pong Mechanism of NQO2 Catalysis 
where Vobs is the observed rate of reaction, Vmax is the maximal rate, [SCDP] and [Md] are 
the concentrations of SCDP and menadione, respectively, KM(SCDP) and KM(Md) are the 
Michaelis constants for substrates SCDP and menadione, respectively, and KI(Md) is the 
competitive binding constant of menadione. Initial values were obtained from the 
previous study of NQO2 kinetics using N-methyldihydronicotinamide (NeMH) as the co-
substrate (29). Kinetic parameters were fit to the data by nonlinear regression using Igor 
Pro (Wavemetrics, Portland, OR); the χ2 values were calculated as  
χ 2 =
y− yi
σ i
"
#
$
%
&
'
2
i
∑  
Equation 4.3 Determination of Chi-squared Values 
where y and yi are the fitted and measured values, respectively, and σi is the estimated 
standard deviation of the measured value.  
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4.2.4 Enzyme Inhibition by TBBz and DMAT.  
To determine the constants for inhibition (KI values) of NQO2 by TBBz and DMAT, 
inhibition kinetics were performed using the same techniques that were used for the 
uninhibited reaction described above. For each inhibitor, kinetic assays were performed 
either with a constant SCDP concentration of 150 µM and a varying menadione 
concentration or with a constant menadione concentration of 5 µM and a varying SCDP 
concentration. Because inhibitors of NQO2 can be competitive against SCDP, 
menadione, or both, we adapted the kinetic equation to account for both types of 
inhibition:  
Vobs =
Vmax[SCDP][Md]
KM(SCDP)app [Md]+ KM(Md)app [SCDP]+ [SCDP][Md]
where KM(SCDP)app = KM(SCDP)(1+
[Md]
KI(Md)
+ [I]KI(α )
)
and KM(Md)app = KM(Md)(1+
[I]
KI(β )
)
 
Equation 4.4 Inhibition of NQO2 Catalysis 
On the basis of equation 4.2, [I], KI(α), and KI(β) were introduced into equation 4.3, where 
[I] is the concentration of inhibitor and KI(α) and KI(β) are the inhibition constants that 
modify the “apparent” Michaelis constants KM(SCDP)app  and KM(Md)app  respectively. That is, KI(α) 
is the constant that accounts for the change in KM(SCDP) in the presence of inhibitor; hence, 
it describes the component of inhibition that is competitive against SCDP. KI(β) is the 
constant that accounts for the change in KM(Md) in the presence of inhibitor; hence, it 
describes the component of inhibition that is competitive against menadione. The kinetic 
parameters KM(SCDP), KM(Md), and KI(Md) were fixed using values determined for the 
uninhibited reaction (Table 4.2), while Vmax, KI(α), and KI(β) were determined by globally 
fitting data to equation 4.4 using nonlinear regression (Igor Pro version 6.34A) with the 
IC50 values as initial values.  
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4.2.5 IC50 Measurements.  
To determine the IC50 value of each inhibitor, reactions were initiated by addition of 154 
pM NQO2 to a reaction buffer containing 150 µM SCDP and 5 µM menadione with TBB 
(0.625-640 µM), TBBz (2.5-640 nM), or DMAT (2.5-640 nM). IC50 values were then 
calculated using a dose-response model and represented as relative inhibition.  
4.2.6 Crystallization of NQO2.  
Oxidized NQO2 (NQO2ox) was co-crystallized with TBBz or DMAT by hanging drop 
vapor diffusion against reservoirs containing 0.1 M Hepes (pH 7.5) and 1.3-2.0 M 
(NH4)2SO4. Because TBBz and DMAT are not soluble in mother liquor, TBBz or DMAT 
(100 µM) was added to a final concentration of 2 mg/mL (77 µM) of NQO2. The NQO2-
inhibitor complex was then concentrated 10-fold to 20 mg/mL and used for 
crystallization.  
To obtain a structure of reduced NQO2 in complex with DMAT, reduction of NQO2ox-
DMAT crystals was performed as previously described (22).  Briefly, N NQO2ox-DMAT 
crystals were repeatedly soaked into 1 µL of a reducing soak solution with 0.1 M Hepes 
(pH 7.5), 2.0 M (NH4)2SO4, 10 mM SCDP, and 1 mM DMAT, for 2 min intervals until 
the crystals were bleached. They were then transferred to a soak without SCDP before 
briefly being passed through a cryoprotectant solution [2.0 M (NH4)2SO4, 0.1 Hepes (pH 
7.5), and 20% glycerol] and plunged into liquid nitrogen. To prevent oxidation of NQO2, 
the entire crystal mounting process from harvesting to cryocooling was performed under 
an anoxic atmosphere in a glovebag purged with N2.  
4.2.7 X-ray Data Collection, Refinement, and Analysis.  
Crystallographic data were collected at Canadian Light Source beamline 08ID-1 or from 
a rotating anode source, processed using MOSFLM (30), and merged using Scala (31). 
The structures were determined by molecular replacement with Protein Data Bank (PDB) 
entry 1QR2 as a starting model (32); refinement was conducted using PHENIX (33). 
Given the high resolution of the crystallographic data, NCS restraints were not used for 
any of the refinements. For structures with detectable anomalous scattering (NQO2ox-
  
86 
TBBz and NQO2red-DMAT), zinc and bromine were refined as anomalous groups. For 
the oxidized NQO2-DMAT structure, the high resolution of the data allowed for 
anisotropic refinement of the zinc and bromine atoms. These refinement strategies 
lowered both Rwork and Rfree.  
Topology files for TBBz and DMAT were generated using PHENIX.ELBOW (33). For 
refinement of the NQO2red-DMAT structure, the FAD topology file was modified to 
allow bending along the N5-N10 axis of FAD: the planarity restraints incorporating N5 
and N10 of the isoalloxazine ring were removed so that it was separated into two planes, 
one incorporating the pyrimidine ring and the second the benzyl ring. Also, the estimated 
standard deviations of the bond lengths attached to N5 and N10 were increased 10-fold, 
and the bond angle and dihedral angle restraints involving N5 and N10 were removed.  
To compare FAD bending among the three structures, each structure was refined three 
times using simulated annealing with the relaxed FAD topology parameters that allow for 
bending of the isoalloxazine ring. The degree of bending in the isoalloxazine ring was 
then calculated using principal component analysis incorporating all atoms in each of the 
two planes, and the angles in each of the three refined structures were averaged. The 
NQO2ox-TBBz, NQO2ox-DMAT, and NQO2red-DMAT final structures were deposited as 
PDB entries 4U7G, 4U7H, and 4U7F, respectively.  
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4.3 Results 
4.3.1 NQO2 Is a Target of TBB, TBBz, and DMAT.  
Halogenated benzotriazoles were identified as inhibitors of CK1 and CK2, with 4,5,6,7-
tetrabromobenzotriazole (TBB) strongly inhibiting CK2 (7). From this starting point, 
brominated benzimidazoles, in particular, 4,5,6,7-1H-tetrabromobenzimidazole (TBBz) 
and 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) (Figure 4.1), that 
increased selectivity for CK2 were developed (11, 14). DMAT is the most potent of these 
compounds, exhibiting a 10-fold lower dissociation constant and a 3-fold lower IC50 
compared to those of TBB and TBBz (Table 4.1). All three compounds target the ATP 
binding site of CK2, and on this basis, it is not surprising that they are also active against 
other kinases (15). On the other hand, it was surprising that both TBBz and DMAT were 
identified as interactors with NQO2, which neither is a kinase nor has a known ATP 
binding site (17). However, NQO2 does bind other kinase inhibitors (24, 27), raising the 
possibility that its active site mimics a kinase binding site. Our goal in this study was to 
characterize the binding and inhibition of NQO2 by these three compounds and compare 
their activities against NQO2 with those against CK2.  
Table 4.1 Binding Affinity and Inhibition of TBB, TBBz, and DMAT towards CK2 
and NQO2 
Inhibitor KD IC50 
 CK2a NQO2b CK2a NQO2c 
TBB 400 nM 7.11 ± 0.04 µM 500 nM 12.8 ± 2 µM 
TBBz 700 nM 18.1 ± 0.4 nM 500 nM 79.4 ± 12 nM 
DMAT 40 nM 36.4 ± 1.7 nM 140 nM 484 ± 80 nM 
a KD and IC50 values for CK2 were reported previously (14, 34). 
b The dissociation constants for oxidized NQO2 were determined by fluorescence 
titrations; values are mean ± standard deviation for three independent titrations.  
c IC50 values for NQO2 were determined by an in vitro assay with 150 µM SCDP and 5 
µM menadione and varying concentrations of inhibitors. Kinetic data were fit to a 
sigmoidal response curve (Figure 4.2B); values are the estimated IC50 ± the range of the 
95% confidence interval. 
 
TBB, TBBz, and DMAT are planar aromatic compounds and as such are expected to bind 
to NQO2 by stacking onto the isoalloxazine ring of FAD. On this basis, fluorescence 
titrations were used to directly measure binding affinities for oxidized NQO2. Both TBBz 
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and DMAT bound tightly to NQO2, with KD values of 18 and 36 nM, respectively, while 
TBB bound much more weakly with a KD of 7.1 µM (Table 4.1 and Figure 4.2A).  
To characterize the ability of these compounds to inhibit NQO2’s enzymatic activity, 
IC50 values were determined using an in vitro assay (Figure 4.2B). NQO2 operates by a 
ping-pong catalytic mechanism: the first step is reduction of the FAD isoalloxazine ring 
by dihydronicotinamide riboside (NRH), followed by dissociation of the oxidized 
nicotinamide and binding of a quinone substrate. For the assay, a commercially available 
NRH analogue, 1-(3-sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine (SCDP), 
which exhibits a change in absorbance at 360 nm upon oxidation by NQO2, was used 
along with menadione as the quinone substrate. All three compounds inhibited the 
enzymatic activity of NQO2. The IC50 values were all higher than the dissociation 
constants, but the difference depended on the compound (Table 4.1). That is, the IC50 
value for DMAT was > 12-fold higher than its KD, while the IC50 value for TBBz was 4-
fold higher; for the relatively weak binding inhibitor, TBB, the IC50 was only slightly 
greater than the KD (Table 1). This indicates that the compounds are inhibiting NQO2 
through somewhat different mechanisms.  
The activity profiles of TBB, TBBz, and DMAT against NQO2 are different from those 
against CK2. First, both TBB and TBBz bind to CK2 with similar affinity (KD values of 
400 and 700 nM, respectively), whereas with NQO2, the binding of TBB is almost 3 
orders of magnitude weaker than that of TBBz. Second, a comparison of DMAT and 
TBBz shows that DMAT binds to CK2 with an affinity more than 1 order of magnitude 
greater than that of TBBz, whereas binding of DMAT to NQO2 is slightly weaker than 
that of TBBz (Table 1). Finally, the large differences between KD and IC50 values 
observed for NQO2 (particularly in the case of DMAT) were not observed for CK2; 
instead, for CK2, the IC50 and KD values for TBB and TBBz were almost equal, and the 
IC50 for DMAT was only 3-fold greater than the KD. On the basis of these binding and 
inhibition data, the properties of the NQO2 binding site do not fully mimic the properties 
of the CK2 ATP binding site. To improve our understanding of the interactions between 
NQO2 and the nanomolar inhibitors TBBz and DMAT, we performed a more detailed 
kinetic analysis to determine the mode of enzymatic inhibition.  
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Figure 4.2 Binding and Inhibition of NQO2 by TBBz, DMAT, and TBB. 
(A) Representative data for binding of TBBz (▲), DMAT (▼), and TBB (■) to oxidized 
NQO2. Binding was characterized by fluorescence titrations of the inhibitors against 
oxidized NQO2 at a concentration of 38.75 nM (TBBz and DMAT) or 775 nM (TBB). 
The stirred sample was monitored at an excitation wavelength of 350 nm and an emission 
wavelength of 430 nm. The solid curves represent the binding isotherms, which were 
determined by nonlinear regression as outlined in Methods; the dissociation constants for 
the inhibitors are listed in Table 1. (B) Inhibition of steady-state catalysis by TBBz (▲), 
DMAT (▼), and TBB (■). Reactions were initiated with the addition of 154 pM NQO2 to 
150 μM SCDP and 5 μM menadione and varying concentrations of the inhibitors; IC50 
values were calculated from these data and are listed in Table 4.1.  
4.3.2 Kinetic Analysis of Inhibition of NQO2 by TBBz and DMAT.  
The ping-pong catalytic mechanism of NQO2 means that the active site cycles through an 
oxidized state and a reduced state for each catalytic turnover. In this study, the steady-
state kinetic parameters of the uninhibited reaction were determined using the NRH 
analogue SCDP as the co-substrate and menadione as the substrate. Because previous 
studies have shown that menadione acts as a competitive inhibitor toward SCDP (29), 
substrate inhibition by menadione was incorporated into the kinetic model (equation 4.2, 
Methods). Consistent with previous results, our kinetic data (Figure 4.3) confirm that the 
binding of menadione to oxidized NQO2 [KI(Md)] is similar to the Michaelis constant of 
menadione [KM(Md) (Table 4.2)]. Thus, menadione exhibits limited discrimination 
between the two redox states of NQO2.  
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Figure 4.3 Steady-state Ping-pong Kinetics of NQO2 with Substrate Inhibition. 
Steady-state kinetic analysis was performed to obtain the kinetic parameters listed in 
Table 2. Initial concentrations of SCDP were 10 (■), 25 (▲), 50 (▼), 100 (◆), and 365 (●) 
μM, and concentrations of menadione varied as indicated. Data points are measured rates, 
and solid curves represent the nonlinear regression fits derived from globally fitting all 
data to equation 4.1 (Methods) that describes a ping-pong kinetic mechanism with 
substrate inhibition by menadione. The χ2 value for the global fit was 7.4 × 104.  
 
 
Table 4.2 Steady-state Kinetic Parameters of NQO2 
Parametera Value 
kcat  981 ± 90.4 s-1 
KM(SCDP) 142 ± 23.2 µM 
KM(menadione) 1.62 ± 0.31 µM 
KI(menadione)  8.07 ± 1.48 µM 
a Calculated by globally fitting rate data to equation 4.2 as described in Materials and 
Methods. 
An inhibitor of NQO2 can be competitive toward the SCDP co-substrate and/or the 
quinone substrate depending on whether the inhibitor binds preferentially to the oxidized 
or reduced form of NQO2. We used equation 4.4 (Methods) to account for the 
competitive inhibition model. In this model, each inhibitor is expected to compete with 
SCDP, menadione, or both, and the inhibition constants KI(α) and KI(β) describe the degree 
to which the presence of the inhibitor alters the apparent Michaelis constants for the 
reaction. Another way of viewing the KI(α) or KI(β) constants is that their relative values 
should indicate the preference of the inhibitor for either the oxidized or reduced form of 
NQO2, respectively. Global fitting of the rate data (Figure 4.4) to equation 4.4 yielded 
values of KI(α) and KI(β) for TBBz and DMAT as well as kcat values (Table 4.3). Thus, the 
inhibition constant of TBBz toward SCDP (KI(α) = 19.6 ± 2.9 nM) is very close to the 
binding affinity of TBBz for oxidized NQO2 (KD = 18.1 ± 0.4 nM). The high value and 
very high standard error for the inhibition constant of TBBz toward the quinone substrate,  
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Figure 4.4 Kinetic Analysis of NQO2 Inhibition by TBBz and DMAT. 
Steady-state rate measurements of NQO2-catalyzed reduction of menadione were taken 
in the presence of TBBz (A and B) or DMAT (C and D) to obtain the values for KI(α), 
KI(β), and kcat listed in Table 3. In panels A and C, assays included a constant menadione 
concentration of 5 μM, while in panels B and D, assays included a constant SCDP 
concentration of 150 μM. The concentrations of TBBz were 0 (■), 50 (▲), 100 (▼), and 
500 (◆) nM (A) and 0 (■), 25 (▲), 50 (▼), and 100 (◆) nM (B). The concentrations of 
DMAT were 0 (■), 100 (▲), 500 (▼), and 1000 (◆) nM (C) and 0 (■), 25 (▲), 50 (▼), 100 
(◆), and 500 (●) nM (D). The solid curves in the panels represent global fits to all of the 
data in panels A and B [to obtain KI(α), KI(β), and kcat for inhibition by TBBz] or panels C 
and D [to obtain KI(α), KI(β), and kcat for inhibition by DMAT]. The χ2 value for the global 
fit to TBBz-inhibited NQO2 (A and B) was 1.4 × 105, while that for the DMAT-inhibited 
NQO2 (C and D) was 4.6 × 104.  
Table 4.3 Inhibition of NQO2 by TBBz and DMAT 
Inhibitor KI(α)a (nM) KI(β)b (nM) kcat (s-1) 
TBBzc 19.3 ± 2.5 801 ± 3280 948.0 ± 34.4 
DMATd 131.2 ± 27.5 252.0 ± 124.0 929.9 ± 24.7 
a KI(α) is the component of the inhibition that is competitive against SCDP. 
b KI(β) is the component of the inhibition that is competitive against menadione. 
c The parameters (with standard errors) were calculated by globally fitting the rate data 
illustrated in Figure 4.4, Panels A and B. 
d The parameters (with standard errors) were calculated by globally fitting the rate data 
illustrated in Figure 4.4, Panels C and D.  
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menadione (KI(β) = 865 ± 3790 nM), indicate that the interaction of TBBz with the 
oxidized form of NQO2 is sufficient to completely account for TBBz-mediated 
inhibition, and therefore, binding to the reduced form cannot be assessed using steady-
state kinetics. The situation for DMAT is more complicated: the inhibition constant of 
DMAT toward SCDP (KI(α)  = 121 ± 20 nM) is 3-fold higher than its affinity for oxidized 
NQO2 (KD = 36.4 ± 1.7 nM). Furthermore, we find that the inhibition constant of DMAT 
toward menadione (KI(β) = 302 ± 131 nM) is similar to its inhibition constant against 
SCDP. This indicates that DMAT is binding to both oxidized and reduced NQO2; it 
exhibits relatively poor discrimination between the two. This was surprising but not 
unprecedented as the substrate menadione also shows poor discrimination between the 
two redox states of NQO2; however, DMAT is the first inhibitor shown to exhibit similar 
affinity for both redox states of NQO2. 
4.3.3 Structures of Oxidized NQO2 with TBBz and DMAT.  
Crystal structures of NQO2−inhibitor complexes were used to determine the structural 
basis for binding of TBBz and DMAT to oxidized NQO2. Cocrystallization of NQO2 and 
TBBz yielded crystals that diffracted to 1.86 Å; the structure was determined by 
molecular replacement and refined to an Rfree value of 0.2288 (Table 4.4). Crystals of 
NQO2 contain a dimer in the asymmetric unit, and TBBz was modeled in two 
orientations in both active sites of the NQO2 dimer. Because TBBz has four bromine 
atoms that contribute to anomalous scattering, the first orientation of TBBz was modeled 
using an anomalous difference map that indicated four prominent peaks (two peaks at 
5−6 σ and two peaks at 4 σ) in the active site of NQO2 (Figure 4.5A). In the first 
orientation, the tetrabromobenzene makes π-stacking interactions with the FAD 
isoalloxazine ring and the phenyl ring of F178. Bromine atoms 4 and 5 of TBBz make 
halogen bonds (35) to the backbone carbonyl of G174 and to the carboxyamide of N161. 
The benzimidazole nitrogen makes a π-hydrogen bond (36) with the benzene ring of the 
W105 indole side chain. During the refinement, inconsistencies in the relative values for 
the atomic displacement parameters (ADPs) within the imidazole ring of TBBz suggested 
that TBBz was binding in an alternative orientation (Figure 4.5B). The second orientation 
of TBBz is related by a 60° rotation around the benzene ring that places a bromine atom  
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Figure 4.5 Binding of TBBz and DMAT to Oxidized (A-D) and Reduced (E-F) 
NQO2 
Complexes between oxidized NQO2 and TBBz or DMAT (A−D) show the inhibitors are 
sandwiched between the isoalloxazine ring of FAD (yellow) and F178 (above the plane 
of the inhibitor). (A) In one orientation, TBBz makes two halogen bonds and a π-
hydrogen bond to N161, G174, and W105, respectively. (B) In its second orientation, 
TBBz is rotated 60° to make three halogen bonds with N161, G174, and W105. (C) 
DMAT makes two halogen bonds to N161 and G174 in one orientation, but the presence 
of the dimethylamine group hinders the imidazole nitrogen from π-hydrogen bonding 
with W105. (D) In the second orientation, DMAT makes three halogen bonds with N161, 
G174, and W105, similar to what was observed for TBBz. In the structure of reduced 
NQO2 (E and F), DMAT occupies a more peripheral position, makes fewer π-stacking 
interaction with FAD, no longer contacts F178, and instead makes somewhat stronger 
hydrophobic contact with F126. (E) In one orientation of DMAT, bromine 6 makes a 
halogen bond to a water molecule, which is in turn bonded to N161, while bromine 5 
makes a halogen bond to W105. (F) In the second orientation with reduced NQO2, 
DMAT is rotated 60° and the same halogen bonds are mediated by bromines 4 and 5. The 
electron density maps represent the Fo - Fc (green mesh) and anomalous (magenta mesh) 
differences calculated after simulated annealing with the inhibitors omitted from the 
structure; all electron density maps were contoured at 3σ around the inhibitors. In all 
three structures, the inhibitor binding orientations are the same for both subunits (the A 
and B chains) of the NQO2 dimer that constitutes the asymmetric unit of the crystal.  
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Table 4.4 Crystallographic Data Collection and Refinement Statistics 
Crystal Oxidized NQO2 Reduced NQO2 
Ligand TBBz DMAT DMAT 
Wavelength (Å) 1.54 1.03 1.54 
Space Group P212121 P212121 P212121 
Unit Cell Dimensions (Å) 56.24, 83.17, 
106.65 
56.25, 83.01, 
106.48 
56.12, 83.14, 
106.46 
Resolution 18.18-1.91 30.02-1.45 17.99 - 1.73 
aRsym  0.098 (0.57) 0.06 (0.43) 0.073 (0.66) 
aI/σ(I) 7.5 (2.0) 9.7 (1.7) 14.8 (2.6) 
aCompleteness 92.8 (57.3) 96.0 (74.5) 89.9 (74.5) 
Redundancy 4.4 4.6 6.2 
Unique Reflections 36697 85781 47314 
Rwork/Rfree 0.1745/0.2288 0.1843/0.1958 0.1840/0.2254 
Ramachandran Plotb (%) 
Most Favoured 
Additionally Allowed 
Generously Allowed 
Disallowed 
 
90.2% 
9.3% 
0.5% 
0% 
 
91.7% 
7.8% 
0.5% 
0% 
 
90.7% 
8.8% 
0.5% 
0% 
RMS Deviations 
Bond Lengths (Å) 
Bond Angles (deg) 
Dihedral Angles (deg) 
 
 
0.009 
1.150 
14.665 
 
 
0.010 
1.353 
14.702 
 
 
0.009 
1.128 
14.238 
Mean A.D.P. values (Å2) 
Protein 
All Atoms 
     Main Chain  
     Side Chain      
Solvent 
Water     
 FAD 
     Inhibitor 
 
 
20.990 
20.084 
21.913 
 
27.553 
22.305 
26.988 
 
 
21.913 
20.285 
23.282 
 
31.850 
22.682 
46.165 
 
 
23.698 
22.608 
24.809 
 
26.960 
25.113 
37.759 
a Values in parentheses refer to the highest resolution shell. 
b Ramachandran plot statistics were calculated using PROCHECK (Laskowski et al. 
1993). 
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in the position of one of the benzimidazole nitrogens. Refinement of the structure with 
the two TBBz orientations yielded consistent values for the ADPs. As a result of the 
rotation, the halogen bonds to G174 and N161 are maintained but are made with 
bromines 5 and 6 rather than bromines 4 and 5 as in the first orientation. In addition, the 
π-hydrogen bond to the W105 indole is replaced with an interaction between bromine 4 
and the W105 side chain. Thus, both orientations of TBBz involve similar interactions 
with NQO2. 
Oxidized NQO2 was also co-crystallized with DMAT. Data from an NQO2ox−DMAT 
crystal were collected to 1.5 Å, and the structure was refined to an Rfree value of 0.2023 
(Table 4.4). Because these data were collected from a synchrotron source at a wavelength 
farther from the bromine edge, the anomalous signal for bromine was weaker. 
Nonetheless, DMAT was modeled in two orientations by anchoring the bromines to 
anomalous scattering peaks (Figure 4.5C,D). Like the NQO2ox-TBBz complex, DMAT 
makes π-stacking interactions with the FAD isoalloxazine ring and the phenyl ring of 
F178. The first orientation of DMAT is similar to that of TBBz, in which the inhibitor 
makes two halogen bonds to the backbone carbonyl of G174 and the carboxyamide of 
N161; however, the dimethylamine substituent of DMAT prevents the benzimidazole 
nitrogen from making a π-hydrogen bond with W105. The alternate orientation of DMAT 
(Figure 4.5D) is rotated 60° clockwise and binds in an orientation almost identical to that 
of TBBz (Figure 4.5B). As one might anticipate from their structures, TBBz and DMAT 
show very similar modes of binding to the NQO2 active site. The fact that the 
dimethylamine moiety of DMAT prevents it from binding optimally in the preferred 
mode explains its slightly lower affinity for NQO2 (a KD of 36 nM compared to a KD of 
18 nM for TBBz).  
4.3.4 Binding of DMAT to Reduced NQO2.  
Our kinetic analysis indicated that DMAT binds with a similar affinity to the reduced and 
oxidized forms of NQO2. To elucidate the mode of binding of DMAT to reduced NQO2, 
crystals of oxidized NQO2 in complex with DMAT (NQO2ox-DMAT) were reduced in a 
soaking solution containing SCDP. A data set from a crystal of the NQO2red-DMAT 
complex was collected to 1.90 Å and the structure refined to an Rfree value of 0.2268 
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(Table 4.4). It was clear that reduction of the FAD co-substrate had a major effect on 
binding of DMAT: it was less deeply buried in NQO2red than in NQO2ox, and the space 
made available was filled with water molecules that mediate interactions between DMAT 
and reduced NQO2. As with the NQO2ox-DMAT complex, DMAT bound to the reduced 
enzyme in two orientations: this was clear from the presence of three strong anomalous 
scattering peaks representing the common positions of the bromine atoms in the two 
orientations (Figure 4.5 E,F). Two of the bromines interact with three water molecules 
(numbers 32, 16, and 85) that in turn are hydrogen-bonded to the backbone carbonyl of 
G174 and the carboxyamide of N161. The third common bromine atom makes a π-
halogen bond to the W105 indole group. The less deeply buried position of DMAT in the 
reduced NQO2 structure means that it no longer makes π-stacking interactions with F178, 
and the area in contact with the isoalloxazine ring is also reduced.  
4.3.5 Structural Changes in FAD in the NQO2red-DMAT Complex.  
The reduction of the planar isoalloxazine ring of FAD leads to a “butterfly bend” along 
the N5-N10 axis (37). On this basis, refinement of the NQO2red-DMAT structure was 
conducted using a modified stereochemical restraint set for FAD, in which planar 
restraints and associated bond and angle restraints around N5 and N10 were removed. 
The final refined structure indicated butterfly bend angles of 3.0° and 5.4° for the 
isoalloxazine ring systems in chains A and B, respectively. To validate that the small 
change in the FAD isoalloxazine structure was due to reduction of the FAD, and not 
simply removal of stereochemical restraints, the refined NQO2 structures were further 
subjected to simulated annealing refinement against data from both oxidized and reduced 
crystals (Table 4.5). In the absence of stereochemical restraints around N5 and N10, the 
isoalloxazine ring of NQO2ox in complex with TBBz refined to 1.8° and 2.4° for each 
FAD co-substrate; for NQO2ox in complex with DMAT, the bend was 2.7° and 2.4° for 
each FAD co-substrate. Thus, FAD is bent approximately 2° upon reduction and binding 
of DMAT.  
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Table 4.5 Conformational Changes in the Isoalloxazine Ring upon Reduction 
NQO2 Inhibitor Subunit N5-N10 bend a,b 
Oxidized TBBz A 1.81 ± 0.06 
  B 2.44 ± 0.04 
  Average 2.13 
 DMAT A 2.74 ± 0.01 
  B 2.39 ± 0.06 
  Average 2.57 
Reduced DMAT A 2.95 ± 0.11 
  B 5.37 ± 0.23 
  Average 4.16 
a Both oxidized and reduced structures were subjected to three separate rounds of 
simulated annealing refinement in the absence of planar restraints for N5-N10 axis and 
angle restraints for the C4X-N5-C5X/C10-N10-C9A angles. 
b The “butterfly” bend along the N5-N10 axis was calculated using the atomic positions 
of the dimethylbenzene and pyrimidine “wings” and principle component analysis to find 
the angle between the two best-fit planes.  
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4.4 Discussion 
TBB, TBBz, and DMAT are ATP-competitive inhibitors of CK2 that reduce the level of 
autophosphorylation of CK2β by CK2α and CK2α′. The three inhibitors induce apoptosis 
in HeLa, Jurkat, and HL-60 cells (10, 14, 17, 34) ostensibly by preventing CK2 function 
to promote cell survival over apoptosis (3, 38, 39). However, both TBBz and DMAT, but 
not TBB, were potent inducers of apoptosis in cells expressing an inhibitor-resistant CK2. 
Furthermore, in cells expressing wild-type CK2, both TBBz and DMAT are more potent 
inducers of apoptosis than TBB (10, 14, 17, 34). On this basis, interactions of TBBz and 
DMAT with molecule(s) other than CK2 appear to contribute to their induction of 
apoptosis. Through a proteomics screen, NQO2 was identified as a target of TBBz and 
DMAT, but not TBB. In the study presented here, we have shown that both TBBz and 
DMAT bind to and inhibit NQO2 at nanomolar concentrations, whereas the interaction 
between NQO2 and TBB is much weaker. The interactions of TBB, TBBz, and DMAT 
with NQO2 therefore correlate with their apoptotic effects in cells transformed with 
inhibitor-resistant CK2 (17). Because several other kinase inhibitors also bind NQO2 (24, 
25, 27, 40), we sought to understand the structural basis for the interaction between 
NQO2 and TBBz or DMAT. In particular, we wanted to determine how similar the active 
site of NQO2 was to the ATP binding site of CK2 and other kinases.  
While TBB, TBBz, and DMAT all bind CK2 with nanomolar affinity (11, 14, 41) (Table 
4.1), the affinity of TBB for oxidized NQO2 is 3 orders of magnitude lower than that of 
TBBz and DMAT (Table 4.1). Similarly, the IC50 values of TBB, TBBz, and DMAT for 
inhibition of NQO2 are dramatically different (Table 4.1), with TBB exhibiting much 
weaker inhibition of NQO2, consistent with its relatively low binding affinity. The 
difference in binding affinities between TBB and TBBz/DMAT can be explained by the 
charge of the inhibitors (Figure 4.1). The triazole function of TBB has an estimated pKa 
of 5 and is expected to be anionic at physiological pH, whereas the imidazole functions of 
TBBz and DMAT have pKa values of approximately 9 and will therefore be neutral at 
physiological pH (34). In CK2, the negatively charged triazole portion of TBB interacts 
with a region of positive electrostatic potential (Figure 4.6A,B) (6, 42). In the case of 
oxidized NQO2, the surface of the active site has a negative electrostatic potential that 
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precludes high-affinity interactions with anionic TBB (Figure 4.6C). Thus, differences in 
the electrostatic potential of the active sites of NQO2 and CK2 explain why TBB binds 
with a relatively low affinity to the NQO2 active site.  
DMAT and TBBz bind with a similar high affinity to oxidized NQO2, and our structural 
analysis shows that they bind in a similar manner, stacking on top of the isoalloxazine 
ring of FAD with the bromine atoms making halogen bonds to nearby carbonyl groups as 
well as the indole side chain of W105 (Figure 4.5). Both TBBz and DMAT bind in two 
orientations. For TBBz, the preferred orientation is one in which two bromine atoms and 
one of the imidazole nitrogens make bonds with two carbonyl groups and W105, 
respectively (Figure 4.5A). The small difference in affinity between TBBz and DMAT is 
likely due to the inability of DMAT to fully adopt the preferred conformation (Figure 
4.5A) because of a steric clash between its dimethylamine function and the indole side 
chain of W105 (Figure 4.5C). Structures of CK2 in complex with TBBz and DMAT 
show that the two inhibitors bind to the CK2 active site in an identical manner (PDB 
entries 1ZOE and 2OXY, respectively) (42, 43). In CK2, the two drugs are sandwiched 
between hydrophobic residues and two of the bromine atoms make halogen bonds with 
backbone carbonyl groups of E114 and V116 (Figure 4.6B). In the case of CK2, DMAT 
binds with 10-fold greater affinity than TBBz because of additional favorable interactions 
mediated by the dimethylamine group.  
In summary, the NQO2 active site appears to mimic the adenine binding site of CK2 in 
the sense that it provides a hydrophobic crevice that can accommodate planar aromatic 
molecules, and there are two carbonyl groups that are well placed to mediate charge 
interactions with the bromine atoms of these inhibitors in a manner similar to that 
observed in CK2. On the other hand, NQO2 provides an environment that allows both 
TBBz and DMAT to bind in alternate orientations, whereas binding to CK2 is limited to a 
single orientation. Furthermore, the presence of the dimethylamine group on DMAT 
favors binding to CK2 but disfavors binding to NQO2. These observations, in addition to 
the striking differences in the electrostatic potential in the two active sites, indicate that 
the binding of TBBz and DMAT to NQO2 is adventitious and on the whole the NQO2 
active site is not a good mimic of the CK2 active site.  
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Figure 4.6 Binding of DMAT to CK2, Oxidized NQO2, and Reduced NQO2. 
(A) The molecular surface of the CK2 active site is shown with bound DMAT (PDB 
entry 1ZOE, (42)) and colored according to electrostatic potential. (B) Details of 
interactions between DMAT (orange carbons) and the CK2 active site. Note that TBBz 
(not displayed) binds in exactly the same manner as DMAT(42). The position of CK2-
bound TBB (green carbons, PDB entry 1J91,(44)) is also shown: the negative charge of 
the triazole moiety (Figure 4.1) causes a shift toward a more positively charged region in 
the CK2 active site (42). (C) Molecular surface of the active site in oxidized NQO2 with 
bound DMAT in two orientations. (D) Details of the binding of DMAT to oxidized 
NQO2. (E) Molecular surface of reduced NQO2 with bound DMAT in two orientations, 
including three water molecules (cyan) that are present in the reduced, but not the 
oxidized, structure. (F) Details of the binding of DMAT to reduced NQO2. Electrostatic 
potentials were calculated using APBS (45), and partial charges were calculated using 
PDB entry 2PQR (46). In the case of oxidized FAD, the sum of the partial charges in the 
isoalloxazine ring yielded an overall charge of -0.2; for reduced FAD, an additional full 
charge was added and distributed roughly evenly between the N1 and O2 atoms. The 
figures were made in PyMol (version 1.7.0.5, Schrödinger, LLC), and the color limits for 
the electrostatic surfaces were set to -12 kT (red) to 12 kT (blue) for all three structures.   
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Another major difference between the active sites of NQO2 and CK2 is that the NQO2 
active site can exist in either an oxidized or reduced form. The origin of the change in 
oxidation state is the isoalloxazine ring of FAD: upon interaction with a reduced 
nicotinamide co-substrate (NRH or SCDP), two electrons are transferred onto the 
isoalloxazine ring of FAD (47). Upon reduction, the N5 atom is protonated and its orbital 
changes from planar sp2 to trigonal pyramidal sp3 hybridization. These changes allow it to 
donate a hydrogen bond, and the change in orbital hybridization also disrupts the 
planarity of the isoalloxazine ring, leading to a small butterfly bend. Thus, reduction of 
FAD leads to a relatively minor structural change in the isoalloxazine ring but more 
importantly imparts a negative charge that will be largely centered around N1 and O2 of 
the isoalloxazine ring. Our crystallographic study indicates that reduction of the 
isoalloxazine ring completely changes the mode of binding of DMAT: it binds in a more 
peripheral location, and the interactions of the bromine atoms with the carbonyl groups 
are mediated through intervening water molecules.  
Compounds that bind with high affinity to only one form of NQO2, either oxidized or 
reduced, exhibit predictable effects on the steady-state kinetics of the system. Thus, 
TBBz binds with high affinity to oxidized NQO2 and competes with SCDP, resulting in 
significant changes in the apparent Michaelis constant for SCDP; furthermore, the 
inhibition constant against SCDP is close to its dissociation constant, as expected. This 
does not mean that TBBz completely fails to bind to reduced NQO2; in fact, given the 
similarity between TBBz and DMAT, it is likely that TBBz binds to the reduced form of 
NQO2 in a manner similar to that observed for DMAT. However, because the affinity of 
the interaction between TBBz and reduced NQO2 is relatively weak compared to binding 
of TBBz to oxidized NQO2, the inhibition observed in the steady-state kinetic analysis is 
due almost entirely to its binding to oxidized NQO2, and therefore, TBBz has little 
impact on the Michaelis constant for menadione.  
The situation appears to be more complicated for an inhibitor such as DMAT that binds 
with similar affinities to both oxidized and reduced NQO2. The lower affinity of DMAT 
for oxidized NQO2 made the interaction between DMAT and reduced NQO2 apparent in 
our steady-state kinetic analysis, where the presence of DMAT had a significant effect on 
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the Michaelis constants for both SCDP and menadione. In this case, changes in both 
Michaelis constants were used to calculate inhibition constants (KI values) of 121 nM 
against SCDP and 302 nM against menadione, both of which are significantly higher than 
the dissociation constant (36 nM) for binding of DMAT to oxidized NQO2. This is a 
confusing result because the inhibition constant is expected to represent a dissociation 
constant for the inhibitor. The relatively high KI values for DMAT are in line with the 
high IC50 for DMAT, which is 6-fold higher than the IC50 for TBBz, despite the fact that 
DMAT binds to oxidized NQO2 with a KD that is only twice as high as that of TBBz. It 
seems as though the ability of DMAT to bind with similar affinities to both the oxidized 
and reduced forms of NQO2 actually weakens its ability to inhibit NQO2-mediated 
catalysis. Although we can only speculate about the molecular origins of this effect, it 
highlights the complicated nature of NQO2 and the fact that binding interactions may 
have unpredictable effects on catalysis and, by extension, in vivo function.  
4.4.1 Inhibition of NQO2 by Other Kinase Inhibitors  
Interestingly, NQO2 was also found to be the only non-kinase target of two Abl kinase 
inhibitors as well as protein kinase C bisindolylmaleimide inhibitors (24, 25, 27). 
Specifically, the cancer wonder drug imatinib and its second-generation derivative, 
nilotinib, were found to bind and inhibit NQO2. Structural investigation showed that 
rings A and B of imatinib that occupy the ATP binding site of the Abelson kinase were 
also found to occupy the active site of NQO2 (26). While imatinib does not inhibit CK2 
(48) and CK2 inhibitors do not inhibit the BCR-ABL kinase (15), both were found to 
interact with the non-kinase target NQO2 (17, 25). Therefore, there are several classes of 
kinase inhibitors that bind NQO2 fortuitously, and the specific cellular effects of these 
kinase inhibitors may be due in part to their interaction with NQO2.  
One of the cellular functions of NQO2 may be the detoxification of quinones by two-
electron reduction; however, the natural substrates have not been identified, and it is not 
obvious why NQO2 would have evolved a preference for NRH over NAD(P)H to fulfill a 
detoxification function. A second possible function for NQO2 may involve cellular 
signalling in response to changes in metabolic and/or redox status. In particular, NQO2 
was shown to stabilize p53 from 20S proteasomal degradation in the presence of NRH 
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(20, 21). While the canonical degradation pathway of p53 is ubiquitin-dependent and uses 
the 26S proteasome, degradation by the 20S proteasome is ubiquitin-independent and is 
modulated by quinone reductase 1 (NQO1) and NQO2 (20, 21, 49). Interestingly, NQO1, 
the “sister enzyme” of NQO2, uses NAD(P)H as a co-substrate and is specific for a 
different set of inhibitors. Given their difference in co-substrate specificity, NQO1 and 
NQO2 may be regulating p53 stability in response to changes in the cellular redox state, 
as reflected in the levels of NAD(P)H and NRH, but this remains a matter of speculation. 
Strikingly, numerous NQO2 inhibitors such as melatonin, resveratrol, chloroquine, 
imatinib, 9-aminoacridine, and quinacrine have been shown to induce p53-dependent 
apoptosis (50–54). Melatonin and resveratrol both induce p53 phosphorylation at serine 
15, which is essential to the transactivation of p53-induced apoptotic genes (50, 53); 
chloroquine, 9-aminoacridine, and quinacrine, on the other hand, increase p53 levels 
without phosphorylation at serine 15, which is thought to lead to transcription-
independent apoptosis modulated by p53 (51, 54, 55). The fact that NQO2 binds all of 
these bioactive compounds is remarkable, but a contribution from NQO2 to the cellular 
effects of these compounds has yet to be demonstrated.  
The cellular roles of NQO2 are still very much a matter of debate. In this regard, the 
cellular effects of two high-affinity (nanomolar) inhibitors of NQO2 have been 
investigated. S29434 was developed by the French pharmaceutical company Servier as a 
compound that inhibits the third melatonin binding site (MT3), which is NQO2, without 
inhibition of the two other melatonin binding sites, both of which are G-protein coupled 
receptors (56, 57). S29434 prevents generation of reactive oxygen species in vitro and in 
vivo, and it prevents paraquat induced toxicity to cell lines in a ROS-dependent manner 
(58, 59). Similarly, NQO2 knockout mice were resistant to menadione induced toxicity 
(60), which likely occurs through oxidative stress resulting from NQO2-mediated 
metabolism of menadione. Therefore, inhibitors of NQO2 can prevent cell death caused 
by compounds that are toxic when they are metabolized by NQO2; however, inhibition of 
NQO2 appears to have little effect on cells in the absence of these toxic compounds.  
A second series of inhibitors, based on an imidazoacridin-6-one core, was identified 
through a computational screen of the National Cancer Institute chemical database (61). 
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The compound that was initially identified (C1311 or NSC645809) is a known DNA 
intercalating agent and an inhibitor of FLT3 kinase (62). This compound, as well as 
related imidazoacridin-6-ones, inhibits NQO2 in the nanomolar range and is cytotoxic to 
cells. N-Oxide derivatives of the imidazoacridin-6-one compounds that retained 
nanomolar affinity for NQO2 but had reduced DNA intercalating properties were 
developed (61). Surprisingly, the presence of the N-oxide modification also decreased 
cytotoxicity by 10 to 20-fold in a variety of cell lines. As such, it appears that the 
apoptotic effects of this class of inhibitors are due largely to their ability to intercalate 
DNA. It was also noteworthy that the seven breast cancer cell lines tested in the study 
exhibited up to 50-fold differences in NQO2 activity but virtually no difference in their 
sensitivity to the imidazoacridin-6-one inhibitors (61). The N-oxide derivatives of the 
imidazoacridin-6-one compounds were much less toxic than the parent compounds but 
still had toxicity IC50 values in the low micromolar range; this toxicity was probably not 
due to inhibition of NQO2, because the IC50 values for NQO2 inhibition were typically 
2−3 orders of magnitude lower than the toxicity IC50 values. That is, for N-oxide 
derivatives of the imidazoacridin-6-one compounds, concentrations that would 
completely inhibit NQO2 do not appear to be cytotoxic.  
Article From the studies with S29434 and the N-oxide derivatives of imidazoacridin-6-
one compounds, it appears that inhibition of NQO2 is not cytotoxic; similarly, NQO2 
knockout mice were almost identical to wild-type littermates, although there were some 
differences, including myeloid hyperplasia due to a decreased level of apoptosis of 
myeloid cells (60). The NQO2 knockout mice were also more susceptible to benzopyrene 
induced carcinogenesis, and the absence of NQO2 prevented TNFα-induced apoptosis in 
an NFκB-dependent manner (63, 64). In summary, it appears that, on its own, inhibition 
of NQO2 or genetic knockout is not toxic to cells. Instead, it may be that inhibition or 
removal of NQO2 in conjunction with other “inputs” – metabolic or oxidative stress, drug 
mediated changes in the activity of kinases, DNA damage, and so on – leads to more 
pronounced toxicity and/or other cellular effects. Because kinase inhibitors are designed 
to be kinase specific, the fact that a number of efficacious inhibitors bind NQO2 with 
high affinity challenges the “single-target” approach in drug discovery. It may be that 
binding of both NQO2 and kinases is important for the cellular effects of the inhibitors, 
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including enhanced apoptosis of transformed cells. As CK2 and other kinase inhibitors 
continue to be developed and used as therapeutics, it will be crucial to characterize off-
target interactions with NQO2 and possibly other non-kinase targets to fully understand 
the cellular effects of these compounds and the roles of the individual targets in these 
effects.  
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Chapter 5 
5 The Binding of DNA Intercalating Agents to Oxidized 
and Reduced Quinone Reductase 27 
Quinone reductase 2 (NQO2) is an enzyme that may also have intracellular signalling 
functions. A wide range of planar aromatic compounds bind NQO2, and we have 
identified three DNA intercalating agents – ethidium bromide (EtBr), acridine orange 
(AO), and doxorubicin – as novel nanomolar inhibitors of NQO2. The cationic EtBr and 
AO bound reduced NQO2 with 50-fold higher affinity than oxidized NQO2, while 
doxorubicin only bound oxidized NQO2. Crystallographic analysis of oxidized NQO2 in 
complex with the inhibitors indicated that inhibitors bound oxidized NQO2 deeply in the 
active site. The aromatic faces were sandwiched between the isoalloxazine ring of FAD 
and the phenyl ring of F178, and their edges making direct contacts with active site 
residues. In reduced NQO2, EtBr and AO occupied a more peripheral position in the 
active site, allowing several water molecules to interact with the polar end of the 
negatively charged isoalloxazine ring. We also showed that AO inhibited NQO2 at a non-
toxic concentration in cells while EtBr was less effective at inhibiting NQO2 in cells. 
Together, this study suggested a role of NQO2 as a sensor for potential DNA 
intercalating agents. 
5.1 Introduction 
Quinone Reductase 2 (NQO2) was historically classified as a detoxification enzyme 
responsible for the reduction of potentially cytotoxic quinones(1). Similar to its sister 
enzyme Quinone Reductase 1 (NQO1), NQO2 catalyzes an obligate 2-electron transfer to 
generate the hydroquinone, thereby preventing production of reactive semi-quinones. 
While NQO1 efficiently catalyzed quinone reduction using NAD(P)H as a reducing 
coenzyme (kcat/KM = 440 min-1ŊµM-1), NQO2 used NAD(P)H inefficiently, with a 
catalytic efficiency 700-fold lower than NQO1 (kcat/KM = 0.62 min-1ŊµM-1) (2). On this 
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basis, it appears that NQO2 has evolved to avoid using the canonical reducing coenzymes 
NADH and/or NADPH. Instead, NQO2 exhibits a preference for unusual, and possibly 
non-physiological, reducing coenzymes, such as dihydro-nicotinamide riboside (NRH) 
(2). Although nicotinamide riboside (NR+) participates in NAD metabolism, it is 
currently unknown how the reduced form, NRH, is generated in cells. On this basis, the 
availability of the reducing coenzyme for NQO2 in cells is currently an open question. 
Furthermore, the only cellular quinone substrate of NQO2 is ubiquinone, which resides in 
the mitochondria and is inaccessible to NQO2 (3). Given its inefficient utilization of 
NAD(P)H and lack of physiologically relevant quinone substrates, NQO2 may have 
important cellular functions beyond reduction of quinones. 
NQO2 has been implicated in cell signalling as well as the formation of reactive oxygen 
species (4–6). Specifically, NQO2 modulated the 20S proteosomal degradation of p53 in 
a NRH-dependent manner (4, 7). Furthermore, NQO2 also indirectly regulates the 
AKT/cyclin-D1/Rb and NFκB signalling pathways (5, 8). Numerous bioactive 
compounds interact with NQO2, raising the possibility that some of the cellular effects of 
the compounds may be attributed to NQO2. These compounds ranged from targeted 
kinase inhibitors (imatinib and nilotinib (9, 10), CK2 inhibitors (11), PKC inhibitors 
(12)), antimalarial compounds (primaquine, chloroquine, and quinacrine (13)), natural 
flavonoids (quercetin (2)), stilbenoid (resveratrol (14)), and hormones (melatonin (15)). 
All of these compounds perturb cellular proliferation and/or apoptosis, but the role of 
NQO2 in these processes is not known. 
The active site of NQO2 is composed of a large hydrophobic pocket with a planar 
aromatic surface provided by the isoalloxazine ring of the FAD cofactor (16). As such, 
the planar aromatic portions of NQO2 inhibitors bind to the active site through pi-pi 
stacking interactions with the isoalloxazine ring and hydrophobic residues. Given the 
planar nature of NQO2 inhibitors, it is perhaps not surprising that a number of them, such 
as imatinib, quinacrine, and 9-aminoacridine can also intercalate DNA (17–19). In fact, 
several compounds known to intercalate into DNA (9-aminoacridine and C1311) were 
identified from an in silico screening of NQO2 inhibitors (8, 20). Given the potential 
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roles of NQO2 in cell signalling and the nature of compounds that bind NQO2, we 
investigated whether NQO2 is a target for additional DNA intercalating agents.  
DNA intercalating compounds are polycyclic aromatic molecules that act as potent 
cytotoxic and mutagenic agents to cells. In 1961, Leonard Lerman proposed and 
eventually showed that these compounds can unwind and extend DNA by inserting 
themselves between two nucleotide bases (21). In highly proliferating cells, these 
compounds are cytostatic by inhibiting DNA replication or transcription (22, 23). For 
cells that overcome replicative stress, the intercalating agents elongate DNA and cause 
DNA slippage leading to indel mutations during DNA replication (24, 25). When present 
in the environment, cells can deal with these harmful compounds by active excretion 
through efflux pumps such as P-glycoprotein (multidrug resistant-associated protein) 
and/or metabolism by cytochrome P450 (26); however, cells unable to clear DNA 
intercalators are at risk of cell growth retardation and genomic instability.  
Since DNA intercalators can be detrimental to cells, we hypothesize that NQO2 can 
recognize potential DNA intercalating agents and function, at least in part, as a sensor for 
these compounds. In this study, we have tested three well-characterized DNA 
intercalating agents – ethidium bromide (EtBr), acridine orange (AO), and doxorubicin – 
and found that they are all nanomolar inhibitors of NQO2. We further characterized these 
three novel inhibitors of NQO2 by means of enzyme kinetics, isothermal titration 
calorimetry, and crystallographic analysis. We found that the cationic EtBr and AO 
bound reduced NQO2 with a 50-fold higher affinity than oxidized NQO2; this can be 
explained by the increased negative electrostatic potential in the active site of reduced 
NQO2. In this regard, we have identified AO to be the highest affinity inhibitor for 
reduced NQO2, with a dissociation constant of 0.36 nM. Structurally, the inhibitors bind 
to the NQO2 active site in a manner that resembles their interaction with DNA. Lastly, 
we demonstrate that a non-toxic concentration of AO can inhibit NQO2 activity in cells. 
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5.2 Materials and Methods 
5.2.1 Reagents 
Recombinant NQO2 was expressed in E. coli and purified as previously described (27). 
1-(3-sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine (SCDP) is an analogue of 
NRH obtained from Sigma-Aldrich. Nicotinamide riboside (NR) was purchased from 
High Performance Nutrition (Irving, CA, USA) and dihydronicotinamide riboside (NRH) 
was prepared according to previously described protocol with NR (28). Ethidium 
bromide was obtained from Bioshop, AO and doxorubicin were obtained from Caymen 
Chemical.  
5.2.2 Enzymatic Activity Measurements and Analysis 
Enzyme activity was measured by monitoring the consumption of SCDP at an absorbance 
peak of 360 nm using a Cary 100-Bio spectrophotometer (Varian). The reaction was 
initiated by addition of NQO2 to a final concentration of 154 pM in a stirred cuvette 
containing 150 µM SCDP and 5 µM menadione (Sigma) at 30°C with EtBr (1.9 nM to 
2.6 µM), AO (7.8 nM to 1 µM) or doxorubicin (80 nM to 50 µM) in a buffer (50 mM 
Tris-HCl pH 7.5, 150 mM NaCl). IC50 values were calculated using a dose-response 
model and represented as relative inhibition.  
The constants for inhibition (KI values) of NQO2 by EtBr were determined using the 
same kinetics assay described for determination of IC50 values. For each inhibitor, kinetic 
assays were performed either with a constant SCDP concentration of 150 µM and a 
varying menadione concentration or with a constant menadione concentration of 5 µM 
and a varying SCDP concentration. NQO2 is subject to substrate inhibition by 
menadione, and inhibitors of NQO2 can be competitive against SCDP, menadione, or 
both. On this basis, we used an equation for steady-state ping-pong catalysis that includes 
a term for substrate inhibition by menadione (KI(Md)), as well as constants for inhibition 
against both the oxidized and reduced forms of the enzyme (29): 
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Equation 5.1 Inhibition of NQO2 Catalysis 
In Equation 5.1, [SCDP] and [Md] are the concentrations of SCDP and menadione 
respectively. KI(MD) is the inhibition constant that accounts for substrate inhibition. [I] is 
the concentration of inhibitor and KI(α) and KI(β) are the inhibition constants that modify 
the apparent Michaelis constants KM(SCDP) and  KM(Md), respectively. That is, KI(α) is the 
constant that accounts for the change in KM(SCDP) in the presence of inhibitor; hence, it 
describes the component of inhibition that is competitive against SCDP. KI(β) is the 
constant that accounts for the change in KM(Md) in the presence of inhibitor, and it 
describes the component of inhibition that is competitive against menadione. Fixing the 
kinetic parameters of the uninhibited steady-state kinetics KM(SCDP) (142 µM), KM(Md) 
(8.07 µM), and KI(Md) (1.62 µM) with values previously determined (29), Vmax, KI(α), and 
KI(β) were determined by globally fitting data to Equation 5.1 using nonlinear regression 
(Igor Pro version 6.34A) with the IC50 values as initial estimates.  
5.2.3 Isothermal Titration Calorimetry  
Isothermal titration calorimetry (ITC) was used to assess the direct binding of the 
inhibitors to NQO2. Titrations were performed using a MicroCal VP-ITC 
microcalorimeter and all data were analyzed using Origin 7.0 (MicroCal). Samples of 
concentrated NQO2 (700 µM in 50 mM Tris-HCl, 150 mM NaCl, pH 7.5) and 
concentrated inhibitors (20 to 60 mM in H2O or DMSO) were diluted into ITC buffer (50 
mM sodium phosphate, 150 mM NaCl pH 7.55) to final concentrations of 8 µM and 80 to 
260 µM respectively. In cases where inhibitor stocks were suspended in DMSO, an equal 
amount of DMSO was also added to the protein sample to match the buffer composition 
Vobs =
Vmax[SCDP][Md]
KM(SCDP)app [Md]+ KM(Md)app [SCDP]+ [SCDP][Md]
where KM(SCDP)app = KM(SCDP)(1+
[Md]
KI(Md)
+ [I]KI(α )
)
and KM(Md)app = KM(Md)(1+
[I]
KI(β )
)
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between the sample and titrant. All solutions were thoroughly degassed by stirring under 
vacuum. All titrations were performed at 25°C or 35°C with 3-10 µl injections spaced by 
3 to 5 minute intervals. The integrated binding isotherms were corrected for the heat of 
dilution using data from titrations of the individual inhibitors into the respective matched 
buffers in the absence of NQO2. For the binding of inhibitors to oxidized NQO2, the 1.35 
mL sample cell was filled with an 8 µM solution of NQO2 and the 250 µL syringe was 
filled with 80 µM EtBr, AO, or doxorubicin. All ITC titration data towards oxidized 
NQO2 were fitted to a single-site binding model with MicroCal Origin7 software. 
Reduced NQO2 is subject to rapid oxidation (30); however, the calorimeter provided a 
closed environment that limited diffusion of oxygen into the solutions. To titrate 
compounds against reduced NQO2, SCDP was added to degassed solutions of both 
NQO2 and the inhibitors to a final concentration of 500 µM. To measure the very high 
affinities of EtBr and AO towards reduced NQO2, competition titrations were performed 
by adding 80 µM of EtBr or AO into 8 µM of NQO2 pre-mixed with 80 µM chloroquine 
(CQ) and 500 µM SCDP. Additionally, the binding of CQ alone to reduced NQO2 was 
determined by titrating 160 µM CQ into 8 µM of NQO2 and 500 µM SCDP. This second 
binding isotherm was fitted to a single-site binding model. Using the thermodynamic 
parameters of CQ to reduced NQO2, the binding isotherms of the displacement titrations 
were fitted to a competitive binding model using MicroCal Origin7 software to determine 
the thermodynamic parameters EtBr and AO.  
5.2.4 Crystal Structure Analysis 
Oxidized NQO2 (NQO2ox) was co-crystallized with EtBr, AO, or doxorubicin by 
hanging drop vapour diffusion against reservoirs containing 0.1 M HEPES pH 7.5, and 
1.3 – 2.0 M (NH4)2SO4. To obtain crystals of reduced NQO2 in complex with EtBr or 
AO, reduction of NQO2ox-inhibitor crystals was performed as previously described (30). 
Briefly, crystals of NQO2ox-EtBr or AO were repeatedly soaked into 1 µL of reducing-
soak solution with 0.1 M HEPES pH 7.5, 2.0 M (NH4)2SO4, 10 mM SCDP, and 1 mM of 
inhibitor, for 2 minute intervals until the crystals bleached. They were then transferred to 
a soak without SCDP before briefly passing through a cryoprotectant solution (2.0 M 
(NH4)2SO4, 0.1 Hepes pH 7.5, 20% glycerol) and plunged into liquid nitrogen. To 
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prevent auto-oxidation of NQO2, the entire crystal mounting process from harvesting to 
cryo-cooling was performed under an anoxic atmosphere in a glove bag purged with N2. 
Crystallographic data were collected from a rotating anode source, processed using 
MOSFLM (31), and merged using Scala (32).  The structures were solved by molecular 
replacement with PDB-ID 1QR2 as a starting model (16); refinement was carried out 
using PHENIX (33). All crystals had the same primitive orthorhombic space group and 
contained a dimer in the asymmetric unit; given the high resolution of the 
crystallographic data, NCS restraints were not used for any of the refinements. Topology 
files for EtBr and AO were generated using PHENIX.ELBOW (33). The “butterfly bend” 
of the isoalloxazine ring was determined by simulated annealing with planar restraints 
removed, as previously described (30). 
5.2.5 DNA Binding Pocket Comparison 
The solvent accessible area in DNA or NQO2 binding pocket was calculated using 
POVME 2.0 (34, 35). Briefly, a contiguous area was generated from an arbitrary point in 
the binding site of the ethidium unwound DNA structure (36) or reduced NQO2-EtBr 
structure for a 10 Å spherical radius. Dimensions of the binding pockets were then 
measured at arbitrary points along the edge of the binding pocket. 
5.2.6 Effect of AO on HCT116 Colon Carcinoma Cells 
To determine the cytotoxicity of AO, HCT116 cells were seeded at 1000 cells per well in 
96-well plates and allowed to attach overnight. Cells were then treated with AO (0.014 to 
230 µM) and grown for an additional 48 hrs before assaying using Sulforhodamine B 
(SRB; Sigma) assay according to established protocol(37). Briefly, cells are fixed with 
trichloroacetic acid for 1 hr at 4°C and washed with water 3 times. Cells were then 
stained with 0.3% SRB in 1% acetic acid for 20 mins at room temperature and washed 
with 1% acetic acid 4 times. The dye was re-solubilized in 10 mM Tris base and 
absorbance was measured using at 560 nm (Victor multi-plate reader, Perkin Elmer). Cell 
growth in treated samples was normalized against controls that were not treated. Data 
were analyzed and plotted using Prism 6.0f (GraphPad Software Inc). 
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To assay the ability of AO to inhibit NQO2, HCT116 cells were seeded at 1000 cells per 
well in 96-well plates and allowed to attach overnight. Cells were then treated with 7.8 
µM to 1000 µM CB1954 with 50 µM NRH, with 50 µM NRH and 78 nM AO, or without 
NRH. Cells grew for an additional 48 hrs before being assayed using MTT dye. Briefly, 
cells were treated with 1 mM of MTT dye and were incubated at 37˚C for 2-4 hrs. Media 
was completely removed and the dye was solubilized in DMSO to be measured at 560 
nm using a plate reader. Cell growth in treatment wells was normalized against cells with 
no treatment and data were analyzed using Prism 6.0f (GraphPad Software Inc).   
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5.3  Results 
5.3.1 DNA Intercalating Agents Inhibit NQO2 
Ashman and co-workers first characterized NQO2 in 1962 and showed that a small 
concentration (10 nM) of a number of anthracene derivatives inhibited its activity (38). 
Since then, many other planar polycyclic aromatic compounds were identified as 
inhibitors of NQO2 including compounds that also intercalate DNA (8, 20, 39). To 
characterize the interaction between NQO2 and DNA intercalating agents in greater 
detail, we investigated the ability of 5 different DNA intercalating molecules to inhibit 
NQO2 (Figure 5.1). Three of the intercalating agents – ethidium bromide (EtBr), acridine 
orange (AO), and doxorubicin – exhibited IC50 values in the nanomolar range; the other 
two, mitoxantrone and methylene blue, showed relatively weak inhibition of NQO2 
catalysis with IC50 values greater than 10 µM (Figure 5.2A and Table 5.1).  
 
Figure 5.1 Chemical Structures of DNA Intercalating Agents. 
NQO2 catalyzes quinone reduction by a ping-pong mechanism: the dihydronicotinamide 
co-enzyme is first oxidized, transferring a hydride ion to the NQO2-bound FAD co-
factor; the quinone substrate then binds to reduced NQO2, and electrons are transferred to 
produce the corresponding hydroquinone. Thus, NQO2 can exist in either an oxidized or 
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reduced state, and inhibitors can be competitive towards the dihydronicotinamide co-
enzyme or the quinone substrate. In a kinetic assay, this means that an inhibitor can raise 
the apparent KM for the dihydronicotinamide coenzyme or the quinone substrate. Using 
our previously established kinetic model (Equation 5.1), the terms KI(α) and KI(β) account 
for changes in the apparent KM of SCDP (an NRH analogue) and menadione (the quinone 
substrate) respectively (29). Our kinetic characterization of EtBr inhibition towards 
NQO2 showed that competition with menadione was the dominant mode of NQO2 
inhibition (KI(β) = 6.7 nM versus KI(α) > 500 nM; Figure 5.2B, Table 5.2). In other words, 
EtBr binds reduced NQO2 with much greater affinity compared to oxidized NQO2, and 
this interaction is responsible for inhibition of NQO2 catalysis.  
 
 
Figure 5.2 Ethidium Bromide, Acridine Orange, and Doxorubicin are Inhibitors of 
NQO2. 
(A) Determination of IC50 values for EtBr (), AO (¢), and doxorubicin (p) against 
NQO2-catalyzed reduction of menadione. The IC50 values are listed in Table 1. (B) 
Determination of kinetic inhibition constants for EtBr. The inhibition of NQO2 by EtBr 
was characterized using a constant menadione concentration (5 µM) and varying SCDP 
(left), and a constant SCDP concentration (150 µM) with varying menadione (right). The 
enzymatic activity was measured in the absence of EtBr () and at EtBr concentrations 
of 2 nM (¢), 10 nM (p), 50 nM (q), and 250 nM (u). The data were globally fitted to 
Equation 5.1 as described in Materials and Methods. The kinetic constants are 
summarized in Table 5.2.  
 
Table 5.1 Inhibition of NQO2 by DNA Intercalating Agents. 
Intercalating Agent IC50 (nM) 
Ethidium Bromide 11.8 ± 0.4 
Acridine Orange 24.6 ± 4.1 
Doxorubicin 254 ± 41.7 
Mitoxantrone > 10 000 
Methylene Blue > 10 000 
  
121 
Table 5.2 Steady-state Kinetic Parameters for Inhibition of NQO2 by EtBr. 
Vmax a 1184 ± 30 s-1 
KI(α) a,c 555 ± 2270 nM 
KI(β) a,c 6.7 ± 1.24 nM 
Km (SCDP)b 142 µM 
Km (menadione)b 1.62 µM 
Ki (menadione)b 8.07 µM 
a Calculated by globally fitting data to equation 1 as described in Methods. 
b Steady state kinetic parameters for the uninhibited reaction were determined previously 
(29) 
c KI(α)  and KI(β)  are the constants for inhibition against SCDP and menadione, 
respectively. 
 
5.3.2 Binding of DNA Intercalating Agents to Oxidized and 
Reduced NQO2 
The preferential binding of EtBr to reduced NQO2 is of interest because the reduced form 
of NQO2 appears to play an important role in cells. That is NQO2 was shown to inhibit 
p53 degradation in the presence of NRH, and on this basis it appears that reduced NQO2 
is the “active” state of the enzyme that is capable of regulating p53 (4). To further 
characterize interactions between DNA intercalating agents and NQO2, the binding of 
EtBr, AO, and doxorubicin to both oxidized and reduced NQO2 was measured using 
Isothermal Titration Calorimetry (ITC). Of the three compounds, AO bound oxidized 
NQO2 with the highest affinity, almost 10-fold greater than both EtBr and doxorubicin 
(Table 5.3, Figure S5.1A-C). Preliminary titrations of AO and EtBr against reduced 
NQO2 indicated that their binding affinities were much higher compared to oxidized 
NQO2.  To accurately characterize the very high affinity binding of both EtBr and AO to 
reduced NQO2, competition ITC was used (40). In competition ITC, a compound with 
high binding affinity is titrated against the target protein in complex with a relatively low 
affinity ligand. In the case of NQO2, chloroquine (CQ) was used as the low-affinity 
ligand. A direct titration of reduced NQO2 with CQ yielded a KD value of 0.57 µM 
(Table 5.3, Figure S5.1G) similar to its inhibition constant (0.6 µM) determined 
previously using enzyme kinetics (13). Consistent with the kinetics assays, EtBr bound 
most tightly to reduced NQO2, with a KD over 60 times lower compared to the oxidized 
form (Table 5.3, Figure S5.1D).  The situation was similar for AO, which bound 
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preferentially to reduced NQO2 with sub-nanomolar affinity (Table 5.3, Figure S5.1E). 
Doxorubicin bound to oxidized NQO2 with sub-micromolar affinity but there was no 
observable binding to the reduced form (Table 5.3, Figure S5.1F).  
Table 5.3 Binding of NQO2 Inhibitors to Oxidized and Reduced NQO2 
NQO2 Inhibitor KD (nM) ΔG  
(kcal/mol) 
ΔH  
(kcal/mol) 
-TΔS  
(kcal/mol) 
Oxidized EtBr 215 ± 33 -9.4 -7.8 ± 0.1 -1.6 
AO 29.4 ± 28.7 -10.3 -7.6 ± 0.2 -2.6 
Doxorubicin 274 ± 49 -8.9 -8.1 ± 0.2 -0.8 
Reduced EtBra 3.47 ± 0.33 -11.5 -6.7 ± 0.1 -4.8 
AOa 0.36 ± 0.12 -12.9 -6.5 ± 0.1 -6.3 
Doxorubicinb NB - - - 
CQ 578 ± 116 -8.5 -17.7 ± 0.5 9.2 
a Thermodynamic parameters were determined by competition titrations against NQO2 in 
complex with CQ as described in Methods. 
b There was no observable binding of doxorubicin to reduced NQO2 (Figure S5.1F).  
5.3.3 Crystal Structures of NQO2 with DNA Intercalating Agents 
There are numerous structures of oxidized NQO2 in complex with a variety of inhibitors, 
but only two in which inhibitor binding to reduced NQO2 has been structurally 
characterized (29, 30). In both cases, reduction of the FAD cofactor led to a striking 
change in the binding mode of the inhibitors. We have extended this comparative analysis 
by solving the high resolution crystal structures of oxidized and reduced NQO2 in 
complex with EtBr and AO, as well as doxorubicin in complex oxidized NQO2 (Table 
S5.1). In all of the oxidized NQO2 inhibitor complexes, the inhibitors are deeply buried 
in the active site and sandwiched between the isoalloxazine ring of FAD and the phenyl 
ring of F178 (Figure 5.3A, C, and E). As such, binding of the inhibitors to oxidized 
NQO2 includes common aromatic stacking interactions.  In the structure of reduced 
NQO2 with EtBr (Figure 5.3B) the overall orientation of ethidium has not changed, but it 
is positioned less deeply in the active site. The space vacated by the ethidium is filled 
with three water molecules that mediate hydrogen bonds between the amino group on the 
ethidium and N161 and G174 of NQO2. The situation is similar for AO: when bound to 
oxidized NQO2, AO is positioned deep in the active site, stacking over the oxygens of 
the isoalloxazine ring and making direct contact with N161 and G174 (Figure 5.3C). 
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However, AO has rotated and occupies a more peripheral location when bound to 
reduced NQO2 (Figure 5.3D), and again the space next to N161 and G174 is filled with 
water molecules. 
The difference in binding mode for EtBr and AO resembles what was observed for 
chloroquine (CQ) (30) and the protein kinase CK2 inhibitor DMAT (29), which both 
bound to oxidized NQO2 such that they were positioned deep in the active site and made 
direct contact with N161 and G174. When bound to reduced NQO2, however, both CQ 
and DMAT were positioned in a more peripheral location, and there were water 
molecules filling the space between N161, G174, and the inhibitors. It appears that the 
properties of the reduced isoalloxazine ring, which include a “butterfly bend” of 
approximately 5° (Table S5.1 and Figure S5.2) and a negative charge that will be 
delocalized between N1 and O2, make the region above the isoalloxazine oxygens less 
suitable for the aromatic stacking interactions observed in the oxidized structures. 
Instead, the inhibitors move away from this region which is then occupied by polar, non-
aromatic water molecules.  
The active site of NQO2 has a negative electrostatic potential that becomes much 
stronger when the isoalloxazine ring is reduced and carries a formal negative charge (29). 
Both EtBr and AO are positively charged at neutral pH, which explains their preference 
towards the negatively charged FADH over neutral FAD. Doxorubicin also has a positive 
net charge, but the charge resides on non-aromatic portions of the molecule that are 
excluded from the active site (Figure 5.3E). Therefore, a positive charge in the planar 
aromatic portions of NQO2 inhibitors appears to determine their preference for reduced 
NQO2. This is consistent with the two other NQO2 inhibitors, chloroquine and 
quinacrine, which both carry a positive charge in their aromatic portions and exhibit a 
marked preference for binding to reduced NQO2 (13).  
NQO2 crystallizes with a dimer in the asymmetric unit, and inhibitors can sometimes 
adopt different orientations in the two crystallographically distinct binding sites. This was 
the case for both the NQO2ox-EtBr and NQO2red-EtBr structures where electron density 
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for a second ethidium molecule in the B-chain active site became evident during 
refinement (Figure S5.3). The second ethidium interacts with the first by means of pi-pi 
 
Figure 5.3 Binding of Ethidium, Acridine Orange, and Doxorubicin to NQO2 
The inhibitors are sandwiched between the FAD co-factor (below the plane of inhibitor) 
and F178 (above the plane of the inhibitor) in oxidized NQO2 (A, C, E), and the 
inhibitors are excluded from this region by water molecules in reduced NQO2 (B, D). (A) 
Ethidium is deeply buried in the active site of oxidized NQO2 making hydrogen bonds 
with N161 directly and to D117, T71, and G68 via two water molecules. (B) Ethidium is 
less buried in reduced NQO2 and makes hydrogen bonds with N161 and G174 via three 
water molecules on the left side of the binding site, and with G68 and T71 directly on the 
right side of the binding site. (C) Acridine orange binds oxidized NQO2 by making 
hydrogen bonds to N161 via two water molecules. (D) In the reduced structure of NQO2 
in complex with AO, AO makes one hydrogen bond to E193 via a water molecule. (E) 
The planar moiety of doxorubicin is inserted into the left side of the binding cleft where it 
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is anchored by a hydrogen bond to N161. All electron density maps surrounding the 
inhibitors are Fc-Fo omit maps generated after three rounds of simulated annealing and 
contoured at 3 σ.  
planar stacking of their benzyl substituents, and the rest of the ethidium is loosely 
sandwiched between surface residues surrounding the B-chain active site and residues 
from a symmetry-related molecule. We believe that this mode of binding is induced 
primarily by crystal packing and likely irrelevant for NQO2 in solution. In contrast to 
EtBr, both AO and doxorubicin bound in exactly the same manner to both subunits of the 
NQO2 dimer.   
5.3.4 Comparison between Intercalators Binding to DNA and 
NQO2 
The high affinity binding of DNA intercalating agents prompted us to compare the 
binding pocket in unwound (intercalated) DNA with the active site of NQO2. Molecules 
that intercalate DNA create a cavity with pi-pi stacking interactions mediated by the 
bases and the potential for hydrogen bonds to the DNA backbone, as shown in the 
structure of ethidium bound to DNA (36) (Figure 5.4A). The binding pocket in the DNA 
could accommodate molecules up to 13.5 Å in length at the major groove side and 7.9 Å 
in length at the minor groove side. Since the DNA is unwound by EtBr, the adjacent base 
pairs are not parallel with the space between them varying between 2.5 Å to 3.7 Å. In 
NQO2, the isoalloxazine ring in the bottom of the pocket provides pi-pi stacking 
interactions, and additional interactions with the other planar face of the inhibitor are 
mediated by hydrophobic and aromatic residues at the top of the pocket (Figure 5.4B). 
Similar to the binding pocket in DNA, the NQO2 active site can accommodate molecules 
up to 13.9 Å in length and 2.7 Å in height. When the reduced NQO2-EtBr structure was 
superimposed to the known DNA-EtBr structure by aligning the coordinates of EtBr, the 
many residues of the NQO2 binding pocket also superimposed with the unwound DNA 
as shown by the overlap of the molecular surfaces of the two molecules (Figure 5.4C). In 
the reduced NQO2-AO to DNA-AO (41) comparison, the positively charged nitrogenous 
base of AO makes two hydrogen bonds to the hydroxyl group of the two adjacent 
guanosine nucleotides via water molecules, in addition to pi-pi stacking interactions 
(Figure 5.4D). Similarly in NQO2, the nitrogenous base of AO is anchored to E193 by 
  
126 
hydrogen bonds via a water molecule. Therefore, the active site of NQO2 bears a 
surprising resemblance to the binding pocket in DNA. 
 
Figure 5.4 Comparison of the Inhibitor Binding Sites in Reduced NQO2 and DNA 
(A-B) Solvent accessible area (green blob) of the unwound DNA in the DNA-ethidium 
structure (A; Cambridge Structure Database ID ETHUAD10) and the NQO2 active site 
(B) viewed from the front (left panel) showing the hydrophobic and polar regions of the 
binding sites. Views from the top (middle), and from the side (right panel) show the 
estimated dimensions in the binding sites. (C) Molecular surface of reduced NQO2 bound 
to EtBr (left), DNA intercalated with EtBr (middle), and superimposition of EtBr (right) 
to compare the molecular surfaces of the NQO2 and DNA ethidium binding sites. (D) 
Molecular surface of reduced NQO2 bound to AO (left) showing that the nitrogenous 
base of AO makes a hydrogen bond to E193 via a water molecule; DNA intercalated with 
AO (middle, CSD ID ACCYGA10) showing that the nitrogenous base of AO makes a 
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hydrogen bond with the hydroxyl group of two adjacent guanosine bases via water 
molecules; and superimposition of AO (right) showing the overlap of molecular surfaces 
between NQO2 and DNA. 
Even though the active site of NQO2 bears some resemblance to the binding pocked in 
unwound (intercalated) DNA, the affinities of DNA intercalators for NQO2 do not 
correlate well with their affinities for DNA. For example, of the agents studied in this 
manuscript, doxorubicin binds DNA most tightly (KD = 384 nM) (42), while binding of 
EtBr and AO is much weaker (KD values of 15 and 36 µM, respectively) (43). In the case 
of NQO2, EtBr and AO bind reduced NQO2 with very high affinity, with dissociation 
constants that are 4 to 5 orders of magnitude lower (i.e. 3.47 and 0.57 nM; Table 5.1) 
than those for their binding to DNA; doxorubicin, on the other hand, displays a relatively 
modest affinity for NQO2, roughly the same as its affinity for DNA. Furthermore, the 
other DNA intercalating agents, methylene blue and mitoxantrone, that did not display 
observable inhibition of NQO2 exhibit bind DNA with similar affinity as EtBr and 
AO(43, 44). In summary, even though there are similarities between the NQO2 active site 
and the space in DNA occupied by intercalators, it does not seem that NQO2 is a 
completely faithful mimic of DNA. 
5.3.5 Inhibition of NQO2 in Cells 
Beyond an in vitro characterization of these novel inhibitors of NQO2, we were also 
interested in whether AO, to our knowledge the highest affinity inhibitor of reduced 
NQO2 characterized to date, could inhibit NQO2 in cells. First, we established the 
cytotoxicity of AO in HCT116 cells. HCT116 cells are colorectal carcinoma cells with a 
high level of NQO2 expression and activity (39); in addition, these cells do not express P-
glycoprotein (45), preventing active efflux of AO and making them a good model to 
assay in-cell inhibition of NQO2 by AO. We found that AO inhibited HCT116 cell 
proliferation with an IC50 value of 3.9 ± 0.5 µM and on this basis concentrations of AO 
below approximately 500 nM do not affect cell proliferation (Figure 5.5A).  
To determine whether NQO2 is inhibited by AO in cells, we used the cancer prodrug 
CB1954 that is specifically activated by NQO2 in the presence of NRH (28). CB1954 is a 
DNA alkylating agent that can be reduced to a much more toxic DNA cross-linking agent 
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by NQO2 in the presence of NRH. Without NRH, the cytotoxicity of CB1954 was 348 ± 
41 µM, and in the presence of 50 µM NRH, the cytotoxicity of CB1954 increased 20-fold 
to 17.8 ± 1.4 µM (figure 5.5B). Addition of a non-toxic dose of AO (78nM) was able to 
partially reverse the NRH-dependent activation of CB1954 and lower its cytotoxicity in 
the presence of NRH to 114 ± 15 µM (Figure 5.5C). We also tested whether EtBr was 
able to inhibit NQO2 with a non-toxic concentration and found that EtBr had an IC50 
value of 9.1 ± 0.9 µM. The highest concentration of EtBr tested (312nM) was only able 
to slightly reverse the activation of CB1954 by NRH (data not shown). Therefore, a non-
toxic concentration of AO can effectively inhibit NQO2 in cells while EtBr is less 
effective at inhibiting NQO2. 
 
 
Figure 5.5 Validation of NQO2 Inhibition by AO in HCT116 cells 
NQO2 is inhibited by AO in HCT116 cells. (A) IC50 of AO in cells. HCT116 cells were 
treated with AO at the indicated concentration for 48 hours before being assayed by SRB. 
Cell growth of the treated cells was normalized to the cell growth of untreated cells and 
the data were fitted to a dose-response curve to calculate an IC50 for AO of 3.9 ± 0.5 µM. 
(B) Induction of CB1954 cytotoxicity by NRH. Cells were treated with the indicated 
concentration of CB1954 with (¢) and without () 50 µM NRH for 48 hours before 
being tested for viability using an MTT assay. (C) Cellular inhibition of NQO2 by AO. 
Induction of CB1954 cytotoxicity with 50 µM NRH was partially reversed by co-
treatment with 78 nM AO (p). Cytotoxicity of CB1954 with (¢) and without () 50 
µM NRH are shown for reference in grey. 
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5.4 Discussion 
We have identified and characterized the binding of three well-known DNA intercalating 
agents to NQO2. Positively charged polycyclic compounds are thought to be better DNA 
intercalating agents because they are recruited to the negatively charged phosphate 
backbone prior to intercalating DNA. Here, we have shown that when the positive charge 
resides in the planar moiety of compounds such as EtBr and AO, they exhibit a marked 
preference for binding to reduced NQO2, with affinities towards reduced NQO2 that are 
over 50-fold greater compared to those for oxidized NQO2. In contrast, a positive charge 
outside the planar aromatic portions of the inhibitor, as in the case of doxorubicin, does 
little to enhance binding affinity for reduced NQO2. The results with EtBr and AO are in 
line with those of two other NQO2 inhibitors, chloroquine and quinacrine, that bind 
preferentially to reduced NQO2 and carry a positive charge in their aromatic ring systems 
(13). In summary, the available data indicate that a positive charge in the aromatic ring 
system of an NQO2 inhibitor will enhance preferential binding to the reduced form of the 
protein. 
As an alternative function to the enzymatic reduction of quinones, NQO2 has been 
implicated in the regulation of p53, where it was shown that NQO2 in the presence of 
NRH protects p53 from 20S proteosomal degradation (4, 7). Thus, the proposed role for 
NQO2 in the regulation of p53 requires the presence of NRH, suggesting that it is the 
reduced form of NQO2 that is the relevant species. Along these lines, however, is the 
question of how NQO2 is reduced in vivo. NQO2 is inefficiently reduced by NAD(P)H, 
and it is not clear that NRH is actually present in cells. On this basis, NQO2 in cells may 
exist primarily in an oxidized state. Molecules that bind with very high affinity to 
reduced NQO2 would be expected to stabilize it and extend its lifetime. Thus, molecules 
such as AO and EtBr, with nanomolar affinities to NQO2, could “prime” the cell to 
respond to impinging DNA damage and/or apoptotic signals.  
NQO2 has been implicated in neurodegenerative disease and cancer tumorigenesis (46, 
47), although the cellular functions of NQO2 remain a matter of debate. NQO2 knockout 
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mice appear to have lower levels of p53, a weaker induction of p53 by cell stressors, and 
decreased apoptosis (47, 48). In addition, NQO2 has been repeatedly identified as a target 
for a variety of bioactive compounds, such as resveratrol (14), melatonin (15), 
antimalarials (13, 30), and kinase-targeted therapeutics (11, 29). Despite these 
provocative observations, the knockout or inhibition of NQO2 does not bring about acute 
cellular effects. For example, Karen Nolan and coworkers found that imidazoacridine-6-
one compounds are potent NQO2 inhibitors but also intercalate DNA at similar 
concentrations (20). An N-oxide modification of the parent compound reduced its ability 
to intercalate DNA and lowered its cytotoxicity 20-fold while retaining its affinity 
towards NQO2 (49). Similarly, we have shown concentrations of AO that are sufficient 
to inhibit NQO2 have no obvious effect on cell proliferation. It appears that the function 
of NQO2 becomes manifest only when cells are challenged by some other insult.   
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5.6 Supporting tables and figures 
 
Figure S 5.1 Inhibitor Binding to NQO2 Assayed by Isothermal Titration 
Calorimetry 
Titration of EtBr (A), AO (B), and doxorubicin (C) to oxidized NQO2. A syringe filled 
with 80 µM of the inhibitor was titrated to a solution of 8 µM NQO2. Competition ITC of 
EtBr (D) and AO (E) to NQO2 in the presence of 500 µM SCDP and 80 µM of 
chloroquine (CQ). Direct titration of doxorubicin (F) and chloroquine (G) to NQO2 in the 
presence of 500 µM SCDP. Titration data were fit to a single substrate model for all 
direct titrations, or to a competitive model using fixed values from binding parameters 
determined by a titration of CQ to reduced NQO2 (Table 5.3). The thermodynamics 
parameters are summarized in Table 5.3.  
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Table S 5.1 Crystallographic Statistics 
Crystal Oxidized NQO2 Reduced NQO2 
Ligand Ethidium 
bromide 
Acridine 
orange 
Doxorubicin Ethidium 
bromide 
Acridine 
orange 
PDB ID 4BUC 4ZVL 4ZVM 4ZVK 4ZVN 
Wavelength (Å) 1.54 1.54 1.54 1.54 1.54 
Space Group P212121 P212121 P212121 P212121 P212121 
Unit Cell 
Dimensions (Å) 
56.81, 82.85, 
106.43 
56.37, 83.06, 
106.27 
56.23, 83.34, 
106.62 
57.02, 82.57, 
106.25 
56.64, 82.86, 
106.23 
Resolution 13.01 - 1.86 15.00 - 1.90 15.54 - 1.97 16.27 - 1.87 19.51 - 1.86 
Rsym a 0.08 (0.64) 0.10 (0.43) 0.10 (0.61) 0.12 (1.11) 0.08 (0.32) 
I/σ(I)a 18.1 (2.6) 13.7 (4.1) 14.3 (2.8) 9.4 (1.3) 15.9 (4.3) 
Completenessa 97.9 (76.3) 98.6 (82.3) 97.9 (73.5) 92.2 (65.8) 98.6 (79.7) 
Redundancy 6.2 7.0 7.0 4.4 6.8 
Unique Reflections 42044 39969 35891 39460 42288 
Rwork/Rfree 0.1535/ 
0.1992 
0.1447/ 
0.1902 
0.1694/ 
0.2289 
0.1518/ 
0.1985 
0.1602/ 
0.1962 
Ramachandran 
Plot (%) 
Favoured 
Allowed 
Disallowed 
 
 
96.8% 
3.2% 
0% 
 
 
96.7% 
3.3% 
0% 
 
 
95.6% 
4.4% 
0% 
 
 
96.9% 
3.1% 
0% 
 
 
96.5% 
3.5% 
0% 
RMS Deviations 
Bond Lengths (Å) 
Bond Angles (°) 
Dihedral Angles (°) 
 
0.007 
1.000 
13.702 
 
0.009 
0.952 
12.033 
 
0.008 
0.980 
11.304 
 
0.008 
0.931 
11.379 
 
0.008 
1.017 
12.978 
Mean ADP (Å2) 
All Atoms 
Solvent     
 FAD 
     Inhibitor 
 
18.89 
26.69 
17.65 
33.40 
 
20.88 
27.99 
19.35 
26.70 
 
25.59 
29.24 
25.35 
46.95 
 
20.31 
24.17 
19.05 
29.73 
 
20.06 
24.79 
18.90 
23.00 
FAD bendb 
Subunit A 
Subunit B 
 
1.51 
1.70 
 
-2.94 
-3.79 
 
-3.05 
3.23 
 
5.27 
4.02 
 
4.86 
5.88 
a Values in parentheses refer to the highest resolution shell. 
b The equations of the two planes of FAD were first calculated from the coordinates of 
FAD using principal component analysis in MATLAB (MathWorks R2015a). The angle 
between the planes was then calculated and each structure was visually inspected for 
direction of bending. Positive values indicates downward bending.   
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Figure S 5.2 Superimposition of FAD Co-enzyme 
Seven atoms from ring A of the isoalloxazine ring were aligned to reveal the downward 
butterfly bend along the N5-N10 axis in ring B. FAD of the oxidized structures in 
complex with EtBr, AO, and doxorubicin were colored in blue, and FAD of the reduced 
structures in complex with EtBr and AO were colored in red. 
 
 
 
Figure S 5.3 Second Binding Site of Ethidium in NQO2 
Two copies of ethidium were modeled in the active site of subunit B of oxidized NQO2 
(A) and reduced NQO2 (B) to account for prominent non-solvent electron density near 
the active site. The electron density map surrounding ethidium is an Fc-Fo omit map 
generated after three rounds of simulated annealing contoured at 3 σ. 
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Chapter 6 
6 Inhibitors of Quinone Reductase 2 Modulate p53 in 
HCT116 cells 
6.1 Introduction 
NQO2 is a cytosolic flavoprotein constitutively expressed in most tissues (1). 
Historically, it was characterized as a detoxifying enzyme that prevents quinone from 
acquiring a single electron and forming cytotoxic quinone radical by catalyzing an 
obligate two-electron transfer from dihydronicotinamide riboside (NRH) to quinone (2). 
By virtue of this detoxification role, inhibition of NQO2 could sensitize cells to oxidative 
stress generated by quinone radicals. In the past two decades, a wide range of bioactive 
compounds was found to inhibit NQO2 catalytic activity. These compounds included 
kinase targeted inhibitors (3–6), antimalarial drugs (7), natural flavonoids (8, 9), 
resveratrol (10), melatonin (11), and DNA intercalating agents (12). All of these 
compounds perturb cellular functions, but it remains unclear whether inhibition of NQO2 
contributes to their effects.  
In addition to catalysis of quinone reduction, NQO2 was shown to modulate cellular 
proteins involved in cell cycle and apoptotic pathways. These proteins included AKT, 
NF-κB, CEBPα, and most notably p53 (13–18). The role of p53 regulation was initially 
discovered in quinone reductase 1 (NQO1). When NQO1 was knocked down, mutated, or 
inhibited in HCT116 human colorectal carcinoma (HCT116) cells, p53 levels decreased 
(19, 20). Further investigation showed that NQO1 mediated the 20S proteasomal 
degradation of p53 in a NAD(P)H-dependent manner (21). From these observations, 
NQO1 was thought to regulate the basal level of p53 in cells (22). Subsequent studies 
revealed that NQO2 stabilized p53 from 20S proteasomal degradation in a NRH-
dependent manner (17, 18)8. Mice deficient for NQO2 had lower p53 levels, and 
developed skin tumors more readily when challenged with a chemical carcinogen 
                                                
8 Reference 17 was retracted as of February 1st, 2015.  
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compared to control mice (23). This suggested that NQO2 functioned as a tumor 
suppressor by maintaining basal p53 levels. From these studies, NQO2 appears to have 
additional roles beyond catalyzing quinone reduction that correlated to its redox state.  
This alternate function of NQO2 in stabilizing p53 in a redox-dependent manner 
suggested that NQO2 could function as a flavin redox switch, which is a class of proteins 
that participate in cell signalling by responding to light and/or changes in redox state 
(24). The first indication of this relationship originated from studies of Lot6p, the sole 
orthologue of NQO1 and NQO2 in yeast (25). Lot6p is a poor catalyst of quinone 
reduction, but it prevented the 20S proteasomal degradation of the transcription factor 
Yap4 in response to elevated NADH levels (26, 27). Similarly, human NQO1 and NQO2 
could be functioning as flavin redox switches by sensing cellular dihydronicotinamide 
levels and modulating 20S proteasomal degradation of p53. Along these lines, structural 
studies of oxidized and reduced NQO2 revealed mechanistic features of a flavin redox 
switch in NQO2 (28). Together, this prompted the present investigation into the 
signalling role of NQO2 and how NQO2 inhibitors modulate this switch function. 
Specifically, two classes of NQO2 inhibitors were investigated: CK2 inhibitors and DNA 
intercalating agents.  
Protein kinase CK2 (CK2) is elevated in many cancer types, and the development of CK2 
inhibitors that induce apoptosis in cancer has received much attention in the past decade 
(29, 30). However, CK2 inhibitors are not very specific and how CK2 inhibitors work 
remains largely unknown (31). For example, the inhibitors 4,5,6,7-
tetrabromobenzimidazole (TBBz) and 2-dimethylamino-4,5,6,7-tetrabromo-1H-
benzimidazole (DMAT), induced apoptosis even when CK2 activity was restored (5). 
Coincidentally, TBBz and DMAT were identified to be targets of NQO2, and further 
analysis showed that they bound NQO2 with nanomolar affinity (32). In contrast, another 
CK2 inhibitor, 4,5,6,7-tetrabromobenzotriazole (TBB), did not induce apoptosis in cells 
when CK2 activity was restored. It also bound NQO2, but with much lower affinity when 
compared to TBBz and DMAT. Therefore, whether CK2 inhibitors induce apoptosis by 
interaction with NQO2 or not remains a topic for further research. 
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Recently, three additional nanomolar affinity inhibitors of NQO2 were identified: 
ethidium bromide (EtBr), acridine orange (AO), and doxorubicin (33). EtBr and AO 
bound to reduced NQO2 with a dissociation constant of 4 nM and 0.4 nM respectively. 
To date, these two compounds have the highest affinity for reduced NQO2. As DNA 
intercalators, these compounds inhibit DNA replication and RNA transcription; for cells 
that overcome this cytostatic stress, they are also mutagenic. Based on these findings, 
interest arose firstly, in how inhibition of NQO2 by DNA intercalators affects cellular 
proliferation, and secondly, if reduced-state NQO2 inhibitors differ from oxidized-state 
NQO2 inhibitors in cells.   
In this present study, endogenous NQO2 was knocked out using CRISPR/Cas9 
technology in HCT116 cells, and the NQO2-specific effects of substrates and inhibitors 
were characterized. Initial findings revealed that the isolated HCT116ΔNQO2 clones had a 
slower growth rate compared to the parental HCT116 cells. The IC50 of CK2 inhibitors 
(TBB, TBBz, and DMAT) and DNA intercalators (EtBr, AO, and doxorubicin) were 
determined to be the same in both HCT116 and HCT116ΔNQO2 cells. Moreover, attempts 
to activate NQO2 by co-treating cells with NRH and the aforementioned inhibitors did 
not alter the inhibitors’ cytotoxicity. The basal level of p53 was also equal in both the 
HCT116 and HCT116ΔNQO2 cells, but the parental cells were found to modulate p53 more 
dynamically in response to inhibitor treatment. Taken together, our results indicated that 
NQO2’s role in p53 regulation was different then that of NQO1’s.  
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6.2 Methods 
6.2.1 Reagents 
TBB, TBBz, and DMAT (Sigma) were a gift from Dr. David Litchfield. Ethidium 
bromide was obtained from Bioshop (Burlington, ON, CAD). AO and doxorubicin were 
obtained from Caymen Chemical (Ann Arbor, MI, USA).  
6.2.2 NRH Synthesis 
Nicotinamide riboside (NR+) was synthesized and purchased from High Performance 
Nutrients (Irving, CA, USA) as a dietary supplement capsule (34). Analysis of the 
commercial preparation by NMR spectroscopy indicated that it was 92% pure, and it 
matched the spectrum of the synthesized compound (Biomolecular NMR Facility, 
Western University, London, ON). Both synthetic and commercial NR+ contained traces 
of nicotinamide.  
Commercial NR+ was then reduced to dihydronicotinamide riboside (NRH) according to 
the established protocol (35). Powder NR+ from the supplement capsule was dissolved in 
water and insoluble material was removed using a 0.45 µm syringe filter (Millipore). 
Roughly 15 mM of NR+ was reacted with 57 mM of sodium dithionite in a 200 mM 
sodium carbonate-sodium bicarbonate buffer (pH 9.9) in ddH2O. The reaction mixture 
was incubated at 37 °C for 30 mins, then cooled on ice. NRH was then separated by 
preparative HPLC using a Waters µ-Bondapak C18 column (19mm x 150mm). The 
reaction mixture was injected 5 mls at a time into the reverse phase column and eluted at 
10 mL/min by an isocratic mixture of 20% acetonitrile in water. The absorbance of the 
eluent was monitored at 280 nm and 340 nm. For each injection, four species with 
absorbance at 340nm were resolved by the C18 column and eluted at distinct time points. 
Each species was collected, pooled, and tested for their ability to reduce MTT (an NQO2 
substrate) in an NQO2-dependent manner. One fraction showed NQO2-dependent 
activity and was lyophilized into a yellow amorphous powder. Absorbance scan of this 
species was identical to NR+ with an additional absorbance peak at 360 nm. 
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6.2.3 CRISPR/Cas9 Knockout of NQO2 
To knockout endogenous NQO2, the NQO2 was disrupted using CRISPR guided Cas9 
nickase to generate single stranded breaks at two neighboring sites in the fourth exonic 
region. The plasmid pSpCas9n(BB)-2A-Puro (PX462) encoding both the CRISPR guided 
RNA cassette and Cas9 nickase was a gift from Feng Zhang (Addgene plasmid # 48141). 
Using an online CRISPR Design Tool (http://crispr.mit.edu/), CRISPR motifs targeting 
nucleotide 46 and 108 of exon 4 were identified as the top sequences with minimal off-
targets (Figure S6.1). Oligonucleotides corresponding to the pair of guide RNAs 
(sgRNA) were cloned into PX462 according to previous protocol (36) to produce the two 
vectors NQO24_46 and NQO24_108 (Table 6.1). HCT116 cells at 70% confluence were 
then co-transfected with the sequence verified vectors NQO24_46 and NQO24_108 using 
Lipofectamine 2000 (Life technologies) according to the manufacturer’s manual. 24 hrs 
after transfection, the media was supplemented with 0.7 µg/mL of puromycin (Alfa 
Aesar, Ward Hill, MA, USA) for 72 hrs. Surviving cells were trypsinized and serially 
diluted into 96-well plates supplemented with puromycin to select for single colonies 
carrying the transfected plasmid(s). After two weeks, five clones were isolated and 
expanded.  
6.2.4 Validation of NQO2 Knockout 
Cellular NQO2 was detected by Western blotting using rabbit anti-NQO2 polyclonal 
antibodies (a gift from Dr. Tim Haystead at Duke University). Cell lysates from each 
clone were resolved using SDS-PAGE, and then transferred onto a PVDF membrane. 
After blocking with 5% non-fat milk, the blot was probed for NQO2 was using a 1:1000 
dilution of the rabbit-anti-NQO2 antibody and visualized with 1:5000 fluorescence 
labeled secondary goat anti-rabbit antibody (Licor). To validate the excision of the 
targeted genome on exon 4, genomic DNA was isolated from each HCT116ΔNQO2 clones 
and parental HCT116 cells according to instructions from DNA extraction kit 
(Froggabio). Primers exon4_F1 and exon4_R1 were designed using Primer-Blast to 
amplify exon 4 of NQO2 (Table S6.2; www.ncbi.nlm.nih.gov/tools/primer-blast/). PCR 
was performed using taq polymerase according to the manufacturer’s instructions 
(Biobasic). PCR products were resolved on a 3% polyacrylamide gel to detect the 
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excision of a DNA fragment in exon 4. Since no PCR products were detected in clones 2 
and 4, two additional primers (exon4_F2 and exon4_R2) were designed to amplify DNA 
regions that flanked the targeted cut sites (Figure S6.1, Table S6.2). PCR amplification of 
these flanking regions would determine whether the exon 4 was present but disjointed or 
was completely absent. Furthermore, primers were also made to validate that the Cas9 
nickase did not introduce unwanted mutations in off-target sites for the paired guide RNA 
used (Table S6.2).  
6.2.5 Functional Validation of HCT116ΔNQO2 cells 
To validate that functional NQO2 was absent in the cells, activation of CB1954 by NRH 
was used as a reporter of NQO2 activity (15). HCT116 or HCT116ΔNQO2 clone 3 cells 
were seeded at 1000 cells per well 96-well plates, and were allowed to attach overnight. 
Cells were then treated with: 1) 7.8 – 1000 µM of CB1954 and 6 – 200 µM of NRH, 2) 
7.8 – 1000 µM of CB1954 alone, 3) 4.8 – 625 µM of NRH alone or 4) nothing (n=3). 
Cells were allowed to grow for an additional 48 hrs before they were counted using 
sulforhodamine B (SRB) assay.   
6.2.6 SRB Assay 
The SRB assay was a technique that stained total protein content of fixed cells (37). Cells 
were first fixed with trichloroacetic acid (TCA) for 1 hr at 4°C, then washed with water 3 
times. They were then stained with SRB dye (Sigma) for 20 mins at room temperature, 
then washed with 1% acetic acid. The dye was re-solubilized in 10 mM Tris base and its 
absorbance was measured using a multi-reader at 560 nm (Victor multi-plate reader, 
Perkin Elmer). Absorbance readings of treated cells were normalized against untreated 
cells, and the data was fitted to a dose-response curve and graphed using Prism 6.0f 
(GraphPad Software Inc). 
6.2.7 Growth Curve of HCT116ΔNQO2 Cell Lines 
To characterize cell growth, HCT116 and HCT116ΔNQO2 cells from clone 3 and clone 5 
were seeded at 1000 cells in 96-well plates. For 8 consecutive days, cells were 
trypsinized and counted using a haemocytometer each day. In a parallel experiment, cell 
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growth of HCT116 and HCT116ΔNQO2 clones 2, 3, and 4 were determined using the SRB 
assay. In the SRB assay, cells were fixed each day with TCA for 20 mins at room 
temperature, washed four times with water, dried, and then returned to the incubator. On 
day 8, all fixed cells were stained with SRB and protein content was measured as 
described above.  
6.2.8 Cell Cycle Analysis by Flow Cytometry 
Cell cycle analysis using flow cytometry was performed as previously described (38). 
Briefly, HCT116 and HCT116ΔNQO2 cells were seeded at 500,000 cells in a 10 cm culture 
dish to grow for 40 hrs until reaching 50-70% confluence. The cells were then labeled 
with bromodeoxyuridine (BrdU) for 1 hr, harvested, fixed in 95% ethanol, and stored at 
4ºC until they were used. Prior to flow cytometry analysis, the cells were stained with 
mouse-anti-BrdU (BD Bioscience), FITC conjugated goat-anti-mouse IgG antibodies, 
and propidium iodide (PI).  
6.2.9 Toxicity of Inhibitors of NQO2 
To determine the toxicity of NQO2 inhibitors, HCT116 and HCT116ΔNQO2 cells were 
seeded in 96-well plates, 1000 per well, and allowed to attach overnight. The two cell 
lines were then treated with one of the following compounds: 7 nM – 115 µM of TBB, 
TBBz, or DMAT, or 14 nM – 230 µM of EtBr, AO, or doxorubicin. The experiment was 
then replicated with the addition of 61 µM of NRH co-treatment to determine whether 
activation of NQO2 sensitize cells to inhibitor-induced cytotoxicity. Cells were harvested 
after 48 hrs and were counted using the SRB assay.  
6.2.10 Western Blot Analysis of Inhibitor-treated Cells 
HCT116 and HCT116ΔNQO2 cells were seeded at 250,000 cells per well in 6-well plates 
and allowed to attach overnight. They were then treated with the concentrations of CK2 
inhibitors and DNA intercalating agents indicated in individual experiments. The cells 
were harvested at the indicated time points by the addition of Tris lysis buffer (50 mM 
Tris HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% Deoxycholic acid) with a cocktail of 
protease inhibitors (1 mM PMSF, 7 µg/ml Pepstatin A, 20 µg/ml Leupeptin, and 2.9 
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µg/ml Aprotinin). Since cells treated with a high concentration of TBB detached from 
their plates, all non-adherent cells were collected and pooled with the adherent cells. The 
concentration of cell lysates was determined using a BCA assay (Bio-RAD) and 
normalized to the least concentrated sample. For each sample, 10 – 15 µg of lysate was 
separated on a 12% SDS-PAGE gel and transferred to a PVDF membrane. The 
membrane was then blocked with 3% milk and probed with one of the following primary 
antibodies: monoclonal mouse-anti-p53 (DO-1, Santa Cruz), monoclonal mouse-anti-
GAPDH (Millipore), polyclonal rabbit-anti-PARP (Cell Signal), or monoclonal rabbit-
anti-cleaved PARP (Asp214, Cell Signal). The blot was then probed with fluorescence 
labeled goat-anti-mouse/rabbit secondary antibodies and visualized on a LiCor scanner 
(LiCor). All the antibodies used were a generous gift from Dr. David Litchfield 
(University of Western Ontario). 
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6.3 Results 
6.3.1 CRISPR/Cas9 Knockout of NQO2 
Disrupting the expression of endogenous NQO2 using RNA interference was effective in 
some cell lines but was challenging in others (39, 40). Previous attempts to knock-down 
NQO2 in Hela cells using shRNA resulted in roughly 60 percent decrease in NQO2 
protein levels (data not shown). Therefore, the decision was made to completely abolish 
endogenous NQO2 expression using CRISPR/Cas9 technology (14). This way, 
unpredictable cellular changes caused by transfection reagents and residual quantities of 
NQO2 were avoided. To minimize off-target DNA double-strand cleavage events, the 
Cas9 nickase was targeted to two neighboring sequences in the fourth exon of NQO2 by 
a pair of guide RNA to generate two single stranded breaks (Figure 6.1A). HCT116 
colorectal carcinoma cells were chosen to model NQO2-mediated p53 regulation for the 
following reasons: they have a normal p53 status, they have high levels of NQO2 
expression and activity, and there is no basal expression of the P-glycoprotein efflux 
pump known to excrete toxic compounds (41–43). Five clonal populations of HCT116 
cells were isolated after transfection of the CRISPR/Cas9 nickase constructs. In four of 
these clones, there was no detectable level of NQO2 expression (Figure 6.1B). To verify 
the success of the NQO2 gene disruption, PCR amplification of the targeted exon was 
performed. Clones 2 and 4 had no PCR amplicon, while clones 3 and 5 had a shorter PCR 
amplicon compared to the parental HCT116 cells (Figure 6.1C). Sequence analysis of the 
PCR amplicon of clones 3 and 5 showed that 18 DNA basepairs were deleted near the 
targeted exonic region. Since these two clones had the same genotype, it is possible they 
originated from the same colony. 
The sequence analysis of the PCR amplicon from parental HCT116 showed a single 
nucleotide deletion in the intronic region upstream of exon 4 in one allele. However, this 
heterozygosity was not present in the PCR amplicons of HCT116 ΔNQO2 clone 3 and 5, 
indicating that only one of the NQO2 exon 4 alleles was amplified. CRISPR/Cas9 
mediated genome editing can cause excessive gene deletion and/or chromosomal 
translocations (44). Furthermore, HCT116 cells are known to be defective in their 
mismatch repair machinery, and their ability to repair DNA damage using non-  
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Figure 6.1 NQO2 Gene Knock Out in HCT116 using CRISPR/Cas9 Nickase. 
(A) Illustration of the knockout strategy. The paired guide RNA was designed to generate 
a single strand nick at positions 46 and 108 of the fourth exon of NQO2. (B) Western blot 
of NQO2 in HCT116 (WT) and five knock out clones (numbered 1-5) transfected with 
the paired guide RNA. Four of the clones (2 to 5) had no detectable amount of NQO2. A 
non-specific band (*) was detected by the polyclonal anti-NQO2 antibody. (C) PCR 
amplification of exon 4 of NQO2 in HCT116 and HCT116 ΔNQO2 clones. Clone 1 showed 
a product size of 425 bp as expected, clones 2 and 4 did not have a PCR product, and 
clones 3 and 5 had a shorter PCR amplicon (top). PCR products were separated on a 3% 
polyacrylamide gel. Regions upstream and downstream of exon 4 were also individually 
amplified (bottom). A PCR product was observed for all clones in the 5’ flank and 3’ 
flank regions of exon 4. Thus, the two flanking regions of exon 4 exist in the genome but 
are disjointed in clone 2 and 4. PCR products of the flanking regions were separated on a 
1% agarose gel. 
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homologous end-joining (NHEJ) is also impaired (45). Therefore, it is also possible that 
HCT116 cells are prone to genomic instability when manipulated by CRISPR/Cas9 
genome editing tools. Accordingly, the regions that flanked the targeted cut sites were 
amplified to determine whether the genomic content was lost or disjointed. To our 
surprise, the 5’ and 3’ regions flanking the targeted cut sites were present in all clones 
and the genomic content was not lost (Figure 6.1C). Therefore, it is likely that a 
translocation event had disjointed the 4th exon of NQO2 in both alleles of clone 2 and 4, 
and in one allele of clone 3 and clone 5. Since one allele could be accounted for in clone 
3 and clone 5, all subsequent experiments were performed using clone 3 unless otherwise 
specified.  
6.3.2 Characterization of HCT116∆NQO2 Cell Lines 
HCT116 cells are colorectal carcinoma cells that have epithelial-like cell morphology. An 
initial comparison in morphology between the parent HCT116 cell and HCT116∆NQO2 
showed no observable differences. However, a slower overall growth rate was observed 
in the HCT116∆NQO2 clones during normal cell passage. Consistent with these 
observations, it was previously reported that knockdown of NQO2 in prostate cancer 
cells slowed cell growth (16). To further investigate changes in proliferation, growth 
curves were generated for the HCT116 parental and HCT116∆NQO2 cell lines. The growth 
rates of HCT116∆NQO2 clones 3 and 5 were markedly slower than the parental cell line 
(Figure 6.2A). The greatest difference in cell counts occurred at the end of an exponential 
growth phase on day 4. At this point, there were 4- and 6-fold fewer cells in clones 3 and 
5, respectively. The growth curves for HCT116∆NQO2 clones 2-4 were also generated 
using SRB assay and similar growth suppression was observed (Figure S6.2).  
To understand the cause of growth suppression, the cell cycle distribution was analyzed 
by flow cytometry using BrdU and PI staining (38). Asynchronous HCT116ΔNQO2 cells 
from clones 2-4 had up to a 2-fold higher distribution in the S phase compared to parental 
HCT116 (Figure 6.2B). HCT116ΔNQO2 also had an overall lower distribution in the G1 
and G2/M phases. In combination with the slow growth phenotype observed in 
HCT116ΔNQO2 cells, a higher distribution of cells in the S phase is indicative of a defect 
in the intra-S phase checkpoint. Since NQO2 was shown to modulate AKT, NF-κB,  
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Figure 6.2 Characterization of HCT116ΔNQO2 clones 
(A) Growth curve of HCT116 (), HCT116ΔNQO2 clone 3 (¢) and clone 5 (p) assayed 
by cell count (left). Cells were initially seeded at 1000 cells/well in a 96-well plate. Each 
day, cells were trypsinized for cell counting using haemocytometer immediately (n=4). 
On day 4, cell counts were plotted on a linear scale to illustrate the difference in cellular 
proliferation between the three cell lines (right). (B) Increased S phase distribution in 
HCT116ΔNQO2 cells. Asynchronously proliferating cells of HCT116 (), HCT116ΔNQO2 
clone 2 (¢), clone 3 (p), and clone 4 (▼) were stained with propidium iodide and BrdU, 
followed by flow cytometry analysis. As a reference, a line was drawn for the cell cycle 
distribution of parental HCT116. 
CEBPα, and p53 (13–16), cell cycle perturbation could be the result of dysregulation of 
these proteins. 
6.3.3 Cytotoxicity of Substrate CB1954 
To determine the catalytic activity of NQO2 in cells, Knox and coworkers established a 
protocol in which the cytotoxic compound CB1954 can be activated up to 1000-fold in 
the presence of NRH when transfected NQO2 was over-expressed (35). Here, it was 
found that as little as 12.5 µM of NRH could maximally induce the cytotoxicity of 
CB1954 in parental HCT116 cells. The IC50 value of CB1954 was decreased over 40-fold 
from 203 ± 19.1 µM to 4.5 ± 0.4 µM (Figure 6.3A,C). In contrast, activation of CB1954 
by NRH in HCT116∆NQO2 cells was completely abolished even when co-treated with 200 
µM NRH (Figure 6.3B-C). As such, cellular activity of NQO2 was completely abolished. 
In the absence of NRH co-treatment, the toxicity (IC50) of CB1954 was the same between 
the HCT116 and HCT116∆NQO2 cell lines. This indirectly indicated that NRH (or any 
other NQO2 reducing co-substrate) was not abundant in HCT116 cells.  
  
150 
6.3.4 Toxicity of NR and NRH 
The bioactivation of CB1954 in cells required the addition of exogenous NQO2 co-
substrate (35). To this end, the cytotoxicity of NR+ and NRH was initially determined as 
an experimental control to find a non-toxic concentration of NRH suitable to activate 
CB1954. Unexpectedly, treating cells with NR+ or NRH alone at concentrations above 
100 µM or 200 µM respectively were cytotoxic to both HCT116 and HCT116ΔNQO2 cells 
(Figure 6.3C). This was contrary to previous findings by Knox and coworkers, who 
indicated that treating cells with up to 10 mM of NRH or other NQO2 co-substrates were 
not cytotoxic in four human cancer cell lines (PC-3 prostate carcinoma, U373-MG and 
U87-MG glioblastoma multiforme, and T98G glioblastoma) (35). Furthermore, up to 1 
mM of the same commercial NR+ used in this experiment was not cytotoxic to human 
aortic endothelial cells, HITC6 smooth muscle cells, and primary mouse smooth muscle 
cells (Krista Hawrylyshyn, personal communications). From these findings, it appears 
that HCT116 cell proliferation was sensitive to high concentrations of NR+ or NRH. In a 
recent study, mice deficient of a gene implicated in NAD+ synthesis more readily 
developed liver tumors when challenged with a carcinogen (46). Restoration of cellular 
NAD+ levels with a high NR+ diet prevented tumor formation and progression. In the 
same regard, an increase of NAD+ levels in HCT116 by NR+ and NRH treatment may be 
the cause of cytotoxicity for these cells, while it was non-toxic to other cell lines.  
6.3.5 Toxicity of NQO2 Inhibitors 
It is well known that CK2 inhibitors (TBB, TBBz, and DMAT) and DNA intercalators 
(EtBr, AO, and doxorubicin) are cytotoxic. These compounds were all previously 
identified to be NQO2 inhibitors (5, 33), but it is unclear how NQO2 inhibition 
contributes to the cellular effects of these chemicals. To explore this question, the IC50 of 
each inhibitor was determined in HCT116 and HCT116ΔNQO2 cells. Surprisingly, the 
status of NQO2 did not affect the cytotoxicity of these inhibitors (Figure 6.3D, Table 
6.1). Since NRH was required by NQO2 to stabilize p53 in vitro (17), NRH co-treatment 
could sensitize cells towards the apoptotic effects of the inhibitors. However, the addition 
of 61 µM NRH did not change the IC50 values of the inhibitors tested. Comparing the   
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Figure 6.3 Cytotoxicity of Substrate, Co-substrate, and Inhibitors in HCT116 and 
HCT116ΔNQO2 cells. 
(A) Cytotoxicity of substrate CB1954. HCT116 (left) and HCT116ΔNQO2 (right) cells 
were treated with CB1954 at the indicated concentration with 6 µM (●), 12.5 µM (■) 25 
µM (p), 50 µM (q), 100 µM (◊), 200 µM (⬣), or without NRH (○) for 48 hrs and 
assayed for cell proliferation using SRB dye (n=3). All cellular growth measured by SRB 
assay was normalized to cell growth without treatment, and data was fitted to a dose-
response curve. Fitted curve was only shown for 100 µM NRH co-treatment cells (◊) for 
clarity. (B) IC50 values CB1954 in HCT116 (●) and HCT116ΔNQO2 (○) cells when co-
treated with NRH. The cytoxicity of CB1954 increased 50-fold in the presence of NRH 
in parental HCT116 but the induction of CB1954 toxicity was completely abolished in 
HCT116ΔNQO2. (C) Cytotoxicity of co-substrate NR+ and NRH. HCT116 (●) and 
HCT116ΔNQO2 (○) cells were treated with NR+ (left) and NRH (right) at the indicated 
concentration for 48 hrs and assayed for cell proliferation using SRB dye (n=3). Cellular 
proliferation was attenuated at NR+ concentrations above 100 µM and NRH 
concentrations above 200 µM as indicated by the dotted line. (D) Representative curve of 
cytotoxicity of inhibitor treatment. HCT116 (●) and HCT116ΔNQO2 (○) were treated with 
TBBz at the indicated concentrations for 48 hrs and assayed for cellular proliferation 
using SRB dye (n=2). Further co-treatment with 61 µM NRH in HCT116 (■) and 
HCT116ΔNQO2 (◻ ︎) cells did not affect cell growth (n=2). All cellular growth measured by 
SRB assay was normalized to cell growth without treatment. Data was fitted to a dose-
response curve and IC50 values are summarized in Table 1. Fitted curve was only shown 
for TBBz treatment of HCT116 WT cells (●) for clarity.  
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Table 6.1 IC50 (µM) of Inhibitors in HCT116 and HCT116ΔNQO2 Cellsa  
 
WT KO WT KO KD (nM) 
NRHb - - + +  
TBB 43 ± 8.1 68 ± 23 57 ± 15 74 ± 23 7110 ± 40c 
TBBz 12 ± 2.4 16 ± 3.9 12 ± 2.5 18 ± 4.1 18 ± 0.4c 
DMAT 182 ± 31 134 ± 18 139 ± 25 147 ± 27 36 ± 1.7c 
EtBr 9.1 ± 0.9 9.5 ± 1.3 12 ± 1.7 8.1 ± 0.9 3.5 ± 0.3d,e 
AO 3.9 ± 0.4 3.8 ± 0.4 4.5 ± 0.5 3.7 ± 0.4 0.4 ± 0.1d,e 
Doxorubicin 0.61 ± 0.14 0.37 ± 0.07 - - 274 ± 49d 
a IC50 values were determined by treatment of inhibitors at various concentrations for 48 
hrs. Fitted curves are shown in Figure S6.2.  
b Cells were co-treated with and without 61 µM NRH 
c KD values of TBB, TBBz, and DMAT towards NQO2 were previously determined using 
fluorescence titration (32) 
d KD values of EtBr, AO, and doxorubicin towards NQO2 were previously determined by 
ITC (To be published) 
e Dissociation constants of EtBr and AO towards reduced NQO2 
IC50 values of each inhibitor to their respective in vitro KD values, the concentrations 
needed to inhibit cell growth were roughly 2 to 3 orders of magnitude higher than their 
dissociation constants for NQO2 (Table 6.1). TBB and doxorubicin were the only 
exception where their cellular IC50 values were similar to their in vitro KD values. 
Altogether, it appears that NQO2 inhibition was not directly responsible for the cytotoxic 
effects of the inhibitors even though the concentrations used adequately inhibited NQO2 
in vitro. 
6.3.6 Modulation of p53 Expression Levels by NQO2 Inhibitors  
NQO2 protected p53 from degradation in vitro. Accordingly, mice deficient in NQO2 
also had a lower expression of p53 (17, 23). According to these findings, a down-
regulation of p53 expression in HCT116ΔNQO2 cells was expected. However, the basal 
level of p53 expression remained the same even when endogenous NQO2 was knocked 
out in HCT116 cells (Figure 6.4A). This was contrary to previous findings and raised the 
question of whether NQO2 is active in stabilizing p53 in tumorigenic cells.  
NQO2 status did not change how CK2 inhibitors and DNA intercalators attenuated cell 
growth, but the six inhibitors modulated p53 levels in an NQO2-dependent manner 
(Figure 6.4B-C). To compare the effects of these inhibitors, HCT116 and HCT116ΔNQO2 
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cells were treated with inhibitors at concentrations of either 1/5th of the IC50 or IC50 for 18 
or 24 hrs (Table 6.1). When cells were treated with inhibitors at 1/5th concentrations of 
IC50, p53 levels did not vary greatly. Specifically, p53 was slightly down-regulated in 
TBB and AO treated cells, while p53 levels increased in doxorubicin treated cells. At the 
IC50 concentration where all the inhibitors attenuated cell growth to the same degree, the 
modulated levels of p53 expression were drastically different. TBBz, EtBr, and 
doxorubicin highly induced p53 expression, while TBB and DMAT down-regulated p53. 
In comparison, AO had the least effect on p53 regulation despite binding most tightly to 
NQO2 in vitro. Therefore, NQO2 inhibitors did not uniformly modulate p53 expression. 
Furthermore, inhibitor-induced changes in p53 levels did not differ much between 
HCT116 and HCT116ΔNQO2 cells. The most drastic difference was observed in TBBz 
treatment at the IC50 concentration where p53 levels was roughly two times greater in 
HCT116 cells compared to HCT116 ΔNQO2 cells. NQO1 inhibitors dicoumarol and 
curcumin induced p53 degradation in HCT116 cells (19, 47), yet our data showed that 
NQO2 inhibitors did not degrade p53 in a consistent manner. Drawing from these 
observations, NQO2 could function differently compared to NQO1 in HCT116 cells. 
6.3.7 Apoptotic Response and p53 Modulation by TBB and TBBz 
Since mutation or down-regulation of endogenous NQO1 prevented inhibitor-induced 
p53 degradation (19, 20, 47), NQO2 could modulate inhibitor-induced p53 degradation. 
As such, apoptotic signalling and p53 modulation by TBB and TBBz were more carefully 
examined. HCT116 and HCT116ΔNQO2 cells were treated with three concentrations of 
TBB and TBBz (corresponding to 1/5th of IC50, IC50, and 5 times the IC50) for 6, 12, 18, 
and 24 hrs. At 5 times the IC50 concentration of TBB, cells detached from the plates after 
12 hrs. Despite detaching, they were still viable as determined by a trypan blue exclusion 
assay. In light of this finding, all cells were pooled for western blot analysis. Initial 
blotting using a polyclonal PARP antibody was unable to reliably detect cleaved PARP 
products (Figure S6.4). Using a monoclonal antibody against cleaved PARP, this 
apoptotic signal was clearly detected and appeared to be no different between HCT116 
and HCT116ΔNQO2 cells (Figure 6.5A). Following TBB treatment, apoptosis was   
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Figure 6.4 Western Blot Analysis of p53 in HCT116 and HCT116ΔNQO2 Cells Treated 
with Six NQO2 Inhibitors 
(A) Western blot of p53, NQO2, and GAPDH in HCT116 cells and HCT116ΔNQO2 clone 
2-5. Fold difference was calculated by integrated intensity of p53 normalized to GAPDH 
compared to levels of p53 of WT cell line. (B) HCT116 and HCT116ΔNQO2 cells were 
treated with six NQO2 inhibitors at 1/5th IC50 and IC50 concentrations for 18 and 24hrs 
(refer to table 6.1). Cell lysates were analyzed by western blot for p53 and GAPDH. (C) 
Quantification of p53 was performed by normalizing the intensity of each p53 band 
against GAPDH band and shown as a bar graph.  
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only apparent in the detached cells treated with 5 times the IC50 concentration at 6 and 12 
hrs. In contrast, TBBz induced apoptosis most strongly at the IC50 concentration at 18 and 
24 hrs, but was almost absent at 1/5th and 5 times the IC50 concentrations. Therefore, 
inhibitor-induced apoptosis was dependent on time and concentration of inhibitors used, 
but not dependent on NQO2 status. 
The inhibitor-induced modulation of p53 also appeared to be time and dose dependent 
(Figure 6.5A-B). Overall, TBB treatment down regulated p53 levels while TBBz induced 
its expression. For the low and medium concentrations of TBB, p53 levels were not 
drastically perturbed. At 5 times the IC50 concentration of TBB, however, p53 was down 
regulated in HCT116ΔNQO2 cells and almost undetectable in parental HCT116 cells. In 
contrast, all three concentrations of TBBz treatment induced p53 expression. At the IC50 
concentration, TBBz induced p53 almost twice as much in HCT116ΔNQO2 cells compared 
to the parental HCT116 cells at 12, 18, and 24 hrs. In terms of temporal differences, 
changes in p53 levels were more gradual in cells deficient of NQO2 compared to 
HCT116 cells for all concentrations of TBB and TBBz treatment. Specifically, inhibitor-
mediated p53 levels rose and fell at an earlier time point in parental HCT116 cells 
compared to the same inhibitor treatment in HCT116ΔNQO2 cells. Finally, HCT116ΔNQO2 
cells had an overall lower p53 levels compared to parental HCT116 cells. The only 
exception was for TBB treatment at the IC50 concentration. On the whole, the data 
showed that NQO2 played a role in modulating p53 in very complex manner. 
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Figure 6.5 Analysis of PARP Cleavage and p53 Modulation in HCT116 and 
HCT116ΔNQO2 Cells Treated with TBB and TBBz 
(A) Cells were treated with 11, 55, or 275 µM TBB and or 2.8, 14, or 69 µM TBBz 
(corresponding to 1/5th IC50, IC50, and 5 x IC50 of the individual inhibitors). At 6, 12, 18, 
and 24 hrs, cells lysed with Tris lysis buffer. At 12, 18, and 24 hrs, cells treated with 275 
µM TBB all lifted from plate. As such, all cells were pooled for analysis. The 
concentration of cell lysates was normalized and 15 µg of each sample were resolved on 
SDS-PAGE. After being transferred onto a PVDF membrane, it was probed with anti-
cleaved PARP, anti-p53, and anti-GAPDH antibodies. The membrane was then probed 
with fluorescence labeled secondary antibodies and visualized using a LiCor imaging 
system. (B) Quantification of p53 was performed by normalizing the intensity of each 
p53 band against GAPDH band and was shown as a bar graph. 
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6.4 Discussion 
NQO2 was traditionally characterized as an enzyme, but recent findings suggest it also 
functions as a flavin redox switch to modulate p53 degradation (17, 28). As such, NQO2 
inhibitors that inactivate catalysis may be modulating NQO2 in an unexpected manner by 
modifying the switch function of NQO2. Furthermore, numerous bioactive compounds 
were found to interact with NQO2 as an “off-target” but how these interactions contribute 
to their effects is poorly understood. To this end, we knocked out endogenous NQO2 in 
HCT116 cells using CRISPR/Cas9 technology to study the effects of NQO2 inhibitors. 
However, the six NQO2 inhibitors studied did not affect cell viability in an NQO2-
dependent manner. Thus, the cytotoxic effects of NQO2 inhibitors were not directly 
caused by NQO2 inhibition. Instead, inhibitors modulated p53 in a time-, dosage-, and 
NQO2-dependent manner.  
In 2001, the modulation of p53 by NQO1 was shown for the first time (19). In that study, 
an NQO1 specific inhibitor, dicourmarol, drastically decrease p53 levels in HCT116 
cells. Since NQO2 was thought to function similarly to NQO1, NQO2 inhibitors were 
expected to affect p53 levels in the same way. However, this was not the case in this 
current study. For the six inhibitors studied, each inhibitor modulated p53 levels 
differently. Some inhibitors induced p53 (TBBz, EtBr, and doxorubicin), others down 
regulated p53 (TBB, DMAT), and one inhibitor didn’t change p53 levels (AO). 
Furthermore, the two inhibitors specific to reduced NQO2 (EtBr and AO) modulate p53 
in an unpredictable way compared to inhibitors specific to oxidized NQO2. From these 
results, the role of NQO2 in modulating p53 appears to be different compared to NQO1.  
The stabilization of p53 by NQO2 and NQO1 was dependent on NRH and NADH 
respectively (17). Since the co-substrate specificity of NQO2 and NQO1 are exclusive to 
one other (8), cellular concentrations of NRH and NADH would be crucial in 
determining how NQO2 and NQO1 modulate p53. However, the availability of cytosolic 
NRH is questionable. On one hand, activation of the NQO2 substrate CB1954 in cells 
required the addition of either NRH or another NQO2 co-substrate (35); as confirmed in 
this study. On the other hand, activation of the NQO1 substrate EO9 in cells did not 
require the addition of NADH (48, 49). Therefore, cellular concentrations of NQO2 co-
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substrates are normally too low for reduction of substrates, while concentrations of 
NQO1 co-substrates are sufficient for catalysis. On this basis, it is possible that NQO2 
remains in an oxidized state in the absence of NRH, unable to stabilize p53 from 
degradation; hence inhibition of NQO2 has no effect on p53. In contrast, NQO1 could 
stay in a reduced state in the presence of NADH, which allows it to maintain basal p53 
levels. The inhibition of NQO1 then prevents NQO1 reduction and induces p53 
degradation. Along these lines, NQO2 and NQO1 may be constantly sensing the balance 
between NR+/NRH and NAD+/NADH levels in cells in regulating p53. Together, NQO2 
as a flavin redox switch appears to be regulated differently compared to NQO1. 
To further complicate the interpretation of our observations, the NQO2 inhibitors used in 
this study were not very specific to NQO2. The six NQO2 inhibitors were studied for 
their NQO2-dependent effects at concentrations that attenuated cell growth by 50% (IC50-
). With the exception of TBB and doxorubicin, the inhibitor’s IC50 were 2 – 3 orders of 
magnitude higher than their dissociation constants (KD) towards NQO2. As such, the 
inhibitors could also be binding to other targets and affecting multiple cellular processes: 
TBB, TBBz, and DMAT were originally designed to inhibit CK2, while EtBr, AO, and 
doxorubicin were well-characterized DNA intercalating agents. Furthermore, some of 
these compounds also inhibited additional targets in cells. For example, TBBz and 
DMAT potently inhibit kinase from three other families, and doxorubicin inhibits 
topoisomerase II (31, 50). Consequently, the cytotoxicity and p53 expression induced by 
inhibitors may not be direct effects of NQO2 interactions.  
Differences in how HCT116 and HCT116ΔNQO2 modulated inhibitor-induced p53 changes 
were initially not apparent in the six inhibitors studied. Further investigation into cells 
treated with TBB and TBBz showed that p53 was modulated in a time-, dose-, and 
NQO2-dependent manner. As such, NQO2-mediated modulation of p53 was not easily 
detected. Owing to the lack of NRH in normal proliferating cells, three possible scenarios 
regarding how inhibitors could affects p53 modulation in an NQO2-dependent manner 
were postulated. Firstly, the direct binding of inhibitors to oxidized NQO2 may generate 
a novel state of NQO2 whose functions are directly responsible for p53 regulation. 
Secondly, since inhibitors also target other cellular processes, oxidized NQO2 may play 
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an indirect role in modulating p53. Lastly, the inhibitors of NQO2 could induce NRH 
production through an unknown mechanism. In turn, elevated NRH concentrations could 
reduce NQO2 to stabilize p53 levels. In all three scenarios, the mechanism of p53 
modulation by NQO2 is complicated and deciphering it will require further investigation 
using specific inhibitors, different cell lines, and robust p53 detection techniques.  
In summary, endogenous NQO2 was successfully knocked out in HCT116 cells using the 
CRISPR/Cas9 genome editing tool. Even though NQO2 was historically characterized to 
function similarly to NQO1, NQO2 inhibitors did not consistently degrade p53 as NQO1 
inhibitors were shown to do. Furthermore, the lack of NQO2 slowed cell growth, but had 
no effect on cell viability when treated with inhibitors. Drawing from these observations, 
the role of NQO2 as a flavin redox switch is complex and is different compared to its 
homologue NQO1.  
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6.6 Supporting information 
Table S 6.1 Oligonucleotides Used for CRISPR Cassette Construct. 
Guide	  RNA	  oligos	   Sequence	  
Exon4_46_top	   CACCGACCTTTGCTTGTAGGCTTCG	  
Exon4_46_bottom	   AAACCGAAGCCTACAAGCAAAGGT	  
Exon4_108_top	   CACCGTGAGCAGAAAAAGGTTCGGG	  
Exon4_108_bottom	   AAACCCCGAACCTTTTTCTGCTCA	  
Table S 6.2 Oligonucleotides Used for PCR Validation of HCT116ΔNQO2 cells 
Primers	   Sequence	  
Exon4_F1	   TGCTAGGTAGCAAGTGCTCAATC	  
Exon4_R1	   CTTCCAGAAGCAGCACAAAACTC	  
Exon4_F2	   CTGACCTAGTGATATTTCAGGTTTGTTTTTCTC0	  
Exon4_R2	   GTTTCCACTCCATAATTGAAAACCTCAGG	  
46oF1	   ATGGAAGCAGGAACTCAAACTCA	  
46oR1	  	   GTACATGCTGGCCTAGAAAACAC	  
108oF1	   AGTAGGACATCACAGAAGTTGGG	  
108oR1	   TTCTGCTCAAAGGTTTCGCC	  
 
 
 
Figure S 6.1 Cartoon Illustration of Primers Used for PCR Validation in of 
HCT116ΔNQO2 Cells. 
PCR amplification of wild-type NQO2 gene using primers Exon4_F1 and Exon4_R1 will 
generate a PCR product of 425bp, while the PCR product of the knockout gene is 
estimated to be 363bp if exonuclease excise single stranded nucleotides up to the targeted 
cut sites. PCR amplification of the 5’ flank and 3’ flank regions in genomes where full-
length PCR products are absent will show that the two ends of exon4 still exist in the 
genomic DNA. This suggests that a chromosomal translocation event has occurred. 
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Figure S 6.2 Growth Curve of HCT116 and HCT116ΔNQO2 Cells Assayed by SRB. 
HCT116 (), HCT116ΔNQO2 clone 2 (¢), clone 3 (p), and clone 4 (▼) cells were 
seeded at 1000 cells/well in a 96-well plate (n=3). Each day, cells were fixed with 10% 
TCA for 20 mins at room temperature and returned to the incubator. On day 8, the fixed 
cells were stained with 0.3% SRB dye and absorbance at 560nm was recorded using a 
plate reader (left). On day 4, HCT116 cell proliferation was markedly higher than any of 
the clones of HCT116ΔNQO2 (right). 
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Figure S 6.3 Cytotoxicity of NQO2 Inhibitors in HCT116 and HCT116ΔNQO2 cells. 
HCT116 (●) and HCT116 ΔNQO2 (■) cells were treated with TBB (A), TBBz (B), DMAT 
(C), EtBr (D), AO (E), and doxorubicin (F) at the indicated concentrations for 48 hrs and 
assayed for cellular proliferation using SRB dye (n=2). HCT116 (p) and HCT116 ΔNQO2 
(q) cells co-treated with inhibitors and 61 µM NRH did not show marked differences in 
proliferation (n=2). All cellular growth measured by SRB assay was normalized to cell 
growth without treatment. Data was fitted to a dose-response curve and IC50 values are 
summarized in Table 1. Fitted curves are only shown for inhibitor treatment of HCT116 
WT cells (●) for clarity.   
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Figure S 6.4 Analysis of PARP Cleavage and p53 Modulation in HCT116 and 
HCT116ΔNQO2 Cells Treated with TBB and TBBz 
(A) Cells were treated with 11, 55, or 275 µM TBB and or 2.8, 14, or 69 µM TBBz 
(corresponding to 1/5th IC50, IC50, and 5 x IC50 of the individual inhibitors). At 6, 12, 18, 
and 24 hrs, cells lysed with Tris lysis buffer. At 12, 18, and 24 hrs, cells treated with 275 
µM TBB all lifted from plate. As such, all cells were pooled for analysis. The 
concentration of cell lysates was normalized and 15 µg of each sample were resolved on 
SDS-PAGE. After being transferred onto a PVDF membrane, it was probed with 
polyclonal anti-PARP, anti-p53, and anti-GAPDH antibodies. The membrane was then 
probed with fluorescence labeled secondary antibodies and visualized using a LiCor 
imaging system. (B) Quantification of p53 was performed by normalizing the intensity of 
each p53 band against GAPDH band and shown as a bar graph. 
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7 Summary and Perspectives 
NQO2 was historically characterized as an enzyme that catalyzed the reduction of 
quinone. However, recent evidence had revealed that NQO2 also had a role in regulating 
the 20S proteasomal degradation of p53. On this basis, my hypothesis is that NQO2 
functions as a flavin redox switch that senses intracellular NRH levels and recognizes 
inhibitors. The work presented in this thesis addressed the molecular aspects of how 
NQO2 behaved as a flavin redox switch, and showed that inhibitors could perturb cellular 
signalling by modulating p53 stabilization. In this chapter, the structural features that 
allow NQO2 to function as a flavin redox switch will be summarized. Next, the 
fundamental differences between how NQO2 and NQO1 function as a flavin redox 
switch will be discussed. Finally, a hypothesis of how NQO2 could function as a multi-
drug sensor will be explored. In each section, some of the unpublished work initiated for 
NQO2 will also be highlighted and the direction of research will be proposed.  
7.1 Structural Indication of NQO2 as a Flavin Redox 
Switch 
The ability of NQO2 to stabilize p53 is redox-dependent (1). However, little is known 
about reduced NQO2. Using one of the two known reduced-state inhibitors of NQO2 at 
that time, the structure of reduced NQO2 in complex with chloroquine (CQ) was solved 
(Chapter 3). This was a challenging endeavor because NQO2 spontaneously oxidizes in 
the presence of oxygen. By reducing the oxidized protein-ligand crystal complex in an 
anoxic environment, NQO2 was kept reduced. Solving this structure, reduced NQO2 in 
complex with an inhibitor was characterized for the first time. Compared to oxidized 
NQO2, three observations were made in reduced NQO2-CQ: an FAD bend, an altered 
hydrogen bond network at the active site mediated by several water molecules, and a 
global conformation change.  
Subsequently, the structures of oxidized and reduced NQO2 were obtained in complex 
with the following four inhibitors: DMAT (chapter 4), ethidium, acridine orange (chapter 
5), and quinacrine (unpublished). Compared to their respective oxidized NQO2-inhibitor 
structures, all the reduced NQO2-inhibitor complexes had approximate a 5º “butterfly” 
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bend at the isoalloxazine ring of the reduced FAD that was repeatedly detected. 
Additionally, all the reduced structures showed a consistent rearrangement of the 
hydrogen bond network mediated by several water molecules at the active site. The water 
molecules prevented the inhibitors from binding in a deeply buried manner, which 
indicated that they were coordinated more strongly in reduced NQO2 compared to 
oxidized NQO2.  
In the reduced NQO2-CQ structure, a global conformation change indicated by a loss in 
crystallographic spacegroup symmetry was also observed. However, this change was 
absent in the other four reduced NQO2 structures. From a technical perspective, the 
change in spacegroup may be only apparent at higher-resolutions. The data of reduced 
NQO2-CQ crystals was collected to 1.25Å, whereas the dataset for the other reduced 
NQO2-inhibitor crystals were collected to 1.9Å. Another explanation for this unique 
conformational change could be attributed to the chemical structure of CQ. Compared to 
the other inhibitors, CQ has a tail moiety in addition to a planar moiety. In the reduced 
NQO2-CQ structure, this tail moiety of CQ was in close contact with I128. This 
particular isoleucine residue was part of a loop region in NQO2 that was in contact with 
symmetry-related NQO2 molecules. Therefore, the “closing” of the loop region mediated 
by CQ (Figure 3.3) could be responsible for the change in spacegroup.  
Since reduced NQO2 underwent a global conformation change in the crystal structure, 
reduction of NQO2 in solution was also investigated using small angle X-ray scattering 
(SAXS). SAXS is a low-resolution technique used to probe conformational changes of 
proteins in solution. To determine whether NQO2 was drastically different in its two 
redox states, oxidized NQO2, reduced NQO2, and reduced NQO2 in the presence of CQ 
were analyzed using SAXS and the data was summarized in Table 7.1. It was found that 
the radiuses of gyration (Rg) between the three samples were no different from each 
other. In essence, conformational changes seen in the reduced crystal structure were too 
small to be observed using SAXS. 
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Table 7.1 SAXS Analysis of NQO2 in Solution a 
	  
I(o)b	   Rgb	   Dmaxb	  
NQO2	  alone	   55.10	   23.31	   71	  
NQO2	  with	  SCDP	   55.80	   23.28	   72	  
NQO2	  with	  SCDP	  and	  CQ	   55.10	   23.12	   72	  
Cytochrome	  C	   27.90	   13.75	   40	  
a Data was collected at the Advance Photon Source BioCAT 18ID Beamline 
b Data was analyzed using Scatter (Robert Rambo, Diamond Light Source (Didcot, UK)) 
To investigate minute changes in reduced NQO2, one approach would be to compare 
protein dynamics at the molecular level. In a crystal structure, the atomic displacement 
parameter of each atom describes how “mobile” a certain residue is. Using this data, the 
normalized atomic displacement factors (nADP, as described in chapter 2) between the 
main chain atoms of oxidized and reduced NQO2-CQ were compared (Figure 7.1). In the 
reduced NQO2-CQ structure, an increase in nADP was localized on one side of the 
protein, while a decrease was localized on the opposite side. These concerted changes in 
nADP indicated that the reduction of NQO2 in complex with CQ facilitated the mobility 
of residues globally. Therefore, these minute changes in protein dynamics may be crucial 
in mediating its interaction with the 20S proteasome and p53.  
 
Figure 7.1 Protein Dynamic Changes in Reduced NQO2.  
The NQO2 dimer was coloured according to the difference in the normalized atomic 
displacement parameter (nADP) between oxidized and reduced NQO2-CQ complex. 
Increases in nADP (indicated in red) was localized to the bottom half of NQO2, and 
decreases in nADP (indicated in blue) was localized to the top half of NQO2 shown in 
this figure. The two views of the NQO2 dimer are related by a 90° turn about the vertical 
axis.  
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Having solved the reduced structures of NQO2 with four other inhibitors, a 
comprehensive comparison of nADP between oxidized and reduced NQO2 could reveal 
trends in protein dynamics. Pairing such analysis with molecular dynamic simulations of 
oxidized and reduced NQO2 could reveal the nature of how NQO2 behaves in a redox 
dependent manner. In conclusion, further molecular analysis will shed more light on the 
protein dynamics of NQO2 as a flavin redox switch.  
7.2 Cellular Inhibition of NQO2 
Historically, NQO2 was thought to function in a similar fashion to NQO1. While the 
mechanism of quinone catalysis was the same, their co-substrate, substrate, and inhibitor 
specificity were exclusive to one another. In this regard, it was unclear whether NQO2 
had the same role in modulating p53 degradation as NQO1. For NQO1, p53 levels 
decreased in response to NQO1 knockdown, mutation, or inhibition, in HCT116 cells (2–
5). Furthermore, p53 was undetectable in mice deficient of NQO1 (6). For NQO2, p53 
degradation was dependent on NRH, and mice deficient of NQO2 had a lowered 
expression of p53 (1, 7). However, it remained unknown how NQO2 inhibitors would 
affect p53 degradation. In chapter 6, six NQO2 inhibitors were shown to modulate p53 
levels, albeit inconsistently, in HCT116 cells. Knocking out endogenous NQO2 had the 
effect of partially dampening the inhibitor-mediated induction/degradation of p53. 
Therefore, NQO2 inhibitors modulated p53 in a different manner compared to NQO1, but 
exactly how NQO2 participates in p53 degradation remains poorly understood (2).  
As a flavin redox switch, the one fundamental difference between NQO1 and NQO2 is 
their co-substrate specificity. NQO1- and NQO2-mediated degradation of p53 in vitro is 
dependent on NADH and NRH respectively (1). On this basis, the ability of NQO1 and 
NQO2 to stabilize p53 would depend on the availability of these dihydronicotinamide 
concentrations in cells. However, endogenous concentrations of NRH or another NQO2 
co-substrate was insufficient to reduce NQO2 specific substrate CB1954 (Chapter 6, (8)). 
In contrast, NQO1 specific substrates EO9 and mitomycin C were readily activated in 
cells without the addition of NADH (9–11). As a result of these findings, the belief that 
NRH is a natural co-substrate of NQO2 is questionable. Inferring from the different 
cellular concentrations of NRH and NADH, it appears that NQO2 is normally in the 
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oxidized state, while NQO1 is in the reduced state in proliferating HCT116 cells. In the 
next section, the potential sources of NRH will be further discussed.  
7.2.1 Source of NRH 
There are three potential mechanisms of NRH production: 1) transfer of a hydride ion 
from NADPH to NR+ by transhydrogenase, 2) truncation of NAD(P)H to NRH by NAD-
consuming enzymes, and 3) reduction of free NR+ to NRH by dehydrogenase. 
Transhydrogenases are proteins found on the inner membrane of mitochondria that 
transfer the hydride ion from NADPH to NAD+ to generate NADP+ and NADH. 
However, no transhydrogenases have been identified to catalyze this function on the 
cytosolic side of a mammalian cell, and it is unclear whether this enzyme can utilize NR+ 
(12). The second potential source of NRH could originate from enzymes that consume 
NAD+. These include poly-ADP ribose polymerase (PARP), mono-ADP-
ribosyltransferase, and deacetylase (ie. Sirtuins). These proteins transfer the ADP-ribose 
moiety of NAD+ to lysine or arginine side chains, leaving nicotinamide as a by-product. 
This way, NR+ may be generated by nicotinamide phosphoribosyltransferase (NAMPT) 
through the NAD+ salvage pathway. However, these enzymes are strictly dependent on 
NAD+ and do not utilize reduced NADH. Therefore, the first two potential sources of 
intracellular NRH seem unlikely.  
In a study investigating NAD+ derivatives in alcohol metabolism, Sicsic and co-workers 
showed that NR+ can be used in place of NAD+ to oxidize ethanol by horse liver alcohol 
dehydrogenase (HLADH) in the presence of AMP (13). Consequently, it is not 
inconceivable that other mammalian dehydrogenases have the ability to reduce NR+ to 
NRH. When cells are insulted by oxidative stress or DNA damage, NAD+ depletion by 
PARP activation is often accompanied by ATP depletion via the inhibition of glycolysis 
(14). In this low energy state, adenylate kinase is known to catalyze the reaction 2 ADP ➜ 
AMP + ATP to maintain high ATP levels for cell survival. Therefore, NR+ and AMP 
could be abundant when cells are insulted by genotoxic and oxidative stress. Along these 
lines, NRH could be produced by an abundant dehydrogenase such as glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). Together, NRH could be produced when NR+, 
AMP, and the reducing substrates are present at the right concentrations within a cell. 
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Identifying enzymes capable of generating NRH will be the first step in understanding 
the mechanism of NQO2 reduction in cells.  
To date, the only physiological condition known to stimulate NQO2-mediated 
stabilization of p53 is the inhibition of dihydroorotate dehydrogenase (DHODH) (15). 
DHODH is part of the de novo pyrimidine biosynthesis pathway, and the inhibition of 
this enzyme depletes pyrimidine nucleotide cells. Even though inhibition of DHODH 
induced p53 stabilization in an NQO2 dependent manner, it was unclear how this type of 
metabolic stress affects NQO2. One possibility is that NRH, or another NQO2 substrate, 
is generated under these circumstances. To determine the cellular concentration of NRH, 
CB1954 could be used as a surrogate reporter because it is strictly dependent on human 
NQO2 and NRH. Using this assay, it would be valuable to determine whether common 
signals of p53 induction such as oxidative stress, UV rays, gamma irradiation, and 
hypoxia, could induce NRH production. Further metabolomics studies using mass 
spectrometry can validate the identity of the NQO2 co-substrate. Altogether, there is a 
need to determine how NRH is produced in cells and how NQO2 is reduced in a cellular 
context. 
7.3 NQO2 as a Sensor of Toxic Compounds 
The function and regulation of p53 is very complex. As a transcription factor, it can 
activate genes responsible for cell cycle arrest and apoptosis. Independent of 
transcriptional activation, p53 can induce apoptosis by directly interacting with pro-
apoptotic signalling proteins (16). Furthermore, it can modulate proteins and 
transcriptional factors involved in other cellular processes. An investigation into six 
NQO2 inhibitors showed that NQO2 was not responsible for the cytotoxicity or apoptotic 
signalling mediated by the inhibitors (Chapter 6). However, TBB and TBBz modulated 
p53 to some degree in an NQO2 dependent manner. This indicated that NQO2’s role in 
cells as a flavin redox switch could involve cellular processes other than p53-induced 
apoptosis. In this section, the subject of identifying CK2 inhibitors and DNA intercalating 
agents as NQO2 inhibitors will be revisited. Given the diverse nature of the compounds 
that bind NQO2, the potential role of NQO2 as a sensor for cytotoxic compounds will be 
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proposed. Finally, a perspective on how to study NQO2’s role as a flavin redox switch 
using a proteomics approach is presented.  
7.3.1 NQO2 inhibition by Kinase Inhibitors 
CK2 is a constitutively active kinase essential for cell survival. It is capable of 
phosphorylating a diverse range of substrates. The long-standing interest in 
understanding the cellular response to CK2 inhibition at David Litchfield’s lab identified 
NQO2 as the unintended target of TBBz and DMAT (17). This prompted a full 
investigation into the kinetic and structural interactions between CK2 inhibitors and 
NQO2 (Chapter 4). The initial rationale for obtaining the structure of NQO2 in complex 
with TBBz and DMAT was to gain insight towards designing an inhibitor-resistant 
NQO2 construct. Such mutant constructs could restore NQO2 activity in cells to study 
NQO2-specific cellular effects. It was previously shown that mutations in the active site 
of NQO2 decreased the affinity of the melatonin derivative [125I]iodo-MCA-NAT9 from 
binding to NQO2 without decreasing its catalytic activity (18). Therefore, it appears 
feasible to design an inhibitor-resistant NQO2 mutant to validate inhibitor-induced 
cellular effects caused by NQO2 inhibition alone.  
Since TBB and TBBz modulated p53 degradation in an NQO2-dependent manner 
(Chapter 6), NQO2’s interactions with other kinase inhibitors may also affect this cellular 
process. To determine whether other CK2 inhibitors bind to NQO2, a more specific CK2 
inhibitor, CX-4945, was found. NQO2 catalytic activity was reduced to 75% in the 
presence of 5 µM CX-4945, thus it was able to inhibit NQO2 weakly (Figure 7.2).  
NQO2 was also known to be an unintended target of BCR-Abl kinase inhibitors imatinib 
and nilotinib. While the BCR-Abl inhibitors do not inhibit CK2 and CK2 inhibitors 
(TBBz and DNAT) do not inhibit Abl-kinase, both inhibited NQO2 (17, 19–22). Even 
though these kinase inhibitors were initially designed to inhibit kinase activity, they are 
further selected based on favorable clinical outcomes. Therefore, there is a possibility that 
                                                
9 [125I]iodo-MCA-NAT: 2-[125I]iodo-5-methoxycarbonylamino-N-acetyltryptamine 
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a compound able to inhibit both the kinase and NQO2 outperformed compounds that only 
inhibited the kinase. In this regard, a comprehensive screen of kinase inhibitors towards 
NQO2 catalysis could show whether or not NQO2 inhibition contributes to the efficacy 
of kinase inhibitors in general.  
 
Figure 7.2 Inhibition of NQO2 Catalysis by CX4945. Data was fitted to a dose-
response curve.  
7.3.2 Inhibition of NQO2 by DNA Intercalating Agents 
Studies demonstrating that some NQO2 inhibitors could intercalate DNA prompted an 
investigation into whether other DNA intercalators could perform likewise (23, 24). In 
Chapter 5, three DNA intercalators were identified to be novel inhibitors of NQO2. Most 
NQO2 inhibitors identified to date are oxidized-state inhibitors, so it was unexpected to 
find ethidium (EtBr) and acridine orange (AO) to be reduced-state inhibitors. The 
common feature between EtBr, AO, and the two previously identified reduced-state 
inhibitors CQ and quinacrine was a positive charge in the planar moiety. It appears that 
positively charged compounds interacted favorably with the reduced FAD. Further 
structural comparisons between extended (unwound) DNA and the NQO2 active site 
showed numerous similarities between the two binding cavities. Drawing from these 
observations, NQO2 has the potential to recognize a diverse range of DNA intercalating 
agents in cell.  
The identification of DNA intercalating agents as NQO2 inhibitors also raised the 
question of whether other NQO2 inhibitors also intercalate DNA. Some NQO2 inhibitors 
such as imatinib, 9-aminoacridine, and resveratrol have been independently shown to 
interact with DNA (25–27). Along these lines, an important question regarding NQO2 
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inhibitors is whether their cytotoxic effects are primarily due to DNA intercalation or 
inhibition of protein targets. A comprehensive analysis of known NQO2 inhibitors’ 
ability to intercalate DNA could clarify why NQO2 inhibitors are cytotoxic to cells.  
7.3.3 Potential Role of NQO2 as a Sensor of Toxins 
Given the ability of NQO2 to recognize low concentrations of CK2 inhibitors and DNA 
intercalating agents, it is unclear if these interactions serve a function. One possible 
downstream effect of inhibitor binding is to induce multidrug efflux pumps mediated by 
p53. Bacterium gain drug resistances by expressing multidrug efflux pumps that excrete 
non-specific compounds (28). Many of these transporters are under transcriptional 
regulation by multidrug binding proteins. For example, BmrR in Bacillus subtilis (29), 
QacR in Staphylococcus aureus (30), and EmrR in Escherichia coli (31) are 
transcriptional regulators of multidrug efflux pumps. BmrR acted as a repressor of the 
efflux pump Bmr by directly binding to the promoter region. In the presence of a toxin, 
BmrR induced Bmr expression by remodeling the DNA structure to be accessed by RNA 
polymerase (32). Additionally, an elaborate study on QacR showed that a range of toxic 
compounds, both hydrophobic and cationic, can activate the QacA efflux pump (33). 
From these studies, it appeared that bacterial multidrug proteins could sense a variety of 
compounds, and act as transcriptional activators and repressors. While these proteins do 
not share sequential or structural homology with mammalian quinone reductase, this 
regulatory pathway could represent a primitive model of how NQO2 functions as a 
mammalian multidrug efflux pump regulator.  
In mammals, P-glycoproteins (MDR1) and the family of multidrug resistance-associated 
proteins (MRPs) are ATP-binding cassette transmembrane transporters (ABC 
transportors) that pumps xenobiotic compounds out of the cell (34). MRPs’ expression 
can be induced by the presence of toxins and drugs, but their mechanism of induction is 
unclear (35). Specifically, no multidrug binding protein that directly recognizes a toxic 
compound has been reported in mammalian cells. As such, the fact that NQO2 is the 
target of a plethora of cytotoxic compounds, and is able to modulate p53, makes it a 
compelling candidate towards its identification as a mammalian multidrug binding 
protein.  
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While the regulation of MDR1 and MRPs is complex, a pathway through which NQO2 
can modulate these proteins is by p53 and the transcription factor Sp1 (Sp1). Sp1 was 
normally down-regulated by direct binding to p53, but it can induce a member of the 
MRP family, MRP1, in response to a range of cytotoxic stresses (36, 37). This regulation 
was further shown by an induction of MRP1 expression when p53 was inactivated or 
mutated (38). Therefore, a basal p53 expression prevented the expression of MRP1, while 
inactivation of p53 induced MRP1 expression. Through this transcriptional regulation 
mechanism, NQO2 inhibitors could induce the degradation of p53 and release Sp1 to 
initiate MRP1 expression. In this regard, NQO2 may be functioning as a multi-drug 
binding protein that signals the activation of a multidrug efflux pump. Furthermore, there 
are also four Sp1 recognition sites upstream of the NQO2 gene (39), which could act as 
positive regulator of MRP1 until the cell clears all cytotoxic compounds. Following these 
suppositions, an investigation of whether NQO2 plays a role in the regulation of MRP1 is 
warranted.  
A myriad of compounds inhibit NQO2 with affinities ranging from high micromolar to 
nanomolar. Given that NQO2-mediated modulation of p53 may have functions other than 
inducing cell cycle arrest and apoptosis, a role for regulating MRP1 efflux pump is 
proposed: toxic DNA intercalating agents recognized by NQO2 could induce MPR1 and 
be excreted in normal proliferating cells. In this regard, the success of chemotherapeutics 
such as kinase inhibitors may not be due solely to their ability to effectively kill cancer 
cells. Instead, it may be due to the ability of normal cells to excrete these compounds 
such that side effects are minimized. Extending this hypothesis, kinase inhibitors 
recognized by NQO2 could also induce multidrug resistance in cancer cells if the 
concentrations used are not high enough to kill the cell. Taken together, NQO2 may act 
as a direct sensor for toxic compounds to modulate signalling events in cells.   
In the next section, the modulation of p53 by NQO2 will be revisited once more to point 
out that NQO2 has the potential to regulate a number of proteins. To investigate the role 
of NQO2 as a sensor for toxic compounds, an analysis of MRP1 and other proteins using 
a proteomics approach will help decipher the complex function of NQO2. 
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7.3.4 Protein Stabilization by NQO2 
Both NQO1 and NQO2 were shown to stabilize p53 from 20S proteasomal degradation 
(1). To understand this biological process, recombinant p53 from E. coli and 20S 
proteasome from lamb liver were purified. However, in vitro degradation of p53 was not 
detected (data not shown). This was contrary to a previous demonstration that in vitro 
translation of p53 by rabbit reticulocyte lysates were degraded by rabbit 20S proteasomes 
(1). This illustrated that p53 may require certain post-translational modifications to be 
degraded, or that the degradation of p53 was mediated by additional components from the 
rabbit reticulocyte lysate. In addition to p53 modulation, NQO2 may also stabilize other 
proteins. For example, NQO1 also directly modulated the degradation of p73α and 
ornithine decarboxylase (5, 40). All three of these proteins have an intrinsic disordered 
region that could be recognized by the 20S proteasome, and were degraded in an 
ubiquitin-independent manner (41–43). This led Yosef Shaul and coworkers to 
hypothesized that quinone reductase could be modulating 20S proteasomal degradation in 
general (44). As for NQO2, it also modulated Rb/cyclin D1 (45), NFκB (46), CEBPα 
(47), and AKT (48) pathways, though it is not clear if these proteins were directly 
modulated. These studies demonstrated that NQO2 could be directly regulating the 
degradation of an array of intrinsically disordered proteins by the 20S proteasome. To 
gain a comprehensive perspective on the function of NQO2, a global proteomics 
approach is needed to decipher how NQO2 regulates protein stabilization. 
Initially, the overall proteome of HCT116 and HCT116ΔNQO2 cells could be compared 
using a 2D gel. Given sufficient changes in protein levels, SILAC-based (stable isotope 
labeling by amino acids in cell culture) mass spectrometry techniques could be used to 
quantify the differences in protein levels on a global scale (49). Having established the 
basal protein difference between HCT116 and HCT116ΔNQO2, the effects of NRH on the 
proteome will demonstrate how the redox state of NQO2 changes the protein stability. 
Super-SILAC can also be used to monitor several NRH concentrations to detect changes 
in protein levels that are most directly and immediately affected by NQO2 (50). To 
further characterize specific proteins that NQO2 associates with in cells, proximity 
labeling of proteins near NQO2 could be identified using cross-linking reagents or a BIO-
  
179 
ID mass-spectrometry based approach (51). Having established these mass-spectrometry 
techniques, a comprehensive analysis of the proteins that NQO2 modulates directly will 
illuminate the function of NQO2 as a flavin redox switch. This general approach can then 
be extended to decipher how high affinity NQO2 inhibitors such as S29434 and acridine 
orange affect the proteome.   
7.4 Conclusion 
The central question in this thesis was how NQO2 functions as a flavin redox switch. To 
this end, structural analyses of NQO2 and NQO2 inhibitors revealed the mechanistic 
features of a flavin redox switch. Cellular studies further identified that NQO2 exists in 
an oxidized state, contrary to NQO1, which exist in a reduced state. Though the role of 
NQO2 as a flavin redox switch was delineated, many questions remain. Answers to the 
following questions will illuminate how NQO2 modulates cellular processes when 
challenged by the diverse range of NQO2 inhibitors: How does the redox state of NQO2 
affect protein degradation? What is the mechanism of NRH production, and is NRH 
really the natural co-substrate? What other compounds do NQO2 recognize? What are the 
consequences of NQO2 activation? What proteins do NQO2 stabilize? By using advance 
techniques such as protein molecular dynamic simulation, high throughput screening of 
NQO2 inhibitors, and biological mass spectrometry, the knowledge of how NQO2 
functions as a flavin redox switch will be further advanced.  
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